From genome evolution to genetic interactions and personalized anti-cancer drug targets by Lu, X.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/160814
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
From genome evolution to genetic interactions 
and personalized anti-cancer drug targets
Xiaowen Lu (陆晓雯)
ISBN: 9789462955172
From genome evolution to genetic interactions 
and personalized anti-cancer drug targets
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op maandag 21 november 2016
om 10.30 uur precies
door
Xiaowen Lu
geboren op 5 februari 1987
te Shanghai, China
Promotor:  Prof. dr. Martijn A. Huynen
Copromotor:  Dr. Richard A. Notebaart
Manuscriptcommissie:
Prof. dr. ir. Joris A. Veltman, voorzitter 
Dr. Wiljan J.A.J. Hendriks
Prof. dr. Lodewijk F. Wessels (TU Delft)
 From genome evolution to genetic interactions and 
personalized anti-cancer drug targets
Doctoral Thesis
to obtain the degree of doctor 
from  Radboud University Nijmegen 
on the authority of the Rector Magnificus prof. dr. J.H.J.M. van Krieken, 
according to the decision of the Council of Deans 
to be defended in public on Monday, November 21, 2016
at precisely 10:30 hours
by
Xiaowen Lu
Born on February 5, 1987
in Shanghai, China
Supervisor:  Prof. dr. Martijn A. Huynen
Co-supervisor:  Dr. Richard A. Notebaart
Doctoral Thesis Committee:
Prof. dr. ir. Joris A. Veltman, chairman
Dr. Wiljan J.A.J. Hendriks 
Prof. dr. Lodewijk F. Wessels (Delft University of Technology)
Content
Chapter 1 General introduction 1
Chapter 2 Genome evolution predicts genetic interactions in 
protein complexes and reveals cancer drug targets
21
Chapter 3 Predicting human genetic interactions from cancer 
genome evolution
47
Chapter 4 Synthetic dosage lethality in the human metabolic 
network is highly predictive of tumor growth and 
cancer patient survival
67
Chapter 5 Experimental design of personalized anti-cancer 
targets
87
Chapter 6 Adaptive evolution of complex innovations 
through stepwise metabolic niche expansion
109
Chapter 7 Summarizing discussion 139
Samenvatting 147
Summary 149
Acknowledgements 151
Curriculum Vitae 153
Publications 155

1General introduction
CHAPTER 1
CHAPTER 1
2
1
1. Genome evolution as a reservoir of biological information
A complete genome sequence, as a record of evolution, can provide information 
on how sequences change under the constraints of functional association[1, 2], in the 
process of function innovation[3] or under environmental pressure  on cell growth[4, 5]. 
In this introduction, I will give an overview on what kind of genome evolution features can 
be extracted from complete genome sequences and what kind of biological information 
can be inferred from them. 
1.1 Homologs as a rich resource of naturally bio-engineered products 
during evolution
Homologous genes are genes in different species that share an evolutionary 
ancestor and are found to exhibit DNA or protein sequence similarity. Products of 
homologous genes are considered to exhibit a conserved molecular function. Provided 
with the bioinformatics tools to efficiently identify homologs, the surging amount of 
genome sequence data of microbes from various environmental niches presents an 
unprecedented opportunity to discover homologs, from which we can search for gene 
products with a certain desired function modification. One example is the in-depth study 
on different homologs of the Argonaute (Ago) family may led to the discovery of a novel 
genome editing system. Such an Ago-based editing system has the potential to overcome 
the limitation of the Cas9 system that requires the presence of a Protospacer adjacent 
motif (PAM) at the end of the targeted DNA sequence in genomes. This Argonaute (Ago) 
family was first discovered to be guided by single-stranded RNA molecules to interfere 
with RNA, i.e., RNA-guided RNA interference[6]. A later study discovered that the 
prokaryotic homolog Ago of Thermus thermophilus (TtAgo) can conduct DNA-guided 
DNA interference[7]. This made it a candidate to develop into a genome-editing tool 
like the CRISPR-Cas system[8]. The constraint on TtAgo is that the function of TtAgo in 
DNA-guided DNA interference requires a reaction temperature higher than 65°C, which 
impedes the application of this enzyme for editing the mammalian genome. Instead of 
diving into the complicated work of protein structure modification to produce desired 
proteins/modules, one possible solution will be to first make thorough use of what 
nature has created during evolution by screening homology in the diverse microbes and 
find a homolog of TtAgo that does not have the reaction temperature limitation and can 
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be constructed into an effective mammalian genome editing system. 
1.2 Genomic-context features contribute to unravel functional 
relationships between genes
In addition to the identification of homologs of certain genes, one can also 
infer genomic-context features from complete genomes, which are valuable to predict 
functional relationships between genes. Three types of genomic-context features will 
be described in the following text, which are well characterized and widely applied in 
studies ranging from predicting functional interaction between genes to understanding 
how function innovation takes place in an organism. 
1.2.1 The conservation of gene order
One type is the conservation of gene order in evolution[9]. Proteins in prokaryotes, 
involved in the same biochemical pathway or in the same cellular processes, tend to be 
encoded by a cluster of genes that are in close proximity on the genome. Previous studies 
have shown that gene neighbors in prokaryotes with the same transcription direction 
(codirectional) are well conserved in evolution due to the prevalence of operons[10]. 
If genes are in a certain operon-structure in many completely sequenced genomes, it 
is likely that the products of those genes are functionally associated. Identification of 
gene clusters with conserved order in genomes can be applied to i) predict the function 
of genes in a conserved gene cluster where the function of some genes are known, 
and ii) predict physical interactions between proteins encoded by conserved gene 
clusters[11-13]. As a complementary phenomenon to the conserved gene order where 
two genes are codirectionally transcribed, functional relationships were also observed 
between adjacent but divergently transcribed genes[14-16]. The conservation of gene 
order between divergently transcribed genes is informative to infer co-regulation or 
regulatory interaction between conserved gene pairs[17]. Furthermore, the conservation 
of gene order can be extended to the conserved order of protein domains encoded in 
gene clusters. A group of domains with evolutionary conserved order in biosynthetic 
gene clusters (BGCs) for secondary metabolites can be proposed to be used as a bioactive 
Lego brick to facilitate the biosynthetic engineering of BGCs for novel compounds[18, 
19].
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1.2.2 The fusion of genes
The second type of a genomic context feature is gene fusion. Gene fusion is 
a process where multiple separate genes become fused into a single chimeric gene. 
The fused genes can not only preserve their original function but also give rise to new 
functions. For instance, the non-fused ubiquitin E2 variant (UEV) only functions in the 
nucleus, but the fusion with cytoplasmically located protein, KUA, enables the activity of 
UEV in the cytoplasm[20]. Moreover, gene fusion can change the regulatory mechanism 
of the previously separated genes and ultimately affect the biological process. One 
example is the gene fusion between trans-membrane protease serine 2 (TMPRSS2) and 
ETS transcription factor genes, i.e., ERG or ETV1, in human prostate cancer. This gene 
fusion subjects the expression of ETS transcription factors to the regulatory sequence 
of TMPRSS2 and leads to overexpression of these factors, which is deemed to be an 
oncogenic trigger for prostate cancer[21]. More interestingly, systematic identification 
and analysis of gene fusion events in genomes of different organisms revealed that gene 
fusions often occur among genes from the same/similar function category[22, 23]. This 
indicates the potential usage of gene fusion to unravel the function organization and 
linkage between genes[24].
1.2.3 Occurrence patterns of gene content
Another type of genomic feature from which functional relationships can be 
inferred is the variability of gene content between species. Gene content describes the 
presence and absence of genes in genomes of species. The very straightforward feature 
that can be inferred from gene content is co-occurrence of genes in genomes, which 
can be routinely used to predict functional interaction between proteins or to infer 
the function of unknown genes when the function of their co-occurring genes is well 
annotated [11, 25, 26]. An alternative feature that is indicative for function association 
between genes is an anti-correlated occurrence pattern where one gene is present and 
the other one is absent from a genome. A conserved anti-correlated occurrence pattern 
indicates the existence of function overlap between genes[27]. 
One can also use the presence and absence of genes in present-day species to 
reconstruct the gene content of ancestral genomes. Complex evolutionary events can be 
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derived from the reconstructed phylogeny profiles, which depict the gain and loss events 
between ancestral and descendent genomes. One example is the contingent gain event 
of a gene pair (A-B) where gene A will be gained in evolution only if B is already present 
in the genome. Notebaart et al have revealed that this evolutionary event is indicative 
for an asymmetric relationship between genes[28]. An asymmetric relationship between 
two genes (A-B) describes a phenomenon where the function of gene A depends on B, 
but not vice versa. An intuitive example is the functional asymmetry between enzymes 
in a metabolic network where multiple pathways converge to a central pathway. In 
such a situation the enzymes in the converging pathways depend on the enzyme in the 
central pathway but the latter enzyme does not depend on any specific enzymes from 
the converging pathways. The functional asymmetry between these enzymes is indeed 
reflected in the contingent gain events, i.e., the enzyme in the converging pathway is 
more likely to be gained when the enzyme in central pathway is already present in the 
genome[28]. Inspired by this study, in Chapter 2, we systematically explored i) what 
other evolutionary patterns can be inferred from the reconstructed phylogeny profiles 
and ii) what is the predictive power of these evolutionary patterns for different functional 
relationships.
The identification of the aforementioned types of genomic-context features is 
carried out by comparing genomes from different species. The number of whole exome 
sequences of human samples with various diseases is exponentially increasing. This is 
particularly true for the number of sequenced tumor samples.  Analogous to defining 
genomic-context features from the presence or absence of genes in genomes from 
different species, it is possible to obtain genomic-context features from mutations 
detected in human genomes. For instance, co-occurrence and mutual exclusivity have 
been observed among mutants in cancer[29], which are informative for unraveling 
functional relationships among mutated genes and ultimately elucidate the molecular 
mechanisms of diseases[30, 31].
2. Genetic interactions and the applications
Functional relationships have a broad definition, ranging from proteins having 
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physical interaction to genes sharing same regulatory mechanisms. Understanding how 
proteins collaborate with each other, i.e., the functional relationships between proteins, 
is the first step to achieve a complete biological network as an abstract representation of 
cells. Such biological networks provide profound information to elucidate the molecular 
machinery underlying cellular processes, physiological and disease phenotypes[32-34]. 
Here, I will focus on genetic interactions (GIs), which reflect a pervasive functional 
relationship between proteins, and discuss in detail how GIs can contribute to different 
biological research fields. 
2.1 Definition of genetic interactions
GIs describe a phenomenon where the effect of a genetic mutant on a phenotype 
depends on at least one other mutation in the genome. Such a relationship can be either a 
pair-wise or a higher-order one, involving multiple genetic loci. The following description 
of genetic interactions focuses on the pair-wise relationship; however, it can be extended 
to the higher-order one. Two gene loci are defined to have a genetic interaction when 
the simultaneous perturbation of both loci leads to a phenotype that deviates from the 
expected double-mutantphenotype when there is no interaction (Figure 1). The most 
commonly used definition of this expected double-mutant phenotype is the product of 
two single mutant phenotypes. Based on the sign of the deviation, genetic interactions 
can be classified into two classes, negative and positive genetic interactions[35]. A positive 
interaction describes a phenomenon where double-mutant phenotype is less severe than 
expected. Positive genetic interactions occur, for instance, when a mutant of one gene 
disrupts the function of the whole pathway or protein complex, thereby concealing the 
phenotypic consequence of an additional genetic mutant of another member within the 
same pathway or protein complex [36, 37]. Conversely, in a negative interaction, a double 
mutant exhibits a more severe phenotype than the expected neutral phenotype[38]. 
Negative genetic interactions are commonly interpreted as a reflection of the functional 
compensation between two genetic loci[38], for instance, two genes encoding enzymes 
that catalyze parallel pathways in the metabolic network[39], or gene pairs arising from 
gene duplication events and sharing a similar function[40, 41].
Genetic interactions and the applications
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2.2 Importance of genetic interactions
A
A 
& 
B 
(e
xp
ec
te
d)B
ne
ga
tiv
e 
GI
po
sit
vi
e 
GI
G
ro
w
th
 d
ef
ec
t
GI networks
Predicting 
gene function
Identifying
functional modules
Explaining
phenotypic variation
Prioritizing
anti-cancer drug targets
Distribution of f 
SNP arrays: 
CNVs
RNAseq: 
expression variations
homDel
hetDel
normal overE
normal
underE
Cancer
genome evolution
f = 
+ +
predictive featurespredictive features
B B CC
B B CC
more
frequent
less
frequent
A A CC
A A CC
vs vs
A C B
A C B
A C B
negative GI: A & B
A depends on C B depends on C
Genome evolution
nutrients biomass
BIOMASS
B
BIOMASS
B
Avs
High ux
Low ux
Metabolic modeling
negGI vs non negGI
Figure 1 Three methods for GI prediction and the applications of GIs in four biological research fields. In 
this thesis, Chapter 2, 3 and 4 describe a method using genome evolutionary profiles, a method integrating 
features from cancer genome evolution and a method that uses metabolic modeling correspondingly. For 
the method based on genome evolution profiles, one example of a predictive feature is illustrated, i.e., gene 
A will be gained more frequently in evolution when C is already present in the genome than the situation 
where C is absent. By using this evolutionary event, we inferred that the function of A depends on C, but 
not vice versa.  A negative genetic interaction is predicted for gene pair A-B if another gene, B, also depends 
on C. For the method based on cancer genome evolutionary profiles, we can infer the predictive features 
from the CNV and RNAseq profiles. For example, we expected that compared with non-negative GIs, genes 
with negative GIs are less likely to be simultaneously homozygously deleted in tumor tissue samples. This 
can be quantified by fraction f, where a homozygous gene deletion is represented by two dashed lines. This 
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fraction is expected to exhibit a distribution difference between negative GI pairs and non negative GI pairs. 
For the method based on metabolic modeling, we can simulate the overexpression and underexpression of 
the enzyme as flux increase and decrease of the reaction. This method is designed to predict a type of GI 
called synthetic dosage lethality (SDL). An SDL is predicted between an enzyme pair (A-B) if overexpression 
of A in combination with underexpression of B lead to decrease in cell growth. These three methods help to 
the construction of comprehensive GI maps in different species. Such maps play a key role in i) predicting 
the function of uncharacterized genes, ii) identifying functional modules in various cellular processes, iii) 
explaining phenotypic variation and iv) prioritizing anti-cancer drug targets. The bar chart within the middle 
ellipse illustrates the definition of a GI.
A systematic map of genetic interactions plays an important role in many aspects 
of biological study (Figure 1). First, the biological function of uncharacterized individual 
proteins and how they are related to other proteins, complexes or pathways can be 
deciphered from large-scale genetic interaction maps[42]. Tong et al have shown that 
gene products involved in the same complex or pathway often exhibit a similar pattern 
of genetic interactions[43]. If a gene shares a pattern of genetic interactions that is highly 
similar to most members of a functional module, like a protein complex or a pathway, 
this gene is predicted to be a subunit of the complex or pathway. For instance, the 
CSM3 gene was identified to function in S-phase replication checkpoint pathway based 
on the observation that it exhibited a genetic interaction pattern that is most similar 
to DNA replication checkpoint genes MRC1 and TOF1 in yeast[43]. More examples of 
predicting molecular function and determining the association with functional modules 
of uncharacterized genes are described in refs. [42, 44, 45]. 
Secondly, identification of genetic interactions is also a powerful method to 
delineate how functional modules cooperate to mediate certain cellular processes, 
such as cell growth, proliferation and evolutionary adaption to genetic or environmental 
perturbations. Functional modules, which are usually composed of a group of functionally 
associated proteins, can be inferred from physical interaction or genomic context 
information. However, it still remains unclear i) whether there are sub modules within 
a large functional module, ii) how different modules are organized to function in certain 
cellular processes. Regarding the first question, multiple studies revealed that genes 
within a functional module usually exhibit similar genetic interaction patterns. Thus, 
applying clustering algorithms to a genetic interaction map for genes of a functional 
module can detect functional sub-modules whose member proteins exhibit a more 
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similar genetic interaction pattern with each other than with the rest of the proteins. One 
example is the Mediator multi-protein complex[46] that functions as a transcription co-
activator in eukaryotes. This complex consists of four distinct sub-modules, i.e., the head, 
middle, tail and CDK modules[47, 48], which can be accurately distinguished from each 
other based on the shared similarity of genetic interaction profiles[37]. Another example 
is that sub-complexes from the 26S proteasome, namely alpha- and beta- rings and the 
regulatory particles, can be clearly separated from each other based on distinct genetic 
interaction patterns[49]. Concerning the second question, measuring genetic interactions 
between components from different modules can provide insight into their functional 
organization. Observing the enrichment of genetic interactions between complexes of 
ER-Golgi and intra-Golgi traffic, and between complexes of intra-Golgi and post-Golgi 
traffic, but not between complexes of ER-Golgi and post-Golgi traffic, Schuldiner et al 
assigned sequential dependency between stages of vesicular trafficking, i.e., ER-Golgi 
traffic à intra-Golgi traffic à post-Golgi traffic[45].
Thirdly, successful identification of genetic interactions can help to disentangle 
the relationships between genotypes and phenotypes. A long-standing issue in genetic 
study is the ‘missing heritability’, where genetic mutants identified by the additive model 
fail to explain the majority of phenotypic variation[50]. There are several mechanisms 
proposed to explain how genetic interactions affect the heritability. The first possible 
explanation for the ‘missing heritability’ is that the model used to estimate the total 
heritability generally assumes that no genetic interactions underlie phenotypic traits. Zuk 
et al showed that such a model can lead to an inflation of estimated total heritability and 
consequently result in the missing heritability issue [51]. Moreover, it has also been shown 
that interactions between genetic loci indeed contribute to the heritability[52], although 
the proportion of the heritability that they explain is not high, 9% on average[53]. The 
third mechanism is that the contribution of one genetic locus to the additive genetic 
variance depends on its allele frequency. With genetic interactions, the allele frequency 
of a genetic variant can be affected by the mutation status of its interaction partner. 
This indicates that one may need to correct the observed allele frequency of genetic loci 
for genetic interactions and use the corrected allele frequency to estimate the additive 
genetic variance[54, 55].
Last but not least, a direct clinical application is that synthetic lethal (SL) 
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interactions, in the extreme case of negative genetic interactions, can provide therapeutic 
treatment strategies for complex human diseases such as cancer. The underlying concept 
is that in an SL pair (A-B), a mutation of one (A) gene in tumor cells but not in normal cells, 
renders the opportunity to selectively kill tumor cells by inhibiting B. The first clinical 
application of synthetic lethality in cancer treatment is the BRCA1/2-PARP (poly(ADP-
ribose) polymerase) synthetic lethality where BRCA1/2 deficient tumor cells are 
selectively depleted by PARP inhibitors[56, 57]. Inhibiting PARP function in the absence 
of normal BRCA1/2 may cause persistent chromatid breaks, leading to cell cycle arrest 
and/or cell lethality[58]. In clinical trials, PARP inhibitors, such as olaparib, not only are 
administered safely but also can significantly inhibit the tumor growth in breast, ovary or 
prostate tumor patients with a BRCA1/2[59, 60] mutation. Alongside the improvement in 
genetic screening approaches for identifying SL interactions, multiple novel targets have 
been identified and their effect on selectively inhibiting the growth of tumor cells have 
been verified in vitro and/or vivo[61, 62]. The promise of these examples established a 
novel paradigm of personalized anti-cancer drug development.
3. Identification of genetic interactions
Systematic screens for genetic interactions have been performed in model 
organisms such as Saccharomyces cerevisiae[42, 43, 45] and Escherichia coli[63, 64]. 
Given the importance of GIs in congenital disease, GI screens have also been carried 
out in metazoa, such as Caenorhabditis elegans, Drosophila melanogaster, mouse and 
human cell lines[44, 65-69] albeit not on a genome scale. The scale limitation is due to 
two reasons. First, the experimental techniques developed in model organisms are not 
easily applicable in higher eukaryotes. Secondly, the enormous number of pair-wise GIs 
make it infeasible and expensive to generate a genome-wide GI map. In this context, 
as an effort towards the accomplishment of a systematic GI map in different species, 
several computational methods have been developed to predict genetic interactions. 
This section focuses on the introduction of the available computational tools to predict 
genetic interactions. Since empirical GIs are used as sources of training data for most 
computational methods, this part begins with a brief description of experimental 
techniques for GI identification and the available GI databases.
Identification of genetic interactions
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3.1 Experimental techniques to identify genetic interactions
For unicellular model organisms, i.e., S.cerevisiae and E.coli, there are mainly two 
different high-throughput platforms for experimentally identifying GIs. The first platform 
is a synthetic genetic array (SGA)[43, 67], which automates the systematic construction 
of double mutants by crossing a query deletion mutant to an array of deletion mutations. 
In SGA, the colony sizes of double and single mutant strains are measured. A negative 
genetic interaction is determined if a double mutant leads to a more severe growth 
defect than the expected growth defect of the two single mutants combined. The other 
platform is diploid-based synthetic lethality analysis with microarrays (dSLAM)[70], where 
deletion mutants are tagged by the unique molecular barcodes and a microarray-based 
technique was developed to measure the relative growth rate of the double mutants 
compared to the single mutants. 
Large-scale screening of genetic interactions has also been implemented in 
metazoan model systems, i.e., the nematode C. elegans[71, 72] and the fruit fly D. 
melanogaster[68]. To obtain double mutants, RNA interference (RNAi) is utilized to 
reduce the expression of two genes. Instead of focusing on the growth defect, the studies 
in C.elegans and D.melanogaster measured a broader range of phenotypes, including cell 
number, nuclear areas and wing morphologies. 
In human cell lines, the studies generally aim to identify genes having a SL 
interaction with specific genes of interest, such as TP53, VHL and many other cancer 
genes. To identify these interactions, shRNA/RNAi-mediated screens are performed in 
isogenic cell lines, where the gene of interest is mutated, and in wild type cell lines[73]. 
The induced growth defect is quantified to infer negative genetic interactions.  Another 
available method for GI identification is via combinatorial GI interactions[69], which 
cross two arrays of RNAi mutants to create double mutants. The RNAi-mediated screen 
platform is used as a routine technique in GI identification. Nevertheless this technique is 
hampered by the possible off-target effect and the temporary function inhibition effect. 
The most recently developed genome editing technique, CRISPR-Cas9[74, 75], which can 
be applied to precisely recognize a target site on the genome and delete and/or insert 
a gene to a genome, bears the potential to largely improve the coverage, efficiency and 
precision of GI identification in human.
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3.2 Databases curating experimentally identified GIs
The empirically identified GIs are curated in multiple databases according to 
the species studied. For S.cereviseae and E.coli, the most comprehensive databases are 
BioGrid[76] and DRYGIN[77]. In addition to BioGrid, DroID[76] is the database specific for 
GI information in D.melanogaster. SynLethDB[78] comprehensively curates SL interaction 
in human, where most are synthetic lethal interactions identified in cancers. From these 
databases, users can retrieve both information of the interaction such as the interaction 
type and score, and the biological description of the genes in the interaction.
3.3 In-silico methods to identify genetic interactions
Provided with the high-throughput empirical identifications of genetic 
interactions, researchers started to characterize the biological and topological properties 
of genetic interactions on both pair-wise and network levels. By exploiting the relationship 
between GI networks and various types of biological networks such as biological process, 
protein-protein interaction (PPI) and phenotype networks, proteins encoded by genes 
with SL interactions are more likely to have a high number of physical interactions and 
shared physical interactions [79] than non-SL pairs. Also, GIs are enriched in genes 
that cause similar mutational phenotypic patterns, have an overlap of gene ontology 
annotations and function in the same protein complexes or pathways[79-81]. 
Such characterizations of genetic interactions provided pivotal sources to develop 
in-silico tools to discriminate GI pairs from non-GI pairs. In principle, the majority of the 
available computational methods are designed in two steps. The first step is to extract 
the predictive features from various types of biological data of a training set. A training 
set is usually composed of experimentally identified GI pairs and non-GI pairs. Predictive 
features regarding the training set are mostly quantified from genomic datasets, such 
as gene expression, PPI, gene ontology annotations and sequence similarity profiles. 
The next step is to use machine-learning algorithms to train the predictive models via 
integrating all extracted features. The predictive performance of the trained models 
can be evaluated by methodologies such as cross-validation or parameters including 
precision, recall, and area under the receiver operating characteristic (ROC) curve.
Identification of genetic interactions
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3.3.1 Predicting GIs in model organisms
Wong et al[82] developed the first GI prediction model for S.cerevisiae. In 
addition to pair-wise function relationships identified from various types of data such 
as co-localization in cellular compartments, co-expression, physical interaction, gene co-
occurrence and conserved gene neighborhood, they expanded the function relationship 
data pool by investigating 2hop features between gene pair A-B. A 2hop feature is the 
functional relationship between A-B inferred through a third gene C. For instance, A-B 
is predicted to have a GI if a physical interaction exists between A-C and a GI is found 
between B-C. In total, 123 functional relationships were integrated by a decision tree 
machine-learning algorithm, which achieved a prediction accuracy of 31%. However, 
including the 2hop relationships, especially those involving GIs, limited the applicability 
of the method to organisms with little GI information. To reduce the dependency of 
the prediction model on the availability of GI data, Pandey et al[83] explored various 
machine-learning algorithms and proposed an ensemble-based model for effective GIs 
predictions, which in principle simultaneously employed prediction results from multiple 
classifiers. This model, which integrated 152 GI-independent features, outperformed the 
prediction performance of the previous method. For multicellular organisms, a logistic 
regression model is trained on various genomic data[84] to generate a GI map, consisting 
of 18,183 interaction pairs in C.elegans. To enrich the genome coverage of the predictive 
features in C.elegans, they transferred functional relationships of gene pairs, such as 
microarray co-expression and PPI, from fly and yeast to worm via orthology mapping. 
For model organisms, several other efforts have been subsequently taken to 
improve the prediction performance in various model organisms either via optimizing 
the machine learning algorithms [85-87] or by identifying and extracting novel predictive 
features, such as protein domains that are enriched with genetic interactions[88] and 
phenotypic similarity between gene mutations[89, 90]. 
3.3.2 Predicting GIs in human
More recently, the nourishment of genomic and phenotypic data measured in 
human presented a great opportunity to develop models for directly predicting GI in 
human. Taking the full advantage of the diverse types of data, such as DNA, RNA sequencing 
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and clinical phenotypes, measured in a tremendous number of tumor samples from 
patients of The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/), DAISY[30], 
a method to predict SL interactions in cancer, was developed by integrating genome-scale 
copy number variations (CNV), single nucleotide variations (SNV), gene essentiality and 
co-expression data measured in tumor samples. The hypothesis that the development of 
DAISY is based on, is that compared with non-SL gene pairs, genes in SL interactions are 
more likely to be over-expressed to compensate for the loss of function mutations in the 
corresponding SL partner genes. 
4. Outline of the thesis
The ultimate goal of this thesis is to develop computational tools for genetic 
interaction prediction, which can i) facilitate the accomplishment of a genetic interaction 
map for different species and ii) prioritize or narrow down the search space for effective 
anti-cancer drug targets (Figure 1). Disentangling the evolutionary relationship between 
molecules can provide insight in their functional relationships. In Chapter 2, we 
developed an innovative method for GI prediction in yeast and human by integrating 
multiple evolutionary patterns inferred from reconstructed phylogenetic profiles. The 
method first identified the asymmetric functional relationship between a gene pair (A-
>C), where A depends on C but not vice versa. Analogous to the converging pathways in a 
metabolic network, a negative genetic interaction is predicted for gene pair A-B if i) A and 
B both depend on C and ii) there is no functional asymmetry between A and B. 
Chapter 3 describes a method that predicts synthetic lethality in human by 
exploiting cancer genome evolution. We first extracted signals from genomic data of 
tumor patient samples with the expectation that SL pairs are less likely to be co-lost 
from genomes than non-SL pairs and that genes are more likely to be over-expressed 
when their SL partner is under-expressed. I constructed an ensemble-based model to 
integrate these predictive features and I present a human genome-scale SL interaction 
map containing 591,000 gene pairs.
In Chapter 4, a metabolic network modeling based method is developed to 
predict a different type of genetic interaction called synthetic dosage lethality (SDL). 
Outline of the thesis
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SDL describes a phenomenon where the overexpression of one gene together with an 
underexpression of another gene results in lethality. The identification of such type of 
genetic interactions is particularly therapeutically attractive for cancer patients with 
oncogenic mutations. Many oncogenes in cancer are also found to be essential in 
sustaining the growth of normal cells. Thus, rather than designing drugs to inhibit the 
oncogenes, their SDL partners appear to be more pharmacologically suitable targets 
since their inhibition can specifically kill tumor cells but not the normal cells. To this 
chapter, I designed and applied two validation analysis of predicted SDLs and found that 
i) enzymes in SDLs with an overexpressed partner are indeed more likely essential for cell 
growth, and ii) SDL pairs are less frequently active in cancer cells. An SDL pair is defined 
to be active when one gene is over-expressed and the other is under-expressed.
One main challenge for the effective treatment of cancer is the prevalent genetic 
heterogeneity, which exists on cancer type level, on patient level and on tumor cell level. 
As an effort to overcome this challenge, we constructed a database in Chapter 5, which 
predicts drug targets in a specific tumor type or on a personal level. The database compiled 
a comprehensive SL interaction list directly identified in human, either computationally 
or experimentally. Moreover, to facilitate the experimental design for in-vitro test of the 
targets, our database can propose suitable test and control cell lines that are genetically 
representative for the cancer type of interest. 
We showed in Chapter 2 and Chapter 3 that genome evolutionary profiles are 
informative to infer the functional relationships between genes. In Chapter 6, I applied 
a genome evolution analysis to test a specific hypothesis with respect to how organisms 
evolve complex metabolic networks. The hypothesis is that complex metabolic networks 
can arise via a purely adaptive process by gaining a gene/enzyme in one environment, 
which allows adaptation to that environment and provides a stepping-stone to adapt to a 
second environment. The existence of such stepwise expansion of the metabolic network 
has been demonstrated in Chapter 6 by three lines of evidence: i) metabolic modeling, ii) 
adaptation of laboratory populations and iii) the evolutionary history of genes. I applied 
phylogenetic analysis of bacterial genomes and found that the acquisition patterns of 
enzymes across evolutionary history support the stepping-stone adaptation hypothesis.
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Abstract
Genetic interactions reveal insights into cellular function and can be used 
to identify drug targets. Here we construct a new model to predict negative genetic 
interactions in protein complexes by exploiting the evolutionary history of genes in parallel 
converging pathways in metabolism. We evaluate our model with protein complexes of 
Saccharomyces cerevisiae and show that the predicted protein pairs more frequently 
have a negative genetic interaction than random proteins from the same complex. 
Furthermore, we apply our model to human protein complexes to predict novel cancer 
drug targets, and identify 20 candidate targets with empirical support and 10 novel 
targets amenable to further experimental validation. Our study illustrates that negative 
genetic interactions can be predicted by systematically exploring genome evolution, and 
that this is useful to identify novel anti-cancer drug targets. 
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1. Introduction 
Knowledge of how proteins interact with each other to exert their function is 
crucial for understanding how disruption of interactions can lead to disease [1, 2] and 
in the development of treatments. In recent years, several system-level maps of protein 
complexes have been constructed from physical interaction data [3-5] to initialize 
understanding of the functional relationships between proteins. These studies are 
important in identifying which proteins are linked to each other in biological processes 
[6]. Yet, these maps do not directly reveal how the proteins interact with each other. More 
specifically, they do not provide information about whether the interaction between two 
proteins is symmetric, in which both proteins are equally important in the function of 
a protein complex, or whether the interaction is asymmetric, in which one protein can 
function in the absence of the other protein, but not vice versa (Figure 1a). One example 
of such asymmetry is the cyclin-Cdc28 complex where the function of the cyclin, Cln1p, 
depends on the Cdc28 kinase, but not vice versa. The function of Cln1p depends on 
Cdc28p since transcriptional activation of CLN1 requires an active Cdc28 kinase[7]. The 
function of Cdc28p, however, does not depend on Cln1p since the presence of Cln2p 
compensates for Cln1p’s absence to activate Cdc28p[8]. Thus, there is a functional 
asymmetry between Cln1p and Cdc28p, where Cln1p depends on Cdc28p and not 
vice versa (Cln1pàCdc28p). Similarly, there is asymmetry between Cln2p and Cdc28p 
(Cln2pàCdc28p). This example shows the relationship between functional asymmetry 
and what is called a negative genetic interaction, where mutations (for example, 
knockout) of two genes (for example, CLN1 and CLN2) reduce the fitness much stronger 
than would be expected based on the decline in fitness of each gene individually[9]. 
The concept of negative genetic interactions is very valuable in the development of 
therapeutic treatments for diseases that can be treated by selectively depleting cells with 
a disease causing mutation. Especially promising are the discoveries of cancer drugs that 
target proteins having synthetic lethal interactions with mutated oncogenes or tumor 
suppressor genes[10, 11]. The mechanism underlying this treatment is that inhibiting 
these genes separately is relatively harmless in a normal cell while it is lethal to a cancer 
cell since it causes a lethal double mutant with mutated oncogenes/tumor suppressor 
genes. Thus, targeting these genes can kill the cancer cells while leaving the normal cells 
relatively unaffected. Prioritizing drug targets in such an approach, by predicting negative 
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genetic interactions between the mutated oncogenes/tumor suppressor genes and other 
proteins, is however not trivial.
Discovering negative genetic interactions mainly depends on laborious and 
specific experiments, which can be expensive and time-consuming, partially because 
of the explosion of the number of pairwise gene combinations. Several computational 
approaches have been developed to predict genetic interactions by integrating multiple 
types of functional genomic data, such as synthetic lethality data, physical interaction 
data and co-expression data [12, 13]. These approaches, however, strongly depend on 
species-specific empirical genetic interaction data as input and therefore do not allow 
predictions for other species where genetic interaction data are largely unavailable.
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Figure 1 Functional asymmetry and negative genetic interactions are linked. (a) Protein A and B have an 
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asymmetric functional relationship, where the function of A depends on B but not vice versa. The asymmetry 
between protein A and B can be due to the presence of protein C, which can compensate for a mutant of 
A. In such a scenario protein A and C are predicted to have a negative genetic interaction. (b) Functional 
asymmetry between enzyme A and B involved in a branched pathway in a metabolic network (A depends 
on B, but not vice versa: AàB). Nodes and arrows represent metabolites and reactions, respectively. The 
asymmetric relationship is due to a converging reaction catalyzed by enzyme C which can compensate for 
A’s absence. Thus, enzyme A and C are likely to have a negative genetic interaction. (c) Flowchart to predict 
negative genetic interactions from genome evolution within a three-member protein complex (protein A, 
B and C). The blue arrow represents the functional asymmetry between two genes inferred from genome 
evolution. The blue line represents that there is no evolutionary evidence for a functional asymmetry between 
two genes. Here, both gene A and C are predicted to have functional asymmetry with B, while gene A and C 
are predicted not have functional asymmetry.
Here, we aim to predict negative genetic interactions in protein complexes 
via the concept of functional asymmetry, which we infer from genome evolution. The 
example of the cyclin-Cdc28 complex showed that functional asymmetry and negative 
genetic interaction are linked. This linkage can also be illustrated by enzyme relationships 
in metabolism. Enzymes in converging pathways have asymmetric relationships with 
an enzyme in an outgoing pathway [14, 15] (Figure 1b). Consequently, the enzymes in 
converging pathways can have negative genetic interactions, as they can compensate for 
each other’s absence. Analogous to metabolism, we expect that two proteins in a complex 
with asymmetry to a third protein will have a negative genetic interaction (Figure 1a and 
1c). Importantly, the functional asymmetry between enzymes in metabolism is indeed 
reflected in genome evolution[15, 16].
On the basis of these prior studies we have developed an evolutionary model 
to predict asymmetric functional relationships and negative genetic interactions in pro-
tein complexes in Saccharomyces cerevisiae[17]. Our model predicts that almost 75% 
of the protein complexes in S. cerevisiae contain functional asymmetric protein pairs. 
By integrating the information of predicted asymmetry in protein complexes, we show 
up to 2-fold increase in the predictive power for negative genetic interactions relative 
to randomly chosen protein pairs from a complex. Moreover, our results show a 2-fold 
increase in prediction precision compared to an alternative model [18]. After mapping 
negative genetic interaction predictions from yeast to human as well as a direct applica-
tion to human protein complexes, we predict 20 cancer drug targets with empirical sup-
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port and 10 completely novel targets not yet experimentally examined. Our study shows 
that higher-order functional relationships can be predicted by systematically exploring 
genome evolution, thereby providing a framework to interpret protein complex function 
with broad application to medical genetics.
2. Results
2.1 Functional asymmetry occurs frequently in protein complexes 
In order to examine if patterns in genome evolution can be used to predict 
negative genetic interactions, we first predicted asymmetry between protein pairs (A-B) 
in protein complexes from evolutionary analysis. We constructed a model integrating 11 
evolutionary variables from the reconstructed ancestral states on a phylogenetic tree 
of 373 species (Figure 2 and methods). For instance, evolutionary asymmetry between 
proteins A and B is inferred from the occurrence of multiple evolutionary loss events 
where only one of the two genes was lost in the descendant while both genes were 
present in the ancestor. If A is more frequently lost than B, then A is expected to be 
functionally dependent on B (AàB, see Figure 2a, b, scenario f1). The model was trained 
on a set of functionally asymmetric enzyme pairs in the genome-scale metabolic network 
of S. cerevisiae[19] to predict the dependency between two enzymes (see method for 
detail). Using a 10-fold cross-validation the model showed a correct classification rate 
of 64.4% and an area under the receiver operator characteristic (ROC) curve of 0.7 (see 
methods for details; Supplementary Figure S1). It should be noted that the performance 
of the model becomes worse when using a simpler model with only single gain and loss 
events (Supplementary Figure S1). We next asked how frequently functional asymmetry 
occurs in empirically determined protein complexes from S. cerevisiae[17]. Our analysis 
predicts that 71% (6145 out of 8711) of the protein pairs in these protein complexes 
are functionally asymmetric. Furthermore, approximately 75% (307 out of 409) of the 
protein complexes are found to have at least one predicted functionally asymmetric 
protein pair (Supplementary Figure S2).  
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Figure 2 Evolutionary variables to predict functional asymmetry. (a) Depiction of an evolutionary event. It 
shows a loss of gene A in the descendant (d) when both A and B are present in the ancestor (a). (b) Evolutionary 
variables used for the Bayesian classifier. The evolutionary variables across history of the dependent protein 
A in an asymmetric pair (AàB) can be expressed via 11 measures, listed in the first columns of two boxes. 
Of these 11, six count the number of times that a dependent protein A is gained or lost independently of 
B, including two that are expected to occur less often and four that are expected to occur more often for a 
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asymmetry (Supplementary Figure S1). (c) Schematic presentation of predicting the functional asymmetry in 
a protein pair (A-B). A TAN classifier was trained on functionally asymmetric enzyme pairs in the metabolic 
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by applying a cutoff on probability (α=max(α
1
, α
2
), see methods). The same procedure is applied to protein 
B. By combining the prediction of both, A-B can be either AàB where A is dependent and B is independent, 
BàA where A is independent and B is dependent, or no evidence for asymmetry when A and B have any other 
combination of predicted relationship. 
2.2 Empirical evidence for functional asymmetry 
The high frequency of predicted functional asymmetry triggers the question 
to what extent our predictions are biologically meaningful. To answer this question we 
asked whether predicted asymmetry is reflected in genome-scale empirical data. We 
first examined asymmetry in gene essentiality. For a predicted functionally asymmetric 
pair (AàB) where only one of the proteins is essential, we expect protein B to be the 
essential one. To test this, we examined those predicted asymmetric pairs where only 
one of the encoding proteins is essential and quantified to what extent the predicted 
asymmetry is consistent with asymmetry in gene essentiality. Our analysis reveals that 
72% (1071 out of 1497) of the asymmetric pairs (AàB) are consistent with asymmetry 
in gene essentiality, i.e. if one of the two genes is essential, it is B (Figure 3a; one-tailed 
Fisher exact test; P < 2.2e-16).
Many predicted asymmetric pairs have, however, no asymmetry in gene 
essentiality, simply because the majority of proteins are not strictly essential under 
standard laboratory conditions (that is, glucose rich medium)[4]. Approximately 40% of 
the predicted asymmetric pairs are composed of two non-essential genes. Nevertheless, 
even when proteins are non-essential they can still contribute to fitness and result in 
significant growth defects after a gene knockout[20, 21]. Similarly to the gene essentiality 
analysis, we expected that if one of the two proteins in a predicted asymmetric pair 
(AàB; both non-essential) has a stronger growth defect, it would be protein B. To test 
this, we examined 511 predicted asymmetric pairs where two non-essential proteins 
cause different growth defects, and quantified the consistency between the predicted 
and empirical functional asymmetry. As expected, 63% (322 out of 511) of the cases are 
consistent (Figure 3a; one-tailed Fisher exact test; P = 1.40e-04), that is, the predicted 
independent protein B has a stronger growth defect when knocked-out. This consistency 
is robust at various cutoffs on empirical growth defect differences (ranging from 0.0001-
0.3). Notably, the level of consistency increased from 63% to 67% when we increased the 
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cutoff to 0.3, that is, where growth defect difference is largest. These results show that 
the evolutionary model is able to capture asymmetric functional relationships in protein 
complexes. ESCRT-I, a protein complex functioning in cargo selection in the multivesicular 
body (MVB) sorting pathway, is one example where the predicted functional asymmetry 
is supported by solid empirical evidence (Figure 3b).
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Figure 3 Asymmetric functional relationships and negative genetic interactions. (a) Empirical support for 
predicted functional asymmetry in gene essentiality[49] and, for non-essential genes, in the growth defect of 
single gene knockout [20, 21]. For predicted asymmetric pairs (AàB), the fraction f
AB
 (f
01
=n
01
/(n
01
+n
10
)), where 
0=non-essential or no fitness defect and 1=essential or substantial growth defect is expected to be larger 
than 0.5 (fraction in pairs with no asymmetry). (b) One example of predicted functional asymmetry with 
experimental support. ESCRT-I is composed of 4 members, Vps23p, Vps28p, Vps37p, and Mvb12p. Mvb12p 
(blue subunit) is predicted to functionally depend on Vps23p, Vps28p, and Vps37p (red) and not vice versa. 
Structural studies revealed that the functionally dependent subunit, Mvb12p, is a structural stabilizer, which 
changes the ESCRT-I core complex (Vps23p, Vps28p, Vps37p) from a fan-shaped structure (upper panel) to an 
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elongated structure (lower panel) [57]. First, the dependency of Mvb12 on the core complex is supported by 
the fact that Mvb12p is unstable in cells lacking any of the other ESCRT-I subunits[58]. Secondly, that Vps23p, 
Vps29p and Vps37p do not strictly depend on Mvb12p is validated by the findings that certain MVB sorting 
pathways, such as carboxypeptidase S (CPS) and Ste2 sorting, are effective even if Mvb12p is absent[58, 59]. 
However, loss of function of Vps23p, Vps28p or Vps37p results in a complete block of the MVB pathway[58]. 
(c) Enrichment of negative genetic interactions in fan-in motif A-C pairs. The fraction of negative genetic 
interaction is defined as f=N
neg
/(N
neg
+Npos+NnoInteraction). P-values in (a) and (c) were calculated with a one-tailed 
Fisher exact test and visualized with an asterisk (*) that stands for a p-value smaller than 0.05.
2.3 Empirical evidence for negative genetic interactions
An asymmetric functional relationship observed between two proteins A and B 
can also be linked to a type of relationship known as a negative genetic interaction[9]. 
The reasoning behind this is that B may not depend on the presence of A, because of the 
presence of another protein C that compensates for A’s absence. We asked whether our 
evolutionary model is capable of predicting such negative genetic interactions in multi-
member protein complexes. We specifically focused on triplets where protein A, B and C 
are predicted to have an evolutionary fan-in motif (Figure 1a). This motif is characterized 
by i) A and C depend on B, but not vice versa and ii) A does not depend on C and vice 
versa. This motif is analogous to converging pathways in metabolism, in which there is 
a mechanistic explanation for the compensatory effect between A and C (Figure 1b). 
We therefore first investigated to what extent converging metabolic pathways [15, 21] 
show negative genetic interactions [20-28] as a proxy for compensation, that is, double 
mutants cause more severe growth defects than expected from the two single mutants. 
Indeed, enzyme pairs in converging pathways show a 3-fold enrichment in negative 
genetic interactions compared to non-converging enzyme pairs (Figure 3c; one-tailed 
Fisher exact test; P = 2.42e-11). 
Given this result we expect that in cases where we predict a fan-in motif within 
a protein complex, the A and C proteins have negative genetic interactions with each 
other. To address this we compared fan-in A-C pairs with randomly chosen pairs from 
the same protein complex (i.e., non-motif A-C pairs). Our results reveal that the fraction 
of negative genetic interactions increases by 50% when applying the evolutionary motif 
(from 23.5% to 35.8%; one-tailed Fisher exact test; P = 0.00085; Figure 3c). It should be 
noted that this enrichment of negative genetic interactions is not due to the functional 
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complementation by homologous genes resulting from intra complex gene duplications, 
since the results are hardly affected by removing homologous gene pairs (from 22.7% 
to 33.0%; one-tailed Fisher exact test; P = 0.012; Figure 3c). Since protein complexes 
are not necessarily active in standard laboratory conditions where genetic interactions 
have been measured, we expected that our test underestimates the predictive power. 
Indeed, when selecting for only protein complexes that are active in the cell (that is, B 
is essential) the predictive power even doubles (from 24.5% to 49.2%; one-tailed Fisher 
exact test; P = 4.39e-05; Figure 3c). Thus, the evolutionary model can predict protein 
pairs that have a negative genetic interaction significantly and substantially more often 
than random pairs from protein complexes. To further assess the performance of our 
model, we compared the prediction precision and sensitivity of it with a model by Pandey 
and co-workers [18] by mapping their results to the protein complexes. This model has 
the highest known prediction accuracy and is also independent on genetic interaction 
information as input. Interestingly, our model has a two-fold higher prediction precision 
(precision - TruePositives/TruePositives+FalsePositives: 0.36 versus 0.18; sensitivity – 
TruePositives/TruePositives+FalseNegatives: 0.47 versus 0.78). Notably, our model still 
has a precision of more than 0.3 when parameterized to the same sensitivity as Pandey’s 
model (Supplementary Figure S3).
In total, our model predicted 273 A-C pairs in evolutionary fan-in motifs in S. 
cerevisiae protein complexes, for most of which (60%) a genetic interaction has not been 
measured. However, to provide empirical evidence for the predicted negative interactions 
we exploited available genetic interaction data in Schizosaccharomyces pombe and 
Drosophila melanogaster via orthology definitions from STRING7.0[29]. Following 
this approach we found that for 10 out of our A-C pairs a genetic interaction has been 
experimentally found in either in S. pombe or in D. melanogaster and, as expected, most 
cases (8/10) show a negative genetic interaction in those species (Supplementary Data 
1).
2.4 Negative genetic interactions reveal cancer drug targets
The screen for negative genetic interactions has been shown to be a valuable 
strategy in the search for candidate cancer drug targets [10, 30]. The common approach 
is to find proteins that have a negative genetic interaction with either an oncogene 
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or a tumor-suppressor gene. Since mutations in these genes cause cancer, the idea is 
that mutations in their negative genetic interaction partner would inhibit cancer cells 
to grow (i.e., synthetic lethality) and leave normal cells relatively viable. Although a 
number of promising examples have been reported to target cancer cells via synthetic 
lethality[10, 11, 30], discovering genetic interactions by experimental approaches is very 
labor intensive. Therefore, we asked whether our model captures conserved genetic 
interactions between S.cerevisiae and other species like D. melanogaster, such that it 
can serve as a framework to establish genetic interactions for medical genetics. Based 
on the ortholog profiles from STRING7.0[29], we found 90.1% (246 out of 273) of the 
predicted fan-in motifs in yeast are conserved in D. melanogaster, i.e., all three genes in 
a fan-in motif are present in D. melanogaster. Of these, 9 have been examined for genetic 
interaction in D. melanogaster [31-33], and all show negative genetic interaction (note, 
7/9 have also been found in S.cerevisiae). This suggests that our model can be used to 
predict negative genetic interactions in other species, such as mouse or human, which 
could provide a basis for prioritizing drug targets.
60: E in cancer
18: NE in cancer
15: unknown
Essentiality prole 
for C in cancer cells
20: NE in normal cell
40: E in normal cell
6: NE in normal cell
5: E in normal cell
4: unknown
Essentiality prole 
for C in normal cells
E = Essential
NE = Non-Essential
6:  A mutated in the same cancer cell line
10: A mutated in the same cancer type
4: unknown
Mutation information for A in cancer cells
93 predicted 
targets
A B
Cneg
C: predicted target
A: mutated oncogene/
  tumor suppressor gene
Figure 4 Prioritized cancer drug targets with empirical support. 30 prioritized cancer drug targets. The 
numbers in red represent the 30 promising targets. The numbers in grey represent the genes that failed to be 
targets since they are either non-essential in cancer cells or are essential in normal cells. In total, 93 genes are 
predicted to have a negative genetic interaction with a cancer-related gene. By examining gene essentiality 
in cancer and non-essentiality in normal cells, we prioritized 30 cancer drug targets. 20 cases are essential 
in at least one cancer type, i.e., breast, ovary or pancreas and non-essential in normal cells. Experimentally 
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detected genetic variation/over-expression of the cancer-related gene and the RNA interference of the 
predicted targets in the same cancer type or the same cancer cell line were combined suggesting a double 
mutant. For most of these (16/20), there is empirical evidence that the cancer-related gene is mutated in 
either the same cancer type or the same cancer cell line as the predicted targets (blue column). For 6 cases 
that are confirmed to be non-essential in normal cells, the essentiality in cancer still needs to be examined 
experimentally. For 4 cases, the essentiality in both cancer cells and normal cells is not yet measured (red 
numbers in the pink column). 
To achieve the highest coverage, we combined two strategies to predict cancer 
drug targets; i) by using orthology mapping from predicted negative interactions from 
yeast to human and ii) by a direct application of our model to human protein complexes 
[34, 35]. By using orthologs of the genes in the predicted fan-in motifs in yeast, we 
predicted ~250 novel negative genetic interaction pairs in human, of which 36 involve a 
cancer-related gene (oncogene or tumor suppressor gene)[36]. Notably, most of these 
pairs (83.4%, 30/36) have not been reported before as negative genetic interactions. 
To apply our method directly on human protein complexes [34, 35], we first trained 
our model with functional asymmetric enzyme pairs from the human genome-scale 
metabolic network [37](see methods). Then we used the model to predict negative 
genetic interaction pairs. Totally we predicted 1012 gene pairs with negative genetic 
interactions of which 57 involve a cancer-related gene. Thus, totally, we predicted 93 
cases with cancer-related genes. The genes that have a negative genetic interaction with 
these cancer-related genes are potential drug targets if they are essential in cancer cells 
while non-essential in normal cells. By examining gene essentiality in cancer cells[38] and 
non-essentiality in normal cells of Mus musculus (mouse), D. melanogaster or Danio rerio 
(zebrafish) (Supplementary Data 2), we found that 30 out of the 93 involve promising 
cancer drug targets (pink column in Figure 4, Supplementary Data 2). Among these 30 
prioritized targets, 20 have been found to be essential in at least one cancer type, i.e., 
breast, ovary or pancreas, and non-essential in a model organism (pink column in Figure 
4). Interestingly, most of these predicted targets (16/20) are essential in the exact cancer 
type where their negative genetic interaction partners, the cancer-related genes, are 
reported to be mutated or overexpressed (blue column in Figure 4, Supplementary Data 
2). This empirical evidence suggests that the lethality of the cancer cells by knockdown 
of the predicted target gene is actually caused by a lethal double mutant of the predicted 
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targets and the cancer related-gene. As expected, when considering only those cases for 
which essentiality is measured in cancer cells (i.e., 60+18 cases, green column in Figure 
4), the predicted targets are more likely to be essential in cancer and non-essential in 
normal cells compared to non-motif gene pairs (fraction
E_cancer+NE_normal
=0.26 vs. 0.12, 
one-tailed Fisher exact test; P = 4.8e-04). The remaining 10 targets have not yet been 
experimentally examined for the essentiality in cancer cells: 6 are non-essential in M. 
musculus or D. melanogaster, 4 have not yet been measured (pink column in Figure 4, 
Supplementary Data 2). Thus, we predicted 30 potential drug targets in total, that is, 
20 with empirical support of essentiality in cancer cells and 10 novel ones (Table 1 and 
Supplementary Data 2). To give an example, one of the predicted drug targets, TLE1, has 
a negative genetic interaction with the cancer-related gene, HDAC1[39]. HDAC1 failed to 
be a direct drug target since the inhibition of mouse Hdac1 caused embryonic lethality 
in normal development[40]. TLE1, on the other hand, has been found to be essential in 
several types of cancer cells[38] and non-essential in D. melanogaster[41]. Additionally, 
TLE1 and HDAC1 have a confirmed negative genetic interaction in D. melanogaster[41], 
which makes TLE1 a promising drug target for further analysis.
Another example is the predicted interaction between NSUN2 and FBXW7 
(Figure 5). NSUN2 is experimentally found to be essential in cancer cells[42] , and FBXW7, 
a tumor suppressor gene, has been found to be mutated in cancer cells[43]. In normal 
cells, NSUN2 and FBXW7 both function to regulate cellular differentiation via two different 
mechanisms. FBXW7 regulates cell differentiation by inhibiting c-Myc[44] and proteins in 
Notch pathway[45], and NSUN2 functions to maintain normal cell differentiation when 
activated by LEF1/β-catenin complex which is part of Wnt pathway[46, 47]. It has been 
found that the loss of FBXW7 results in elevated expression of c-Myc[44], which results 
in an up-regulation of NSUN2[48]. As a result, NSUN2 stabilizes the mitotic spindle in fast 
cell proliferation in cancer cell growth[42]. Thus, targeting NSUN2 can kill cancer cells 
while leaving normal cells relatively unaffected, due to the compensatory FBXW7-Notch 
pathway. This is further supported by the non-essentiality of NSUN2 in normal mouse 
model[47]. 
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Table 1 List of predicted cancer drug targets
Cancer-related    Genes Predicted Target Genes with Empirical Evidence:
Essential in cancer cell
Non-essential in normal cell
Novel Predicted Target Genes:
* Unknown essentiality in normal cell 
and cancer cell
** Non-essential in normal cell and 
unknown essentiality in cancer cell
DDB2|FBXW7|EML4
LSMD1 PPIB|PPIC|PPID**
HDAC5|HDAC6 NTG1|GNL3L|SSTR5**
PPWD1|PPIH|PPIE
KIAA0564
NSUN2|NSUN5
BCL3|NOTCH2|CDKN2C|NFKB2
HDAC5|HDAC6 PPIB|PPIC|PPID**
PPWD1|PPIH|PPIE
MSI2 DENR
CREBBP|EP300|BRD4|P-
BRM1|BRD3|TRI-M24|SMARCA4
USP12|USP22|USP30 USP45**
PIK3CA USP12|USP22|USP30 USP45**
HDAC1 TLE1
DDX5|DDX6|DDX10|EIF4A2 ATAD2*
PBRM1 ACTG1
MED12 MED14
HIST1H4I H3F3A
EZH2 EED
RPN1 MAGT1
PIK3R1 ESR1
SMAD4 JUND
CCNE1 SKP1
CREBBP KAT2B
FANCF C17orf70*
FANCC FANCB*
FANCF FANCB*
SEPT9 SEPT11**
20 predicted cancer drug targets with experimental evidence (2nd column) and 10 novel targets (3rd column). The grey-shaded 
rows show targets predicted by using orthology mapping and the rows without show targets predicted directly from human 
protein complexes. Each grey-shaded cell represents a Clusters of Orthologous Group (COG) of cancer related genes or predicted 
drug targets. The 1st column shows the cancer-related genes. The 2nd column shows 20 predicted drug targets with empirical 
evidence where each gene is essential in at least one cancer cell and non-essential in model organisms. The 3rd column shows 10 
novel targets for which the essentiality in cancer cells has not yet been measured. 
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Figure 5 A cancer drug target revealed by predicted negative genetic interactions. NSUN2 is 
predicted to have a negative genetic interaction with FBXW7. Targeting NSUN2 can kill the cancer 
cells while leaving the normal cell relatively unaffected. In normal cells, the tumor suppressor gene 
FBXW7 has functional redundancy with NSUN2 in regulating cellular differentiation. In cancer 
cells, loss of function of FBXW7 results in an elevated expression of c-Myc. Activation of c-Myc 
results in the upregulation of NSUN2 that is essential for cell proliferation. Due to a synthetic 
lethality between FBXW7 and NSUN2, targeting NSUN2 kills cancer cells, while leaving normal 
cells relatively unaffacted. A solid line represents an active protein e.g., FBXW7 inhibiting the 
accumulation of NOTCH1 and NOTCH3 in normals cells [45]. A red cross illustrates the disruption 
of the function of a protein, that is, transcriptional regulation of NSUN2 by c-Myc2 is repressed in 
normal cell, or the disruption of a cellular function, that is, differentiation or proliferation.
3. Discussion
Even though various experimental techniques are available to study protein 
function, understanding their functions within protein complexes and their relationships 
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between each other in a complex remains a challenge. Here, we have developed a model 
to predict functional relationships within protein complexes using the evolutionary history 
of genomes in terms of gene gain and loss events. We first focused on the relationships 
in which the function of one protein A depends on the function of another protein B, 
but in which the reverse relationship is much weaker. We predicted such asymmetry by 
integrating various evolutionary scenarios, such as, gene B is more frequently gained 
across evolutionary history in the absence of gene A than vice versa. So, B can occur 
without A, but A cannot occur without B. To validate the method, we showed that the 
predicted functional asymmetry is consistent with various sources of empirical evidence, 
such as asymmetry in gene essentiality and single knockout growth defects. However, 
one-third of the gene pairs in the same complex with asymmetry in gene essentiality 
(633/2130) have not been captured by our model. Perfect prediction can, however, not 
be expected, because it is strictly based on complete gene loss and gain. Our model may 
therefore benefit from more fine-scale evolutionary events, such as the incorporation 
of mutation rates. Thus, in species where both A and B are still present, there might 
be asymmetry in the extent to which they have diverged at the sequence level from 
their respective ancestors. Secondly, the essentiality and growth defect data sets[4, 49] 
cover specific nutrient environments, which might not be experienced by species in our 
evolutionary model. Such differences in physiological conditions may result in different 
genome evolution and, as such, it could negatively affect model predictions. 
Interestingly, functional asymmetric relationships can be used to predict negative 
genetic interactions in those cases where multiple proteins, for instance, A and C, have 
asymmetry with the same protein B. The underlying idea is that functional asymmetry is 
due to the fact that A and C can compensate for each other’s absence. Indeed, we have 
shown that our model increases the predictive power for negative genetic interactions 
in S. cerevisiae protein complexes by 50-100% relative to random protein pairs from the 
same complex. Moreover, we predict many novel genetic interactions, of which eight 
have been experimentally verified in S. pombe and D. melanogaster. Although this 
number is not high, this is not unexpected given that genome-scale genetic interaction 
screens have only been performed in S. cerevisiae[20] and S. pombe[50]. Moreover, 
only one screen under standard nutrient condition has been conducted for these two 
species respectively and it remains to be seen how genetic interactions vary across other 
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nutrient conditions. It would therefore be interesting to apply our model to study the 
variation of interactions across conditions, for example, to re-evaluate evolutionary 
theories that are based on adaptive landscapes (e.g., robustness against mutations in 
single environments) initialized by studies on metabolism[51]. One strategy would be 
to integrate gene expression profiles across a wide range of nutrient conditions with 
protein complex data to remove unexpressed subunits from protein complexes and thus 
obtain condition-specific complexes. Additionally, condition-specific essentiality profiles 
[4] could be used to constrain the independent protein (B) to be essential. As a result, 
one could predict fan-in motifs that are specific for a given condition. Our finding that the 
predictive power of negative genetic interactions doubles when incorporating essentiality 
supports such a strategy.
Various recent studies have stated that the discovery of (negative) genetic 
interactions is a very important step towards a full understanding of the genetic basis 
of complex diseases and providing a framework to discover drug targets[52-54]. Even 
though there are a number of very promising candidate drug targets discovered by 
using genetic interactions[10, 11], effectively identifying them experimentally remains a 
major challenge. In contrast to other prediction models[12, 13, 18], our model does not 
depend on genetic interaction screens, which are available in a very limited number of 
species. Thus, our model can be applied to predict genetic interactions in species even 
when no empirical genetic interaction information is available. Moreover, compared to 
Pandey and co-workers [18], our model has a significantly higher prediction precision. 
Our approach is therefore useful to prioritize drug candidates. We found 20 cancer drug 
targets for which there is empirical evidence that they are essential in tumor cells and 
predicted 10 novel drug targets. Notably, the majority (25/30) has not been measured 
in yeast or predicted by other computational approaches [13, 18]. These targets are 
promising given the empirical evidence that all are essential in at least one cancer type, 
such as breast, pancreas, or ovarian cancer, while non-essential in model organisms. 
Future studies should reveal to what extent these targets are i) non-essential in the same 
human healthy cell type, ii) conserved across different tumor types and iii) vulnerable for 
drug compounds.
In the light of medical genetics, the presented approach can be applied to 
mammals when future protein-protein interaction networks become available for cancer 
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and normal cell lines. This would allow for more specific predictions of cancer drug 
targets. It should be noted that although we focused on protein complexes, our model 
might be used to predict interactions for any gene pair, as long as they are known to have 
a functional relationship between them. Taken together, this study shows that negative 
genetic interactions in protein complexes can be predicted by genome evolution, which 
has an application in searching for drug targets and in understanding human diseases.
4. Methods
4.1 Protein complexes 
409 and 2468 protein complexes of S. cerevisiae[17] and human[34, 35] were 
used to predict negative genetic interactions within them, respectively. For each 
protein complex, all pair-wise combinations of proteins were generated as input for our 
evolutionary model. 
4.2 Reconstruction of ancestral states
We used presence and absence of orthologous genes across 373 species 
obtained from STRING 7.0 orthologous groups[29] to reconstruct ancestral states of 
genes. We inferred the most parsimonious ancestral presence/absence states of each 
gene by using a rooted trifurcation (Achaea/Eukaryote/Eubacteria) phylogenetic tree of 
373 species. All results were obtained using a gain/loss cost ratio of 2/1 and a delayed 
transition assumption (‘DELTRAN’) in PAUP[55] From the ancestral state reconstruction 
we generated 11 evolutionary variables as inputs to the following classification step. The 
integration of these 11 evolutionary variables gives the highest correct classification rate 
compared to alternative integrations of evolutionary variables.
For each gene pair A-B, we examined the following six evolutionary scenarios: 
i) both genes were absent in the ancestor (a) and one was gained in the descendant (d)
(a00_d10 or a00_d01), ii) the presence of only one gene in the ancestor was maintained 
in the descendant (a10_d10 or a01_d01), iii) both genes were present in the ancestor and 
one was lost in the descendant (a11_d01 or a11_d10), iv) a gain of one gene occurred 
when the other was present in the ancestor (a01_d11 or a10_d11), v) only one gene 
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was present in the ancestor and was lost in the descendant (a10_d00 or a01_d00), and 
vi) only one gene was present in the ancestor and was lost in the descendant while the 
other gene was gained (a10_d01 or a01_d10)(Figure 2b).
For gene A, we also calculated five fractions that reflect evolutionary asymmetry 
between A and B, f1: a11_d01/(a11_d01+a11_d10), f2: a01_d11/(a01_d11+a10_d11), 
f3: a01_d01/(a01_01+a10_d10), f4: a01_d11/(a01_d11+a00_d10), f5: a01_d11*[a01_
d11-a00_d10+1]/[a01_d11+a00_d10].
4.3 Evolutionary information to predict asymmetry of gene pairs
First, we reconstructed ancestral states for 2400 directionally coupled enzyme 
pairs (functional asymmetry; AàB) in the yeast metabolic network[19] and generated 
the 11 evolutionary variables. Directional coupling was found by constraining the 
reaction flux of one to a finite value followed by minimizing and maximizing another, 
and vice versa[14]. AàB is found when the minimum flux through A is zero while the 
maximum is a finite value (when constraining B to a finite flux), and the minimum and 
maximum flux through B is unequal to zero when A is constrained to a finite value. Thus, 
the activity of A depends on the activity of B, but not the reverse (AàB). Each of the 11 
evolutionary variables is a predictor for functional asymmetry between an enzyme pair 
(AàB) since the 11 variables of a dependent A differ from those of an independent B. 
More specifically, for evolutionary events i) and ii), A is expected to occur less often than 
the independent B. For the other four evolutionary events, A is expected to occur more 
often than the independent B. Furthermore, we expect f1, f2, f3, f4 to be larger than 0.5, 
and f5 to be larger than 0 for asymmetric functional relationships (Supplementary Figure 
S1).
Given the fact that these 11 variables are not independent from each other, we 
used a Tree Augmented Naïve Bayes (TAN) classifier to integrate these predictors. The 
TAN classifier relaxes the assumption of independence of input variables. The classifier 
is trained on the 2400 directionally coupled enzyme pairs using WEKA[56]. The classifier 
estimates conditional probabilities of one gene being independent (α1) or dependent 
(α2), where α1 + α2 =1. The gene is predicted to be either independent (if α1 > α2) or 
dependent (if α1 < α2) with a conditional probability (α), where α = max (α1, α2). To predict 
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the functional relationship in protein complexes by this classifier, we first reconstructed 
ancestral states for 8711 protein pairs (A-B) and generated the 11 evolutionary variables 
for A and B. The functional relationship of A-B is determined as follows, i) the classifier 
generates class predictions for A with a probability estimate (α); ii) identifying predictions 
with high confidence by a cutoff on α (any prediction where α is smaller than the 
cutoff remains unclassified); iii) protein B is predicted in the same way; iv) combining 
the classification result of A and B, A-B is predicted as functionally asymmetric when 
A is dependent and B is independent or vice versa. Otherwise, there is no evidence for 
functional asymmetry and the pair becomes unclassified (Figure 2c). 
4.4 Gene essentiality 
Essentiality data was obtained from MIPS database[49]. If a gene is annotated 
as both essential and non-essential in different sources, the essentiality is assigned 
according to the majority rule. Otherwise, a gene was marked as ambiguous.  
For predicted asymmetric pairs (AàB), we counted cases where only B is 
essential (n01) and cases where only A is essential (n10). For symmetric pairs (A-B), it is 
expected that n01 is equal to n10. To test against the null hypothesis of no relationship 
between predicted functional asymmetry and asymmetry in essentiality, we subjected 
the 2×2 contingency table of essential/non-essential vs. symmetric/asymmetric to a one-
tailed Fisher exact test.
4.5 Growth defect of single gene knockouts in rich medium
Growth defect of single gene knockouts was obtained from two studies[20, 
21], which cover 75% of all genes in S. cerevisiae. A growth defect was considered as 
substantial if a gene knockout causes a growth defect larger than 10%[4]. 
For predicted asymmetric pairs with two non-essential genes (AàB), we counted 
cases where knockout of B causes a more severe growth defect (n01) and cases where 
knockout of A causes a more severe growth defect (n10). For functional symmetric pairs 
(A-B), it is expected that  n01 is equal to n10. To test against the null hypothesis of no 
relationship between predicted functional asymmetry and asymmetry in growth defect 
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we subjected the 2×2 contingency table of n01/n10 vs. symmetric/asymmetric to a one-
tailed Fisher exact test.
4.6 Negative genetic interactions in the metabolic network
We obtained fan-in motif A-C pairs for metabolic reactions (Figure 1c) by using flux 
coupling between enzymes within the genome-scale metabolic network of S. cerevisiae 
(see above). The fan-in motif A-C pairs have two characteristics: i) A and C both depend 
on a third essential protein B (AàB and CàB), and ii) the A-C pair is uncoupled. For 
experimental validation we used an empirical genetic interaction profile from Szappanos 
et al. (obtained from the supplementary information [21]). If no significant genetic 
information was available for a pair of genes, we determined it as not measured and 
excluded it from the analysis. 
To test against the null hypothesis of no enrichment of negative genetic 
interactions in fan-in motif A-C pairs, we summarized the motif A-C/non-motif A-C pairs 
vs. with/without negative genetic interaction in a 2×2 contingency table and subjected it 
to a one-tailed Fisher exact test. 
4.7 Negative genetic interactions in protein complexes
We obtained A-C pairs with evolutionary fan-in motifs (Figure 1a) from asymmetric 
functional relationships predicted by the TAN model (Figure 2c). The evolutionary fan-in 
motif is characterized by i) A and C depend on B, but not vice versa and ii) A does not 
depend on C and vice versa. To ensure A-C is not an asymmetric pair, we applied the cutoff 
for significant functional asymmetry to α >= 0.7. At this cutoff, the correct classification 
rate increases the most at the smallest cost of samples size (Supplementary Figure S4).
Genetic interaction data was obtained from BioGRID [31]. Since BioGRID does not 
specify whether the genetic interaction of a gene pair has been measured, we integrated 
the original data from 9 high-throughput data sets[20-28], to generate a list of measured 
genetic interactions (either positive, negative or no interaction). If a pair of genes has 
both a negative and a positive genetic interaction, the genetic interaction was assigned 
according to the majority rule.
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To test against the null hypothesis of no enrichment of negative genetic 
interactions in pairs with a fan-in motif, we summarized motif A-C/non-motif A-C vs. 
with/without negative genetic interaction in a 2×2 contingency table and tested using a 
one-tailed Fisher exact test.
4.8 Prediction of cancer drug targets
We mapped predicted negative genetic interactions from yeast to human via 
orthology from STRING7.0[29]. To retrieve drug targets, we first mapped cancer gene 
information from the Cancer Genome Project[36] to the predicted genetic interactions to 
extract predictions involving one oncogene or tumor-suppressor gene. Then we mapped 
gene essentiality measurements in cancer from Marcotte et al. [38] to the predictions. 
In addition, non-essentiality of the drug targets in normal cells/tissues was examined by 
literature mining covering M. Musculus, D. melanogaster or D. rerio.
To predict targets directly from human protein complexes, we trained our 
model on functional asymmetric enzyme pairs from the human genome-scale metabolic 
network[37] via Flux Coupling Analysis (see also above for yeast and [14]). Subsequently, 
we used experimentally determined protein complexes [34, 35] to predict human-specific 
negative genetic interactions via the evolutionary fan-in motifs. Finally, we examined 
gene essentiality among predicted drug targets in cancer and normal cells/tissues as 
outlined above.
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Abstact
Synthetic Lethal (SL) genetic interactions play a key role in various types of 
biological research, ranging from understanding genotype-phenotype relationships to 
identifying drug-targets against cancer. Despite recent advances in empirical measuring 
SL interactions in human cells, the human genetic interaction map is far from complete. 
Here, we present a novel approach to predict this map by exploiting patterns in cancer 
genome evolution. First, we show that empirically determined SL interactions are 
reflected in various gene presence, absence, and duplication patterns in hundreds of 
cancer genomes. The most evident pattern that we discovered is that when one member 
of an SL interaction gene pair is lost, the other gene tends not to be lost, i.e. the absence of 
co-loss. This observation is in line with expectation, because the loss of an SL interacting 
pair will be lethal to the cancer cell. SL interactions are also reflected in gene expression 
profiles, such as an under representation of cases where the genes in an SL pair are 
both under expressed, and an over representation of cases where one gene of an SL pair 
is under expressed, while the other one is over expressed. We integrated the various 
previously unknown cancer genome patterns and the gene expression patterns into a 
computational model to identify SL pairs. This simple, genome-wide model achieves 
a high prediction power (AUC = 0.75) for known genetic interactions. It allows us to 
present for the first time a comprehensive genome-wide list of SL interactions with a high 
prediction precision, covering up to 591,000 gene pairs. This unique list can potentially 
be used in various application areas ranging from biotechnology to medical genetics. 
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1. Introduction
A synthetic lethal (SL) genetic interaction is defined as a functional relationship 
between two genes where the loss of either gene is viable but the loss of both is 
lethal [1]. A comprehensive map of SL interactions sheds light on the relationships 
between genotype and phenotype[2-5], potentially advancing the understanding of the 
mechanisms of complex human disease[6, 7], and even providing therapeutic treatment 
strategies for human diseases such as cancer[8]. For instance, several studies have 
shown that inhibiting one gene in an SL pair could be lethal to cancer cells in which the 
other gene of that pair is mutated [9-11]. The underlying concept is that, in a cancer 
cell, a mutation in one (A) of the two genes in an SL pair (A-B), which is not mutated in 
the normal cell, allows for selectively killing tumor cells by inhibiting B. Despite recent 
breakthroughs in technologies to identify SL interactions on a genome-wide scale [12-15], 
these interactions remain largely unknown in human, underlining the need for predictive 
computational approaches. 
Previous computational approaches have mostly been developed to predict 
SL interactions in model microorganisms, such as Saccharomyces cerevisiae and 
Caenorhabditis elegans[16-18]. However, genetic interactions are not strongly conserved 
between species, for instance only 29% of genetic interactions were found to be 
conserved between the fungi S.cerevisiae and Schizosaccharomyces pombe[19] and 
the conservation of SL interactions between microorganisms and human still has to be 
established. Recently, a study proposed to use cancer genomic data [20] to identify SL 
interactions by using a ‘compensation‘ pattern: one gene (A) is inactive while the other 
one (B) is highly active, thereby selecting against the situation that both genes become 
lost and, as such, causing a lethal phenotype. We recently showed another genomic 
pattern of SL interacting gene pairs: SL interactions are reflected in present-day species 
genomes and their ancestral genomes in a way that the combined loss of two genes 
in an SL pair does not frequently occur across evolutionary history [21]. This raises the 
question whether we can use this ‘co-loss underrepresentation’ pattern to predict SL 
pairs from human cancer genomes (Figure 1a). Here, we used copy number variations, 
i.e. gene loss or gene gain, across hundreds of cancer genomes to ask i) are empirical 
SL interactions reflected in cancer genome evolution and, if so, ii) which gain and loss 
patterns correlate most with SL interactions, and iii) can they be captured into a simple 
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computational model to predict SL interactions genome widely? 
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Figure 1 Patterns across cancer genomes reflecting selection against gene co-inactivation, and the work-
flow to predict SL interactions. (a) A SL interaction SL1 between gene A and B can show a ‘compensation’ 
pattern across cancer genomes in which it is more likely that when A is inactive (denoted by -1), B is overactive 
(denoted by 1) to compensate the inactive A (genomes 1–10), compared to when A is active (genomes 11–30). 
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SL interaction SL2 can, show a ‘co-loss underrepresentation’ in which a combined loss of A and B (denoted by 
-1 and -1, genome 10) across cancer genomes is underrepresented compared to a loss of either one of the two 
(genomes 2–9 and genome 14–18). Note that SL1 can also be identified via the co-loss underrepresentation 
pattern, but the SL2 can only be identified via the co-loss underrepresentation pattern. (b) The model requires 
two types of data as input, i) CNVs measured by SNP arrays and ii) gene expression variations measured 
by RNAseq. In CNVs, the status of a gene can be a homozygous deletion (two dash lines), a heterozygous 
deletion (one dash and one solid line) or normal (two solid lines). For CNVs, we generated three fractions to 
quantify the likelihood that a gene pair has a homozygous co-loss (f1), a heterozygous co-loss (f2) or a mixed 
co-loss (f3) event. In gene expression variations, a gene can be under-expressed (one dash line), normal (one 
solid line) or over-expressed (one bold line). For expression status, we generated two fractions, f4 and f5. f4 is 
the likelihood that both genes in a gene pair are under-expressed. f5 is the likelihood that a gene pair has an 
expression up-down event where one is over-expressed while the other one is under-expressed. All these five 
fractions showed a distribution difference between SL and non-SL pairs. By integrating these five fractions 
into a prediction model, we can identify SL interactions that can be presented as a network.
By exploiting the availability of gene expression data for a large number of 
cancer samples[22] and recent empirically measured SL interactions in human[23, 24], 
we  found that genes with SL interactions are more likely to have an expression pattern 
where one gene is over-expressed while the other one is under-expressed, thereby 
confirming earlier observations[20]. Strikingly we observed that SL pairs are less likely to 
be co-lost and co-under expressed than non-SL gene pairs. On the basis of these findings, 
we present a simple ensemble-based computational model that captures the genomic 
patterns to predict genome-wide SL pairs with high accuracy. We provide a unique 
and comprehensive map of the human SL interaction network with a high prediction 
precision of 67%, i.e., 14-fold higher than expected from chance, covering 591,000 pairs. 
This map is expected to be highly valuable in the light of understanding human diseases 
and designing therapeutic strategies.
2. Results
2.1 Synthetic lethal interactions are reflected in cancer genome evolution
We first asked whether empirically observed SL interactions are reflected in 
gene presence/absence and gene expression in cancer cells. To answer that, we used 
two types of genome variation from the Cancer Genome Atlas (TCGA)[22], i.e., i) copy 
number variations (CNVs) and ii) gene expression variations. The TCGA consortium 
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measured 14136 tumor samples for CNVs and 7362 tumor samples for gene expression 
variations. To determine whether genes in cancer samples are significantly over- or 
under-expressed, we determined their expression-levels relative to normal samples of 
the same tissue type (Methods). We obtained the empirical SL interactions from two 
recent studies[23, 24] that measured SL interaction in colon tumor cell lines and have 
the highest genome coverage among all the studies available. In total we collected 270 
SL pairs and 5660 non-SL pairs.
We first tested whether SL pairs are less likely to be co-lost in a genome than non-
SL pairs. A gene can either be homozygously or heterozygously deleted. We first focused 
on homozygous losses in which both copies of a gene are lost. We express the likelihood 
of homozygous co-loss of both genes in a gene pair by the fraction f = n1/n2, where n1 is 
the number of tumor samples with a co-loss of both genes and n2 is the number of tumor 
samples in which at least one gene is lost (see Methods and Figure 1). Indeed, we found 
that SL pairs are less likely to be homozygously co-lost than the non-SL pairs (0.00728 vs 
0.0104, one-sided Wilcoxon rank test, P = 0.008, Figure 2a). 
We performed several additional analyses to show that this result is valid and 
robust. First, we showed that the difference in co-loss events is not caused by the 
difference in single gene loss rates. Indeed the homozygous gene deletion rate of the 
genes in SL pairs is not different from the deletion rate of the genes in non-SL pairs 
(0.00402 vs 0.00406, two-sided Wilcoxon rank test, P = 0.38). Secondly, given the limited 
genome coverage of the known SL and non-SL pairs available for our analysis, we also 
compared the likelihood of co-loss events of SL pairs with random pairs from the human 
genome. We found a significant difference in co-loss between SL pairs and random pairs 
(0.00728 vs 0.0128, 1000 randomizations, P
adj. 
= 0.012, Figure 2a). This shows that the 
difference in the likelihood of co-loss events between the SL pairs and the random gene 
pairs is a consistent signal across the human genome. The difference between SL pairs 
and random pairs is larger than the difference between SL pairs and non-SL pairs (Figure 
2a). This is likely due to the fact that the genes included in the experiments tend to 
be biased towards those that are frequently lost, i.e. the homozygous deletion rate of 
genes in SL/non-SL pairs is higher than that in random pairs (0.0049 vs 0.0042, one-sided 
Wilcoxon rank test, P = 0.04). It should furthermore be noted that we require the gene 
pairs included in the analysis to be composed of genes on different chromosomes. The 
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reason for this is that the presence of arm-level copy number variations will always cause 
a high probability of co-loss for the gene pairs on the same chromosome regardless of 
whether they have an SL interaction or not.
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Figure 2 SL pairs are reflected in copy number variations. SL pairs are less likely to have (a) homozygous co-
loss events, (b) heterozygous co-loss events and (c) mixed co-loss events than non-SL pairs or random pairs. 
The fractions for these three types of co-loss events are described as f
1
, f
2
, f
3
 in Methods and Figure 1. Each 
dot is the fraction for a given pair and the horizontal bar represents the mean of the fractions. P-values for 
the comparison between SL and non-SL pairs were calculated using one-sided Wilcoxon rank test. P-values 
for the comparison between SL and random pairs were calculated from 1000 randomizations. P-values were 
adjusted for multiple comparison using the Bonferroni correction (see details in methods).
Besides the homozygous co-loss, where both genes are homozygously deleted, 
there exist the possibilities of a heterozygous co-loss where both genes are heterozygously 
deleted and a mixed co-loss where one gene is homozygously deleted and the other is 
heterozygously deleted. For the heterozygous co-loss and for the mixed co-loss event 
we carried out the same analysis as done above for the homozygous co-losses. For both 
types of co-loss events, we found a significant and robust signal, i.e., the SL pairs are less 
likely to be co-lost than the non-SL pairs (for heterozygous co-loss 0.1935 vs 0.216, one-
sided Wilcoxon rank test, P
adj. 
= 1.08e-08, Figure 2b; for mixed co-loss 0.189 vs 0.2008, 
one-sided Wilcoxon rank test, P
adj. 
= 0.02, Figure 2c). As was the case for the homozygous 
co-losses, both signals are consistent when SL pairs are compared with random gene 
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pairs (for heterozygous co-loss 0.1925 vs 0.218, P
adj. 
< 0.004, Figure 2b; for mixed co-loss 
0.189 vs 0.210, P
adj. 
= 0.032, Figure 2c).
We next examined gene expression levels, where we expected to find a similar 
signal to the one we found at the level of gene absence/presence, since the under-
expression of one gene can also result in the loss of its activity. Indeed, we found that SL 
pairs are less likely to be both under-expressed than non-SL pairs (0.0443 vs 0.0586, one-
sided Wilcoxon rank test, P
adj. 
= 2.39e-10, Figure 3a). Only pairs composed of genes on 
different chromosomes are included in the analysis. Again the signal is consistent when 
SL pairs are compared with random gene pairs (0.0443 vs 0.0570, P
adj. 
< 0.004, Figure 3a).
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Figure 3 SL pairs are reflected in gene expression variations. (a) SL pairs are less likely to be co-underex-
pressed relative to the control i.e., non-SL or random pairs. The fraction for co-underexpression events is 
described as f
4
 in methods and Figure 1. (b) SL pairs are more likely to have expression up-down events where 
one gene is over-expressed while the other in under-expressed. The fraction for such pattern is described as f
5
 
in Methods and Figure 1. Each dot is the fraction for a given pair and the horizontal bar represents the mean 
of the fractions. P-values for the comparison between SL and non-SL pairs were calculated with a one-sided 
Wilcoxon rank test. P-values for the comparison between SL and random pairs were calculated from 1000 
randomizations. P-values were adjusted for multiple comparison using the Bonferroni correction (for details 
see Methods).
Previous studies [25, 26] have shown another pattern in genes in SL pairs at the 
transcription level. In this pattern one gene of an SL interacting pair is over-expressed 
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while its partner is under-expressed. Thus, we expected that compared with non-SL 
pairs, SL pairs would have higher probabilities to have an expression pattern where one 
gene is over-expressed while the other is under-expressed. We refer to this as expression 
up-down. The probability of this expression pattern is quantified by the fraction f=n1/
n2, where n1 is the number of tumor samples that have the pattern and the n2 is the 
number of tumor samples that have an under-expression of at least one of the genes 
(see Methods and Figure 1 for details). As expected, we found that SL pairs are more 
likely to have this expression pattern (0.250 vs 0.211, one-sided Wilcoxon rank test, P = 
2.10e-04, Figure 3b). Again, we validated the consistency of the signal by comparing the 
likelihood of this expression pattern in the SL pairs against its likelihood in random pairs 
(0.250 vs 0.146, 1000 randomizations, P
adj
 < 0.002, Figure 3b). We note that the difference 
between SL pairs and random pairs is higher than that between SL pairs and non-SL pairs. 
This is possibly due to the fact that the genes included in the experiments were biased 
towards those that are more likely to be over-expressed when one is mutated, i.e., the 
over-expression of genes in non-SL pairs is higher than that of random genes (0.0957 
vs 0.0789, one-sided Wilcoxon rank test, P = 1.08e-06). We also analyzed a genomic 
pattern at the gene presence/absence level by calculating the probability for each gene 
pair to have a CNV pattern where one gene is duplicated or amplified while the other 
one is homozygously or heterozygously deleted, referred to as genomic up-down in the 
remainder of the text. We found that SL pairs indeed have a higher probability to have 
the genomic up-down combination at the DNA level than non-SL pairs (0.300 vs 0.274, 
one-sided Wilcoxon rank test, P
adj
 = 1.65e-07), but this is not significant when compared 
with random pairs.
In total, we found five patterns in the CNVs and gene expression variations in 
cancer cells, all of which showed that synthetic lethal interactions are reflected in cancer 
genome evolution. These five patterns fall into two categories: i) genes in SL pairs are 
more likely to be over-expressed when their interaction partner is under-expressed and 
ii) genes in SL pairs are less likely to be co-lost either at the DNA level or at the gene 
expression level.
2.2 An ensemble-based model for predicting synthetic lethal interactions
We next asked whether these five genomic patterns are strong enough to 
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reliably predict SL pairs in human on a genome-wide scale. To do that we developed an 
ensemble-based model that integrates the five patterns. It should be noted that we did 
not include the genomic up-down pattern found in CNVs since SL pairs are not significantly 
different from random pairs. An ensemble-based model is a classifier that combines the 
prediction results from multiple classifiers, such as decision trees and logistic regression. 
It is known that such an ensemble-based model can improve performance relative to a 
single classification procedure[27], especially for complex problems such as SL prediction 
involving noisy inputs[28]. 
We used the empirically measured 270 SL pairs and 5660 non-SL pairs as described 
in the previous analysis. To construct the prediction model, we first needed to handle the 
imbalance of sample size between the negative class, i.e. non-SL pairs, and the positive 
class, i.e. SL pairs. The skewed distribution of the classes can affect the performance of 
prediction models [29]. To solve this issue, we randomly under-sampled the negative 
class (non-SL pairs, 95.4% of the training set) to produce a set of negative samples of 
the same size as the positive class (SL pairs, 4.6% of the training set). This balanced 
combination of two sets is used to train an ensemble-based model for SL prediction. 
Note that the under-sampling is only applied to the training set. In total we selected 
seven different single classifiers as the base for the ensemble model: AdaBoost[30], 
J48[31], LogitBoost[32], RandomForest[33], Logit[34], JRip[35] and PART[36] which are 
either robust against noisy data or over-fitting. After being trained with the balanced set, 
each single classifier generates a probability that a gene pair has an SL interaction. Then 
we integrated all seven probabilities from these single classifiers by calculating the mean 
of the seven probabilities and used that as the final predicted probability.
To assess the performance of the ensemble-based prediction model, we used 
a 10-fold cross-validation on all the empirically measured 270 SL pairs and 5660 non-
SL pairs. The plot of sensitivity (i.e., true positive rate) versus false positive rate of the 
ensemble-based model shows that our model achieves an area under ROC curve (AUC) 
of 0.75 (standard error = 0.016, Figure 4b). It should be noted that this high AUC is only 
achieved when combining all patterns (Figure 4a). We also found that the ensemble-
based model achieved the highest AUC compared to all seven single classifiers (Figure 
4b). In order to predict a genome-wide SL interaction map, we estimated the average 
precision and recall values from the 10-fold cross-validation (Figure 4c). We then applied 
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the model to all gene pairs on the genome. Among ~115 million pairs for which gene 
expression and CNV data were available, we predicted more than 591,000 SL interactions 
based on a probability score threshold of 0.81 (Figure 4c), which corresponds to an 
estimated precision of 67% based on our training set, i.e., 14-fold higher than expected 
from chance (S1 Dataset). Note that the model achieves a similar precision (60% at p = 
0.81) when using an independent set of experimentally measured SLs (Figure C in S1 File).
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Figure 4 Receiver operating characteristic (ROC) curves. (a) The ensemble-based prediction model based on 
all five combined patterns has an area under curve (AUC) of 0.75 (blue line), which is estimated by 10-fold 
cross validation. Ensemble-based prediction models based on the non-combined individual patterns, i.e., co-
loss in CNVs, co-underexpression and expression up-down, are shown in red, green and purple respectively, 
and have lower AUCs. Standard error bars are added to each ROC. (b) The ensemble-based prediction model 
CHAPTER 3
58
3
(the blue ROC curve) has a better performance than all the seven single. (c) The precision and recall curve is 
estimated from 10-fold cross validation. Standard error bars are added. The curve is colored according to the 
cutoff of probability. The color panel of the probability is plotted at the right side. The cutoffs of probability 
scores (p(x)), 0.81, are printed at the corresponding curve positions. The grey line represents the prediction 
precision by chance alone.
3. Discussion
In this study we present a novel computational model that identifies SL 
interactions from cancer genomic data on a genome-wide scale. To develop such a model, 
we first systematically explored how SL interactions are reflected in cancer genomes and 
their gene expression levels. We found that compared with non-SL pairs, genes in SL 
pairs are significantly less likely to be co-lost in a cancer genome, both at the level of 
gene expression and at the level of copy number variation. Moreover, SL pairs are more 
likely to have an expression up-down pattern where one gene is over-expressed while the 
other one is under-expressed, which is consistent with another recent study[20]. Based 
on these results, we constructed an ensemble-based model to predict SL interactions via 
integrating these unique patterns in cancer genome variations, achieving a high prediction 
performance (AUC= 0.75). Our work presents a direct way to predict SL interactions 
from cancer genomic data, in contrast to most existing computational models, which 
identify SL interactions either specific for the model organisms yeast and C. elegans [16-
18], or predict SL pairs in human in an indirect way by mapping SL interactions from 
yeast to human via orthology [37]. A strategy that uses human genomes by exploring 
the ‘compensation’ pattern also requires, as an additional criterion, that the genes are 
generally co-expressed[20]. As SLs have the characteristic that only one of the two genes 
is strictly needed, co-expression is not crucial. As such, co-expression as an additional 
criterion limits the coverage of SL interactions encoded in the genome, which is reflected 
in the total number of predicted SL pairs by Jerby-Arnon L et al. (2816 with accuracy of 
0.779)[20]. In contrast, our approach, which does not rely on co-expression, predicts 
many more SL interactions with a comparable accuracy (591,000 with an estimated 
accuracy of 0.75).
Future work should focus on the following issues to improve the performance of 
the model. First, given the genomic and microenvironment heterogeneity among different 
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types of tumors[38, 39], the empirically detected SL interactions included in our analysis 
might be only specific to the colon cancer in which the experiments were carried out. As 
genetic interactions were found to be growth condition specific[40], it might be that two 
genes are co-lost in certain tumors simply because the functions of these SL pairs are 
not essential for that particular cancer type. Such discordance of the tissue types might 
dampen the signals we discovered. To improve this, one can focus on gene-expression 
and CNVs that are taken from the same tumor type as the empirical SLs. A model can 
then be constructed to predict tumor type specific SLs, which is valuable to overcome 
the challenges posed by inter-tumor heterogeneity in cancer treatments. Secondly, our 
model only considered the function gain or loss caused by CNVs and variations in gene 
expression. There are other mutations that can result in gain or loss of gene functions, 
such as mutations of miRNA[41, 42] and epigenetic mutations[43, 44]. When knowledge 
becomes available on how these other types of genomic variations affect gene function 
and genetic interactions, these mutations could also be taken into account. Thirdly, our 
model achieves a good prediction performance by a 10-fold cross validation. However, 
we note that the model is trained on a relative small number of available SL and nonSL 
pairs, which constraints a precise estimation of the model performance for genome-
wide prediction. The performance can be better estimated in the future when more 
empirically measured SLs become available. Finally, it still remains to be seen to what 
extent these predicted SL interactions from cancer genomes are relevant to understand 
other diseases. For diseases where CNV or gene expression data are available, one can 
prioritize disease-associated SL interactions from our prediction list by selecting pairs 
that are co-lost in the disease.
Taken together, we systematically investigated and showed that SL interactions 
are reflected in genome evolution of cancer in various forms. Based on the unique patterns 
discovered in cancer genomics, we proposed a simple approach to identify SL, which 
strongly improves existing frameworks. We generated a unique SL interaction network in 
human at the genome-scale covering up to 591,000 pairs with a high estimated precision. 
In the light of medical genetics, this list is highly valuable in the search for anti-cancer 
drug targets and in understanding human diseases.
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4. Materials and Methods
4.1 Data sources
We retrieved the experimentally measured SL pairs and non-SL pairs from two 
studies[23, 24]. We collected 297 SL pairs and 6358 non-SL pairs in total. After excluding 
the pairs of which both genes are located on the same chromosome, we obtained 270 SL 
pairs and 5660 non-SL pairs (S1 Table).
The CNV data is directly retrieved from the cBioPortal for Cancer Genomics[45]. 
The CNV signals in the database are generated as homozygous deletion, heterozygous 
deletion, normal copy, duplication and amplification. Using the ‘cgdsr’ R-package, we 
obtained the CNV data for 14136 tumor patients from 31 cancer types.
The RNAseq data are obtained from the Broad Institute’s Genome Data Analysis 
Center (GDAC) Firehose[46]. The link for downloading the RNAseq data is http://gdac.
broadinstitute.org/runs/stddata__2014_03_16/data. For each cancer study, we first 
downloaded the files named as ‘_RSEM_genes_normalized_data.Level_3’, which contains 
the estimated expression levels for each gene in human genome from RNAseq data by 
using the RSEM package[47]. In total we collected an expression profile for 7362 tumor 
patients with coverage of 26 cancer types. Then, for each gene in a tumor, we computed 
the Z-score and P-value to infer its over- or under-expression relative to expression levels 
in normal tissue. If at least 25 normal samples from the same tissue type as that of the 
cancer are available, we used this as the comparison set. Otherwise, all normal tissue 
samples, regardless of the tissue specificity, were used. The numbers of normal samples 
for each type of tumor are listed in Table S2. To adjust for multiple hypothesis testing, we 
used the False Discovery Rate (Benjamini-Hochberg) method to adjust p-values[48, 49] 
in R. A cutoff of the adjusted P-value, 0.05, was applied to generate the over- or under-
expression signal.
4.2 Extract the pattern for SL pairs from genomic variations
The copy number variations can be, -2 = homozygous deletion, -1 = heterozygous 
deletion, 0 = normal copy, 1 = duplication, and 2 = amplification. For a gene pair (A, B), 
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the co-loss event can be i) homCL: homozygous co-loss (-2, -2), ii) hetCL: heterozygous 
co-loss (-1, -1) or iii) mixCL: mixed co-loss (-2, -1 or -1, -2). For each co-loss event, we 
defined a fraction that quantifies the likelihood of the co-loss event. For instance, for the 
homozygous co-loss event, we defined the fraction for a gene pair A-B as f1 = nhomCL/nt, 
where n
homCL 
is the number of patients with the homozygous co-loss of A-B and n
t
 is the 
total number of patients where A-B have a status as (-2, -2), (-2, 0) or (0,-2). We calculated 
the f1 of a gene pair without including samples that have homozygous deletions of more 
than 2000 genes (tail of the distribution in Figure A in S1 File). We noticed that several 
tumor samples have a very high number of homozygous deletions (Figure A in S1 File). 
Such samples can lead to an inflation of the co-loss likelihood regardless of whether 
they have an SL interaction or not. Similarly, we defined two fractions, f2 and f3, for 
heterozygous co-loss event and mixed co-loss events correspondingly(Table1 and Figure 
1). It should be noted that we did not use an approach in which we, in order to quantify 
under representation of co-loss events, compared the empirically observed co-loss rate 
of gene pair A-B with the product of the single loss rates for genes A and B. This approach 
assumes independency between the loss of randomly chosen genes, which is not what 
we observe (Figure B in S1 File).
The variations in gene expression can be: -1 = under-expression, 0 = normal, 
and 1 = over-expression. Here, we defined two fractions, f4 and f5 (Table 1 and Figure 1). 
f4 quantifies the likelihood of both genes in a pair (A, B) are under-expressed. f5 is used 
to quantify how likely gene pair A-B has the expression up-down events, i.e., A is over 
expressed and B is under expressed or vice versa. 
Here, each defined fraction is a signal where SL pairs show difference from 
non-SL pairs. For f1, f2, f3 and f4, we expected that SL pairs have smaller values for these 
fractions than non-SL pairs. However, for f5 we expected that SL pairs have larger values 
than non-SL pairs. To test these hypotheses, we compared the fractions in SL pairs with 
the fractions in non-SL pairs via one-sided Wilcoxon rank tests in R. We carried out four 
comparisons of homozygous deletion, heterozygous deletion, mixed deletion and co-
underexpression to estimate the difference of co-loss tendency between SL and non-
SL pairs. In the analysis of up-down compensation, we carried out two comparisons of 
expression up-down or genomic up-down. Bonferroni correction was used to correct for 
4 multiple comparisons in the analysis of co-loss tendency and 2 multiple comparisons in 
CHAPTER 3
62
3
the analysis of up-down compensation (p-values are indicated with P
adj.
).
To validate the robustness of the signals, we compared the fractions in SL pairs 
to the fractions in random pairs. In each randomization, we first generated 300 random 
pairs from all human genes for which gene expression and CNV were available and then 
compared the mean of the fractions in the random pairs with the mean in SL pairs. We 
expected that the random pairs have a smaller mean of f1, f2, f3 or f4 but a larger mean 
of f5 than SL pairs. To test the hypotheses, we counted the randomizations (n1) where 
the difference of mean between the random pairs and SL pairs is contradictory to the 
expectation. For each comparison, we conducted 1000 randomizations and calculated 
the P-value for each hypothesis test as P = (n1+1)/1001.
Table 1 Five fractions derived from genomic variations for SL interaction identification
f1 = nhomCL/nt nhomCL =
8><>:
A = 2
and
B = 2
nt =
8><>:
A = −2, and B 2 Z
or
A 2 Z, and B = −2
, where Z = 0 or − 2
f2 = nhetCL/nt nhetCL =
8><>:
A = 1
and
B = 1
nt =
8><>:
A = −1, and B 2 Z
or
A 2 Z, and B = −1
, where Z = 0 or − 1
f3 = nmixCL/nt nmixCL =
8><>:
A = 2, and B = 1
or
A = 1, and B = 2
nt =
8><>:
A = −2, and B 2 Z
or
A 2 Z, and B = −2
, where Z = 0 or − 1
f4 = nco_under/nt nco under =
8><>:
A = 1
and
B = 1
nt =
8><>:
A = −1, and B 2 Z
or
A 2 Z, and B = −1
, where Z = 0 or − 1
f5 = ncomp/nt ncomp =
8><>:
A = 1, and B = 1
or
A = 1, and B = 1
nt =
8><>:
A = −1, and B 2 Z
or
A 2 Z, and B = −1
, where Z = 1, 0 or − 1
4.3 Under-sampling
The training set is significantly skewed with only 4.6% of the pairs belonging to 
the positive class (SL pairs) and the rest belonging to the negative class (non-SL pairs). 
Such a skewed training set can affect the performance of most standard classification 
algorithms[29]. Thus, we generated a more balanced training set by randomly under-
sampling the negative class so that the number of gene pairs in it is equal to that of the 
positive class. The under-sampling is conducted with ROSE package in R[50] and repeated 
100 times. All the classifiers in the study are trained on this balanced set.
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4.4 Construct the ensemble-based prediction model
We adopted an ensemble-based model to integrate the aforementioned 5 signals 
for predicting whether a gene pair has an SL interaction or not. 80% of the retrieved 270 
SL pairs and 5660 non-SL pairs are used as the training set and the other 20% are test 
set. The balanced training set (described above) was used to train the ensemble-based 
prediction model that combines multiple classifiers, namely AdaBoost, J48, LogitBoost, 
RandomForest, Logit, JRip and PART. The combination rule is simply based on the mean 
function, p(x) = 1
N
NX
i=1
pi(x), where x is a given gene pair and pi(x) is the probability that x is 
predicted to be SL by classifier i. The probabilities p
i
(x) from all classifiers, except for 
RandomForest, are obtained from the ‘RWeka’ package[51]. The RandomForest classifier 
is implemented with the ‘randomForest’ package in R[52].
To quantify the performance of the ensemble-based model, we used a 10-fold 
cross-validation framework on all empirically measured 270 SL pairs and 5660 non-
SL pairs. In each cross-validation, the ensemble-based model is trained on nine of the 
randomly constructed 10 fractions and predictions are made for the test samples in the 
remaining fraction. The performance of the model in each cross-validation is evaluated 
by a ROC curve, the corresponding AUC score and a precision-recall curve. Repeating 
this procedure 10 times, a mean ROC curve, a mean AUC score and a mean precision-
recall curve are calculated as the evaluation for the performance of the ensemble-based 
prediction model.
4.5 Construction of the genome-wide human SL interaction map
To predict SL interactions in human at a genome-wide scale, we first selected 
15620 genes that are measured for both CNV and mRNA variations in cancer cells. 
As mentioned in the results section, due to the presence of arm-level copy number 
variations, gene pairs on the same chromosome are more likely to be co-lost regardless 
of the status of SL interaction. Thus, we applied our model to ~115 million genes pairs 
that are located on different chromosomes. To construct a highly accurate SL interaction 
map, we predicted a list of more than 591,000 SL interactions based on a probability 
score (p(x)) threshold of 0.81, which achieved a precision of 67% at a recall of 10%.
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Significance
Synthetic dosage lethality (SDL) denotes a genetic interaction whereby an 
underexpression of gene A combined with an overexpression of gene B kills the cell. 
Although many overexpressed oncogenes driving tumor growth are difficult to target 
directly, targeting their SDL partners may kill cancer cells. We present what is, to our 
knowledge, the first network-level modeling approach that is able to predict metabolic 
SDLs. As expected, we find that the predicted SDLs are less frequently active in tumors 
to avoid lethality. Cancer tumors with more and stronger SDLs have smaller tumor size 
and lead to increased patient survival. Beyond facilitating the development of novel 
anticancer therapies, model-based identification of metabolic SDLs can be used to model 
pathogenic bacteria and provide leads to new antibiotic targets.
Abstract
Synthetic dosage lethality (SDL) denotes a genetic interaction between two 
genes whereby the underexpression of gene A combined with the overexpression of 
gene B is lethal. SDLs offer a promising way to kill cancer cells by inhibiting the activity of 
SDL partners of activated oncogenes in tumors, which are often difficult to target directly. 
As experimental genome-wide SDL screens are still scarce, here we introduce a network-
level computational modeling framework that quantitatively predicts human SDLs in 
metabolism. For each enzyme pair (A, B) we systematically knock out the flux through 
A combined with a stepwise flux increase through B and search for pairs that reduce 
cellular growth more than when either enzyme is perturbed individually. The predictive 
signal of the emerging network of 12,000 SDLs is demonstrated in five different ways. (i) 
It can be successfully used to predict gene essentiality in shRNA cancer cell line screens. 
Moving to clinical tumors, we show that (ii) SDLs are significantly underrepresented in 
tumors. Furthermore, breast cancer tumors with SDLs active (iii) have smaller sizes and 
(iv) result in increased patient survival, indicating that activation of SDLs increases cancer 
vulnerability. Finally, (v) patient survival improves when multiple SDLs are present, 
pointing to a cumulative effect. This study lays the basis for quantitative identification of 
cancer SDLs in a model-based mechanistic manner. The approach presented can be used 
to identify SDLs in species and cell types in which “omics” data necessary for data-driven 
identification are missing.
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1. Introduction
Synthetic dosage lethality (SDL) denotes a genetic interaction between two 
genes whereby the underexpression of gene A combined with the overexpression of 
gene B is lethal. SDLs offer a promising way to kill cancer cells by inhibiting the activity of 
SDL partners of activated oncogenes in tumors, which are often difficult to target directly. 
As experimental genome-wide SDL screens are still scarce, here we introduce a network-
level computational modeling framework that quantitatively predicts human SDLs in 
metabolism. For each enzyme pair (A, B) we systematically knock out the flux through 
A combined with a stepwise flux increase through B and search for pairs that reduce 
cellular growth more than when either enzyme is perturbed individually. The predictive 
signal of the emerging network of 12,000 SDLs is demonstrated in five different ways. (i) 
It can be successfully used to predict gene essentiality in shRNA cancer cell line screens. 
Moving to clinical tumors, we show that (ii) SDLs are significantly underrepresented in 
tumors. Furthermore, breast cancer tumors with SDLs active (iii) have smaller sizes and 
(iv) result in increased patient survival, indicating that activation of SDLs increases cancer 
vulnerability. Finally, (v) patient survival improves when multiple SDLs are present, 
pointing to a cumulative effect. This study lays the basis for quantitative identification of 
cancer SDLs in a model-based mechanistic manner. The approach presented can be used 
to identify SDLs in species and cell types in which “omics” data necessary for data-driven 
identification are missing.
Synthetic lethality (SL) occurs when the combined loss of two nonessential 
genes renders a lethal phenotype[1]. SLs have been studied by using experimental[2, 
3] and computational approaches[4-6] to address various questions of cell function and 
evolution. The potential of SLs for cancer therapy has been recognized and accelerated 
the development of many SL screens[7-11]. (See refs. [12-14] for reviews of SLs applied 
in the context of cancer research.)
Less studied are the so-called synthetic dosage lethality (SDL) interactions. An 
SDL is a genetic interaction between two genes whereby the underexpression of gene 
A (A↓) together with the overexpression of gene B (B↑) is lethal[15]. The observation 
that an interaction with an overexpressed gene can be lethal makes it particularly 
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interesting for targeting cancer cells with (over)expressed oncogenes. This is because 
many oncogenes that drive tumor growth are essential to cell function and thus 
difficult to target directly. Targeting the oncogenes’ SDL partner, which is a nonessential 
gene in normal cells, may nevertheless kill cancer cells. That SDLs can have important 
implications for cancer research, for instance to aid in the design of new therapies, has 
also been recognized[12, 16-18]. Moreover, it has been shown that the overexpression 
of specific genes can be detrimental to cancer cell growth[19]. Recently, a data-mining 
approach was used that identifies SLs and SDLs by analyzing large volumes of cancer 
genomic data[20]. Here we aim to complement data-driven computational efforts with 
a biological network model approach to identify SDLs. This has recently become feasible 
in the realm of metabolism, with the advent of genome-scale metabolic modeling. We 
introduce a method that uses a constraint-based genome-scale model of metabolism 
(GSMM)[21-25] to predict metabolic SDLs. GSMMs have successfully resolved a wide 
range of research questions in model organisms[23, 26-30] and have been the basis for 
many computational studies of cancer[7, 8, 31-34]. Furthermore, they have contributed 
to a systematic understanding of the underlying mechanisms leading to lethality and 
SL[3-7]. A major advantage of a model-based approach is that it can provide insights into 
the underlying network mechanisms causing SDLs. Furthermore, the modeling approach 
presented is general and can be used to identify SDLs in species and cell types in which 
“omics” data are missing.
We introduce a computational approach for identifying dosage lethality effects 
(IDLE) in metabolism. IDLE predicts enzymatic SDLs from a GSMM with application to 
cancer. For each enzyme pair (A, B) in the human GSMM, we systematically knock out 
the enzyme flux through A combined with a stepwise flux increase through enzyme B 
and quantify the level of growth reduction. Pairs in which the growth is significantly more 
reduced than when either enzyme is perturbed individually are ranked as SDLs (A↓, B↑) 
with a corresponding value of “strength.”
We demonstrate the predictive power of our approach in five different ways: First, 
by analyzing genome-wide experimental shRNA screens, we show that A↓ in predicted 
SDLs (A↓, B↑) is indeed more likely essential in an overexpressed enzyme B↑ background 
than when B is not overexpressed. When A is underexpressed and B is overexpressed in 
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a predicted SDL in a given tumor sample, we denote that SDL as “active,” that is, bearing 
potential functional effects on the tumor growth and the patient’s survival. Second, we 
show that SDLs are less frequently active across patients with cancer compared with 
randomly selected enzyme pairs, indicating that tumor cells select against the presence 
of SDLs to avoid cell death. Third, we illustrate that tumor size in patients with breast 
cancer (BC) with one or more active SDLs is significantly smaller than in patients expressing 
randomly selected enzyme pairs. Fourth, we show that the predicted impeding effect of 
active SDLs on tumor growth correlates with a significantly longer patient survival time. 
These results become even more pronounced when one includes only highly ranked 
active SDLs (that show a stronger A↓, B↑ pattern at the transcriptional level), illustrating 
that our method successfully identifies the clinical impact of SDLs. Finally, we report that 
observed effects become stronger when more active SDLs are present in a given tumor, 
pointing to the cumulative effect of active SDLs in clinical tumors.
2. Results
2.1 Overview of IDLE algorithm
The IDLE method (Figure 1 and SI Appendix 1) computes the effect on cell growth 
when an enzyme B increases its activity (referred to here as the reference GSMM) 
compared with its activity in a KO GSMM in which, additionally, enzyme A is knocked 
out. The objective of IDLE is to find enzyme pairs (A, B) in which this differential growth 
effect is marked, searching over the space of all possible pairs. For a given pair (A, B), we 
define a reference WT GSMM and compute the maximum growth (biomass, µ
max
) with 
flux balance analysis[35]. Similarly, µ
max
 is computed for the KO GSMM, whereby reaction 
A is knocked out. In both models, the maximum flux through B is computed without 
any constraint on µ (i.e., lower bound is zero; Figure 1A and B show the reference and 
KO GSMM, respectively). Now, the lower bound of the biomass reaction is increased 
stepwise (by using n = 10 steps) toward µ
max
 in both the reference (Figure 1C) and KO 
(Figure 1D) model. For each increase, the maximal allowable flux through reaction B is 
computed again. The increasing growth pressure may affect the allowable flux through 
reaction B and, if so, it must decrease. The basic idea behind IDLE is that this argument 
is reversible: if the growth requirement constrains the maximum allowable flux through 
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B, then a further flux increase through B must decrease growth. This effect is quantified 
and expressed as a vector (Figure 1E). The angle θ between the reference and KO vectors 
measures the difference between the effects on cellular growth of overexpressing 
enzyme B in the WT (A, B↑) and after KO of enzyme A (A↓, B↑). If growth reduction is 
stronger in the KO situation (A↓, B↑), then we define θ positive and the enzymes (A, 
B) form an SDL. SDLs with the largest angle are predicted to have the maximum effect 
and are termed “high-impact” SDLs. We can therefore rank-order SDLs based on the 
computed angle θ (Figure 1F).
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Figure 1 Conceptual overview of the IDLE method. (A) The maximum flux through enzyme B is computed 
when there is no biomass pressure (i.e., lower bound flux is zero). (B) This process is repeated for the KO 
model. (C) The biomass pressure is increased in stepwise fashion and the maximum flux through enzyme B 
is computed at each step. (D) This is repeated for the KO model. (E) The maximum relative flux of B (V
B,max
) is 
plotted at each biomass step (µ
max
) and the angle θ between the reference and KO vector is computed. (F) SDL 
pairs are ranked based on their growth impact, quantified by their angle θ (SI Appendix, Figure S1).
2.2 The metabolic SDL network
Our method discovered 12,447 SDL interactions (SI Appendix 2 and Dataset 
S1). Reassuringly, the ranked list of SDLs significantly matches the top-ranked metabolic 
SDLs identified by the data mining synthetic lethality identification pipeline (DAISY), an 
approach for data-driven inference of genetic interactions in cancer that is based on the 
discovery of underrepresented gene pairs in cancer genomic data[20] (Wilcoxon rank-
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sum P < 0.0038).
SDLs are asymmetrical by definition, i.e., A↓, B↑ denotes a different interaction 
than A↑, B↓, and each may have a very different magnitude; in the first interaction, 
enzyme A is the KO partner, whereas, in the second interaction, it is the overexpressed 
partner. Surprisingly, we discovered that six enzymes are major “master” hubs, being 
the KO partners of many other overactivated B↑ in the SDL network (SI Appendix, 
FigureS2). These major hubs (TPI, ENO, PGM, PYK, PGK, and GAPD) all reside in the 
glycolysis pathway. Interestingly, when examining the hub partners, we observed that 
the B↑ partners are the same for ~80% of the SDLs. The metabolic pathways that are 
enriched for these overexpressed partners are shown in SI Appedndix, Table S3.
To better understand the putative mechanisms underlying the workings of these 
SDLs, we conducted a further model-based analysis. First, we charted SL interactions of 
the six master hubs, i.e., searched for genetic interacting pairs involving these six hub 
reactions in which the growth reduction after their combined KO is larger compared 
with that observed after the single KOs. We were surprised to see that, although these 
SDL hub reactions are highly sensitive to a synthetic dosage load (each being essential 
for ~500 overexpressed partners), they have only very few SL partners (a list of these 
reactions and their pathways is shown in SI Appendix, Table S4. 
Examining the SDL partners of the six central glycolytic hubs, we find that 
they are quite distributed across the metabolic network in 10 different pathways that 
are significantly enriched with the SDL partners (SI Appendix, Table S5). When further 
investigating these SDLs, we discovered that glycogen production is decreased by (on 
average) 60% when such SDLs are active compared with the WT and KO conditions. 
Interestingly, it has recently been shown that glycogen metabolism and its initial 
accumulation is a key pathway induced by hypoxia, and its activity is necessary for 
optimal glucose utilization in tumors[36].
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2.3 SDL is predictive of in vitro shRNA essentiality screens
We expect that a knockdown of enzyme A (A↓) will be lethal in a B↑ background 
in the case of an SDL (A↓, B↑). To study this, we exploited gene essentiality at a genome-
wide scale in cancer cell lines by using experimental shRNA screens[37] and matched 
it with gene-expression profiles[38]. In a typical shRNA screen in a given cell line, each 
gene is individually knocked down by targeting its mRNA (inhibiting and degrading it) by 
specific shRNAs that bind to it. Then, the effect of each individual gene knockdown on 
cell growth is measured, from which scores are calculated that indicate gene essentiality 
[a P = 0.05 cutoff was used to consider a gene essential[37].
For each cancer cell line, we divided SDLs into two groups: group 1 consists of SDLs 
in which at least one of the B enzymes that form an SDL with enzyme A is overexpressed 
(B↑) and group 2 consists of SDLs in which none of the B enzymes are overexpressed 
(Materials and Methods provides the definition of overexpression and SI Appendix, 3, 
provides mapping genes to reactions). Then, the number of essential and nonessential 
A enzymes observed experimentally in the shRNA screen was compared between group 
1 and group 2 in each cell line (one-tailed Fisher exact test). Using a P = 0.05 cutoff, we 
counted the number of cell lines in which enzymes A from group 1 are more frequently 
essential compared with these enzymes in group 2. This procedure was also repeated 
5,000 times for a set of random enzyme pairs of equal size. As expected, the number of 
cell lines in which essentiality of A in a B↑ background is enriched (group 1) is significantly 
higher for SDL than for random pairs (empirical P = 0.002).
2.4 Cancer cells select against SDL
Cancer cells are expected to select against the negative effect that SDLs have on 
(tumor) growth. Thus, when the enzyme pair (A, B) is an SDL, underexpression of enzyme 
A and overexpression of enzyme B should occur less frequently than for random enzyme 
pairs. We analyzed a gene expression dataset of 7,362 patients from the TCGA cohort[39] 
and determined for each gene whether it is underexpressed (↓), overexpressed (↑), or 
unchanged compared with expression levels in normal tissue samples[40] (SI Appendix, 
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4). We then computed for all SDLs the number of patients, F
SDL
, with an active SDL (A↓, 
B↑) relative to those patients having only enzyme A underexpressed (A↓, B) or having 
only enzyme B overexpressed (A, B↑; SI Appendix, 4). This was repeated for 5,000 
randomly constructed enzyme pair sets of equal size (F
RANDOM
). As expected, F
SDL
 is 
significantly smaller thanF
RANDOM
, illustrating that an underexpression of A combined 
with an overexpression of B when A and B have an SDL relation occurs significantly less 
frequently than when the enzyme pair have no SDL relation (Figure 2). In fact, when 
the angle θ increases, the fraction of patients that have an active SDL approaches zero, 
testifying to the strong negative selection exerted on such SDLs.
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Figure 2 Percentage of active enzyme pairs (i.e., A, B) with A underexpressed and B overexpressed. When 
the angle θ increases, the fraction of active SDLs approaches zero. SDLs are significantly less frequently 
active than randomly chosen enzyme pairs. For all cutoffs, the P values obtain their maximum (1+1/5,000+1) 
significance.
2.5 SDL correlates with smaller BC Tumor size
As SDL negatively affects growth in cancer cell lines, we expect that the tumor 
size will be smaller for patients with at least one active SDL compared with those who 
do not. To address this, we used a dataset in which gene expression and matched tumor 
size data are available for 1,587 patients with BC[41]. We divided the patients in this 
heterogeneous dataset based on the estrogen receptor (ER) sensitivity of their tumor 
(key properties of the data set are provided in SI Appendix, 5).
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We analyzed whether the tumor size of patients with an active SDL (A↓, B↑) is 
significantly smaller compared with patients who have one of the single effects, meaning 
only an under- (A↓, B) or overexpression (A, B↑) of enzyme A or B, respectively. To 
investigate A↓, B↑ in relation to A↓, B, we separated patients into two groups: patients 
whose tumor overexpresses enzyme B (Materials and Methods provides the definition 
of overexpression) with varying underexpression of enzyme A (σ between 0 and 3 
given the underlying gene expression distribution) and patients whose tumor does not 
overexpress enzyme B with varying underexpression of enzyme A. When comparing A↓, 
B↑ with A, B↑, we also separated the patients into two groups: patients who have enzyme 
A underexpressed (Materials and Methods provides the definition of underexpression) 
with varying overexpression of enzyme B (σ between 0 and 3 given the underlying gene 
expression distribution) and patients who have enzyme A not underexpressed with 
varying overexpression of enzyme B. Finally, we created random enzyme pairs (n = 5,000) 
to serve as control for testing the specific effects of the SDLs. Statistical significance for 
all comparisons was computed with a signed Wilcoxon rank-sum test, analogous to the 
signed Kaplan–Meier test as previously defined[20] (SI Appendix, 6).
Angle (θ)
Un
de
re
xp
re
ss
io
n 
of
 e
nz
ym
e 
A 
(σ)
 
 
1174
1174
1126
784
324
113
33
1174
1174
1142
857
359
126
38
1174
1174
1163
917
402
143
46
1174
1174
1174
1054
541
207
71
1174
1174
1170
964
450
165
71
1174
1173
1042
535
208
71
34
1174
1136
861
407
150
60
22
1174
1117
805
378
138
55
21
−30 −20 −10 0 10 20 30
0
0.5
1
1.5
2
2.5
3
20
20.5
21
21.5
22
22.5
23
23.5
24
24.5
25
Angle (θ)
Un
de
re
xp
re
ss
io
n 
of
 e
nz
ym
e 
A 
(σ)
 
 
1174
1174
1166
965
455
163
57
1174
1174
1171
1030
516
188
67
1174
1174
1173
1074
565
211
79
1174
1174
1173
1121
689
268
101
1174
1174
1173
1068
573
213
90
1174
1174
1156
849
375
139
52
1174
1174
1121
723
295
109
35
1174
1174
1119
719
293
109
35
−30 −20 −10 0 10 20 30
0
0.5
1
1.5
2
2.5
3
20
20.5
21
21.5
22
22.5
23
23.5
24
24.5
25
Angle (θ)
O
ve
re
xp
re
ss
io
n 
of
 e
nz
ym
e 
B 
(σ)
 
 
1169
1151
1082
849
537
335
211
1172
1163
1114
956
657
446
310
1174
1170
1144
1015
728
508
352
1174
1174
1172
1121
920
677
479
1173
1172
1160
1100
920
690
467
1147
1094
977
802
626
461
303
1040
927
792
668
533
399
267
1014
885
730
610
459
313
202
−30 −20 −10 0 10 20 30
0
0.5
1
1.5
2
2.5
3
20
20.5
21
21.5
22
22.5
23
23.5
24
24.5
25
Angle (θ)
O
ve
re
xp
re
ss
io
n 
of
 e
nz
ym
e 
B 
(σ)
 
 
1174
1174
1174
1150
974
645
391
1174
1174
1174
1166
1090
862
581
1174
1174
1174
1171
1116
909
636
1174
1174
1174
1174
1147
999
746
1174
1174
1174
1172
1123
956
722
1174
1174
1174
1160
1064
855
604
1174
1174
1173
1147
1030
785
539
1174
1174
1170
1134
945
670
422
−30 −20 −10 0 10 20 30
0
0.5
1
1.5
2
2.5
3
20
20.5
21
21.5
22
22.5
23
23.5
24
24.5
25
a
c d
b
Results
77
4
Figure 3 Median BC tumor size (in millimeters) for patients with ER+ disease. Arrowheads denote the median 
tumor size for all patients with ER+ BC (22 mm). The number of patients that express at least one enzyme pair 
are denoted inside the figures. (A) Patients with at least one active SDL (A↓, B↑) with constant overexpression 
of enzyme B. (B) Patients whose disease only underexpresses enzyme A (A↓, B) of the SDL. (C) Patients with 
at least one active SDL (A↓, B↑) with constant underexpression of enzyme A. (D) Patients whose disease only 
overexpresses enzyme B of the SDL (A, B↑).
As expected, we observed in ER+ BC that patients with (at least one active) SDL 
have significantly smaller tumors compared with patients with only overexpression of 
enzyme B (P < 4 × 10−8; Figure 3). We found for ER− disease that the tumor sizes in patients 
with SDL are also significantly smaller compared with patients with only overexpression 
of enzyme B (P < 5 × 10−5), as well compared with those with only underexpression of 
enzyme A (P < 7 × 10−5). Moreover, smaller tumors are observed for patients with ER−and 
ER+ disease with active SDLs compared with patients with randomly selected enzyme 
pairs with the A↓, B↑ pattern active (P < 2 × 10−3).
2.6 SDL correlates with increased cancer survival
As SDLs decrease BC tumor size, we hypothesized that their presence also affects 
patient survival. For the BC data, matched survival times were available such that we 
could correlate them to the level of SDL activation[41]. We hence performed a survival 
analysis analogous to the tumor size analysis described earlier. The significance of the 
results obtained for SDL were compared with the single effects and random pairs by a 
modified signed Kaplan–Meier test introduced in a previous publication[20] (SI Appendix, 
6).
As expected, we found that patients with ER+ BC with at least one active SDL have 
significantly better survival times compared with patients with only an underexpression 
of enzyme A (P < 4 × 10−3, Figure 4A and B). Patients with activated highly ranked SDLs 
show the longest ER+ BC survival times, as long as a median of more than 12 y (Figure 4A). 
In line with expectation, the survival time of patients with active SDL is significantly better 
compared with patients with only enzyme B overexpressed (P < 3 × 10−4; Figure 4C and D). 
Moreover, significantly longer survival is also observed for patients with SDLs compared 
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with those with random enzyme pairs with the A↓, B↑ pattern active (P < 1 × 10−3). SI 
Appendix, 7, provides survival analysis of ER− patients. As overexpression of enzyme B is 
generally not beneficial when enzyme A is not underexpressed, we wondered whether 
underexpressing enzyme B alone would be beneficial. SI Appendix, Figure S5, indicates 
that this is not the case. In particular, severe underexpression of enzyme B correlates 
with increased tumor sizes (SI Appendix, Figure S4A and C) and decreased survival times 
(SI Appendix, Figure S4B and D) in patients with ER+ and ER− BC.
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Figure 4 Median ER+ BC survival time (in years). Arrowheads denote the median survival for all patients with 
ER+ BC (7.4 y). The numbers of patients whose disease expresses at least one enzyme pair are denoted inside 
the figures. Note that the axis of figure a scales differently. (A) Patients with at least one active SDL (A↓, B↑) 
with constant overexpression of enzyme B. (B) Patients whose disease only underexpresses enzyme A (A↓, B) 
of the SDL. (C) Patients with at least one active SDL (A↓, B↑) with constant underexpression of enzyme A. (D) 
Patients whose disease only overexpresses enzyme B of the SDL (A, B↑).
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SDLs predicted by IDLE are not expected to be specific for BC. To examine their 
predictive power in another cancer type, we analyzed a large cancer type-specific cohort 
of 921 patients diagnosed with serous epithelial ovarian cancer (OC)[42] with matched 
survival times. Indeed, the same observations were made as in the case of patients with 
ER+ BC, i.e., patients with OC with at least one active SDL have significantly better survival 
times compared with those with the single or random effects (P < 0.09 vs. A↓, B and P < 
0.01 vs. all others; SI Appendix, Figure S5). These results are even more apparent in 
the relapse-free survival times (OC-RFS) of these patients (P < 0.02 vs. A↓, B and P < 9 × 
10−4 vs. all others; SI Appendix, Figure S6).
2.7 Cumulative effect of SDLs in a tumor correlates to better survival
As SDL activity in a tumor correlates to survival prognosis, we asked if survival 
time would increase when patients have more SDLs active. We tested the presence of 
such a cumulative effect in the two largest cancer subtypes: patients with ER+ BC (n = 
1,174) and those with serous epithelial OC (n = 921). Patients were categorized into three 
groups, those having one to three, four to eight, or more than eight active SDLs in their 
expression profiles (over- and underexpression are defined in Materials and Methods).
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Figure 5 Kaplan–Meier survival curves for patient groups that have one to three, four to eight, 
or more than eight active SDLs. (A) Survival times for the patients with ER+ BC. (B) Survival times 
for patients with serous epithelial OC.
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The Kaplan–Meier survival curve in Figure 5 shows, as expected, better survival 
for patients with large numbers of active SDLs compared with those with only a few active 
SDLs. Indeed, a log-rank test[43] revealed significantly improved survival times in both 
cancer types when the number of active SDLs increases (P < 8 × 10−3 for ER+ BC and P < 
2 × 10−3 for OC and OC-RFS). The largest cumulative effect in the BC survival is related to 
SDLs being active with enzyme A as one of the major glycolytic hubs. Interestingly, the 
observed cumulative effect in OC is already present for patients who have four to eight 
active (Figure 5B). The underactivated enzymes A in these SDLs are enriched for pathways 
that use glutamine through glutamate metabolism, the TCA cycle, and mitochondrial 
transport (P < 0.001, hypergeometric test). It has recently been shown that severe types 
of OC, such as the epithelial subtype we considered, are driven by glutamine metabolism, 
in contrast to BC tumors that depend on an overactivity of glycolytic enzymes[44].
3. Discussion
Here we introduce what is, to our knowledge, the first computational method 
that captures enzymatic SDL effects in metabolic networks. Our method does not only 
identify SDLs that are strictly lethal to the cell, but also those that have a significant 
effect on tumor growth or proliferation in clinical settings (i.e., “synthetic dosage sick”). 
We show that our method is able to assign a measure of strength θ to each SDL, which 
correlates to its predictive power in an array of different tumor clinical attributes. It is 
therefore of interest to focus further research toward therapeutic interventions on the 
basis of “high-impact” pairs, which may have the largest beneficial effect on killing cancer 
cells.
We show that SDLs are less frequently active than expected in cancer cells. This 
shows that rapidly expanding cancer cells select against interactions that reduce their 
growth rate. The activation of “high-impact” SDLs is associated with smaller tumor sizes 
and longer patient survival. The effect strongly depends on the extent to which SDLs 
are activated, but most SDLs we found do not require a complete enzyme KO to exert a 
functional predictive signal. Last, we demonstrated a cumulative effect of SDL presence; 
the more SDLs active in a tumor sample, the better this is for a patient’s prognosis. This 
observation may shed light on targeting cancers that rely on glycolysis. Down-regulating 
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glycolytic enzymes that are the major hubs in the SDL network is hence expected to have 
a large growth-inhibitory effect in tumor cells that overexpress many of the glycolytic SDL 
partners. As glycolysis is usually less active in normal cells, and SDL partners of glycolytic 
hubs are less frequently overexpressed in normal cells compared with cancer cells in 
the majority of tissue types (SI Appendix, 2.2), targeting these glycolytic SDLs may be of 
therapeutic interest, especially when a large number of their partners are overexpressed.
The present study, being the first of its kind of which we are aware, naturally 
focuses on harnessing the generic human metabolic model to identify a common core 
of SDLs that may be shared by many different cancer types. However, the IDLE approach 
is general and could be extended in the future to identify cancer type-specific SDL 
interactions more precisely by integrating patient- and tumor-specific omics data such as 
gene expression or proteomics.
The results of our metabolic network modeling do not support the hypothesis 
that SDLs arise as a result of draining alternative compensatory pathways that 
compensate for the loss of the KO enzyme. This is because we do not find that the flux 
in such backup reactions of the major key glycolytic enzyme hubs is reduced following 
the overexpression of their SDL partners. Intriguingly, we do find that disrupted glycogen 
metabolism is predicted to be the major mechanism by which hundreds of SDLs of key 
glycolytic enzymes exert their growth-inhibitory effects. Indeed, it has recently been 
shown that glycogen metabolism and its initial accumulation is key for optimal glucose 
utilization in tumors[36]. Thus, SDL relations do not arise via simple proximal interactions, 
but are likely to be the result of complex stoichiometric network relations that withdraw 
flux from biomass production through activation of other pathways.
Our results testify to the potential contribution of model-based approaches to 
identify and uncover the mechanisms behind SDLs. Model-based SDL prediction via IDLE 
is widely applicable and not limited to cancer. It could be used to identify SDL networks in 
pathogenic bacteria or fungi, providing new antibiotic therapeutic leads. Other possible 
applications include metabolic engineering to increase the yield of valuable metabolic 
byproducts. Specifically, this may be achieved by engineering an SDL effect to inhibit the 
production of undesired byproducts, or inversely, neutralizing the SDL effect to force an 
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increased flux through desired pathways. Taken together, IDLE is expected to contribute 
to various research fields ranging from medical sciences to biotechnology.
4. Material and Methods
IDLE requires a GSMM with m metabolites, n reactions, and a well-defined cellular 
objective function. We used the human metabolic network (recon1)[45], supplemented 
with a biomass reaction to simulate growth. A rich environment was simulated by allowing 
a maximum metabolite uptake rate of 5.0 mmol/gram dry weight/h through all boundary 
reactions. The goal of IDLE is to find SDL enzyme pairs (A, B) that severely interrupt cell 
growth when the flux through enzyme A is decreased and the flux through B is increased 
(denoted as A↓, B↑). As illustrated in Figure 1  and SI Appendix, 1, SDL is measured by an 
angle θ. Only those enzyme pairs with a significant difference between the reference and 
KO were analyzed, i.e., all pairs with |θ| ≥ 2° were selected, resulting in a list of 12,447 
putative SDLs. SI Appendix, 1, provides a detailed description of IDLE with an example.
In all analyses, we defined an enzyme/gene to be under- or overexpressed when 
its expression was below or above 0.5σ to 1.0σ from the mean in the gene expression 
distribution (see Results for references to gene expression datasets).
Detailed procedures of mapping gene expression to enzyme reaction level and 
calculating the fraction of SDLs in cancer cells (F
SDL
) and descriptions of tumor size and 
patient survival statistics are provided in SI Appendix, 1.
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Abstract
Synthetic lethal (SL) interactions describe the functional relationship between 
two genes where the combined mutation of both genes leads to a more severe phenotype 
than the expected effect of two single mutations. Such interactions are valuable to provide 
therapeutic strategies for cancer. However, broadly spread inter- and intra- heterogeneity 
of tumors limit the efficiency of systematically finding anti-cancer target via SL 
interactions. Here, we present the Human Synthetic Lethality Database (HuSLDB), storing 
618513 human SL interactions, among which 15614 are based on direct experimental 
identification and 602899 are based on computational inference. To overcome the 
challenge in cancer treatment presented by prevalent genetic heterogeneities, our 
database provides a web interface to predict drug targets at the level of tumor type and 
at the level of individual patients, by integrating copy number variations and expression 
profiles of tumor samples. To facilitate the design of experimental validation of predicted 
targets, HuSLDB proposes test cell lines that resemble the genetic features of the tumor 
type most, and control cell lines as a proxy of cells in normal healthy tissue. Thus, HuSLDB 
is a valuable resource tool for researchers working on identifying personalized anti-cancer 
targets from prediction to experimental design.
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1. Background
Two genes have a synthetic lethal (SL) interaction if the fitness defect of a 
double mutation is more severe than the expected effect of two single mutations. It 
has been shown that this type of functional relationship can provide information on 
various aspects, ranging from understanding the relationships between genotypes 
and phenotypes[1-3] to revealing the molecular mechanisms of different cellular 
processes[4, 5]. More importantly, SL interactions provide a clear conceptual framework 
for anti-cancer therapeutic treatment strategies, i.e., inhibiting one gene of a SL pair can 
selectively kill tumor cells in which the second gene is mutated, while leaving the normal 
cell relatively unaffected. 
With the current development in experimental techniques[6-9] and 
computational methods[10-12], multiple large-scale SL interaction datasets have been 
generated in human cells [13-15], which provide a valuable resource to discover new 
anti-cancer targets. Recognizing the value of a comprehensive overview of SL interactions 
for identifying anti-cancer targets Guo et al[16]  constructed a database including 16913 
SL interactions (2792 computationally predicted and 14121 experimentally identified). 
The database provides functional information for the potential anti-cancer targets, such 
as drug sensitivity. With such database in hand, cancer researchers can more effectively 
search for potential targets. However, there are still limitations to systematically explore 
potential targets. First, the widespread genetic heterogeneity within and between 
tumors poses a major challenge for successful anti-cancer treatments and is a major 
explanation for the failure of some existing drug treatments[17-19]. Inhibiting a target 
gene will only be effective for patients whose tumor tissue has a dysfunctional SL 
interaction partner gene. Such genetic background variation between different cancer 
types and between patients underlies the necessity to find cancer-type specific anti-
cancer targets at a personalized level. Secondly, after obtaining potential targets from 
the database, an in-vitro experiment needs to be set up to further validate whether the 
target will indeed inhibit growth of tumor cells but not normal cells. One main challenge 
in such experimental design is to find the most representative tumor cell lines, i.e., i) 
the cell lines should be genetically similar to clinical tumor sample tissues and ii) the SL 
interaction partner of the targets should be dysfunctional[15], e.g. by a point mutation, 
gene deletion or under-expression. 
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Here, we present the Human Synthetic Lethality Database (HuSLDB), a 
comprehensive database of 618513 unique SL interactions in human, which identifies 
potential anti-cancer drug-targets at tumor type and individual patient level, and which 
proposes the experimental design to validate the targets. HuSLDB contains the most 
up-to-date data from both empirically and computationally identified SL interactions in 
human[12, 14-16], up to 30 fold more interactions than most comprehensive existing 
database[16]. On top of that, HuSLDB integrates copy number variation (CNV) and 
expression profiles of tumor tissue samples to handle genetic heterogeneity and to 
facilitate designing the experimental validation in cell lines. HuSLDB proposes targets 
specific to 33 tumor types and to individual patients by selecting targets whose SL 
interaction partner is dysfunctional. Most interestingly, for each predicted target, HuSLDB 
screens the genetic profiles of more than 1000 tumor cell lines and proposes test and 
control cell lines for further experimental validation in vitro.
2. Methods and Materials
2.1 Compilation of synthetic lethal interactions
The compiled SL interactions are either experimentally identified in human cells 
or computationally predicted in human cells. In total, we retrieved 618513 unique SL 
interactions, among which 15614 are detected via direct experiments and 602899 are 
computationally predicted [12, 14, 15]. We first directly retrieved a list of more than 
591,000 SL pairs predicted by our Cancer Genome Variation method[15] and a list of 
around 2800 SL pairs by DAISY[14]. These two methods predicted SL pairs based on the 
assumption that compared to non SL pairs, genes with SL interactions are less likely to be 
simultaneously co-lost in human genome[15] or more likely to have an over expressed 
gene when the other gene of a gene pair is under expressed[14]. Secondly, to increase 
the genome coverage of SL pairs predicted via the Genome Evolution method[12], we 
applied this prediction model to a protein-protein interaction network containing more 
than 99,000 physical interaction pairs identified in human  (Supplementary Table 2). In 
total, more than 8800 SLs were predicted by Genome Evolution. Thirdly, we retrieved 
14121 experimentally identified SL pairs that are curated in SynLethDB[16]. These pairs 
are collected from i) multiple high-throughput genetic interaction screening assays and 
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ii) text mining results from 1000 publications. Additionally, we compiled ~1500 SL pairs 
from most recent literature by searching for literature published after 2011 that contains 
key words as synthetic lethality/genetic interaction, screening, cancer and human in the 
title or abstract (Supplementary Table 3). 
2.2 Identifying over- or under-expressed genes in different tumor types
For each tumor type, we retrieved the normalized RNAseq reads generated by 
an Expectation Maximum pipeline (RSEM)[20] from the Broad Institute’s Genome Data 
Analysis Center Firehose[21]. In total, gene expression profiles are compiled for 33 types 
of tumors. Then, for each gene in a tumor type, we inferred differentially expressed genes 
via comparing the Log2-transformed gene expression value in the tumor samples with 
that in the same tissue type from the normal samples. The P-value is calculated using 
the two-sided Wilcoxon rank test implemented in R. False Discovery Rate (Benjamini-
Hochberg) is applied to adjust for multiple hypothesis testing. A cutoff of the adjusted 
p-value, 0.05, and a cutoff of the Log2-ratio, +/-0.6, were applied to determine over/
under-expressed genes. The normal comparison group is defined as follows: if more than 
25 normal samples of the same tissue as the tumor are available, we use them as the 
comparison group. Otherwise all normal samples, 761 in total, of all tissue types are 
used[15].
2.3 Compiling focal copy number variants in different tumor types
The copy number variants (CNVs) for each tumor type are directly downloaded 
from TCGA level 4 data[21], which applied GISTIC2.0[34] to generate focal CNV calls by 
excluding the chromosomal arm-level mutations. In total, we compiled focal CNV profiles 
for 33 types of tumors.
2.4 Proposing test and control cell lines for experimental validation of 
predicted targets
We first retrieved CNV profiles for more than 1000 cancer cell lines directly from 
the Cancer Cell Line Encyclopedia (CCLE)[22], which contains log2(CN/2) ratios for all 
genes in each tumor cell line. These cell lines have a coverage of 28 cancer types. We 
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applied both high- (0.3) and low-level (0.1) thresholds to determine gene copy number 
variations of all cell lines. In each cell line, genes with log2 ratios that exceed the high-
level threshold are annotated as a homozygous duplications or deletions (2/-2), and 
those that exceed the low-level threshold but not the high-level one are annotated as 
heterozygous duplications or deletions (1/-1).
By integrating the CNV profiles, we proposed cell lines that can be used as test or 
control in experiments for validating the predicted targets (Table1). The test-control cell 
lines are determined on both the stringent and the medium level. On the stringent level, 
if gene A is the predicted target, cell lines where gene B is homozygously deleted and gene 
A is retained as normal copy or duplicated are identified as test samples. Correspondingly, 
cell lines with a CNV status of, where A , but not B, is homozygously deleted, are proposed 
to be control samples. For test-control cell lines on a medium level, the only difference 
between the stringent level ones is that gene B is heterozygously deleted.
For 5 tumor types, i.e.,adrenocortical carcinoma (ACC), cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC), rectum adenocarcinoma (READ), 
testicular germ cell tumors (TGCT) and uveal melanoma (UVM), there are no CNV profiles 
available from cell lines. In total, we proposed the test and control cell lines for each 
predicted anti-cancer target in 28 tumor types. 
Table 1 Proposing test and control cell lines based on CNV profiles of cell lines.
A is the target (A:B)
1: test (stringent) 2: control (stringent) 3: test (medium) 4:control (medium)
0:-2 -2:0 0:-1 -1:0
1:-2 -2:1 1:-1 -1:1
2:-2 -2:2 2:-1 -1:2
-2/-1 represents homozygous/heterozygous deletion of a gene. 2/1 represents homozygous/heterozygous duplica-
tion of a gene.
2.5 Calculating genetic similarity scores between cell lines and the 
corresponding tumor tissue samples
We also generate a score to quantify the genetic similarity between the cell lines 
and their corresponding tumor tissue. The method to calculate this score is adapted 
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from the method developed by Domcke et al[23]. For each cell line, the genetic similarity 
score, S, is composed of four parameters and formulated as S = A + B -C -D, where A is 
the correlation of the CNV of a cell line and the mean CNV of the corresponding tumor 
tissue, B quantifies the shared mutations between a cell line and its corresponding tumor 
tissue, C quantifies the number of genes that are mutated in the cell line and in tumor 
samples of different tissue origin, and D is 1 for hyper-mutated cell lines and 0 otherwise. 
The score, S, is normalized by scaling within the range of 0 to 1. In the following section, 
we describe the calculation of these four parameters in detail.
A is the Pearson correlation coefficient between the CNV profile of a cell line 
and that of tumor samples with the same tissue origin. The CNV profile for each cell line 
was directly retrieved from the Cancer Cell Line Encyclopedia (CCLE)[22]. The mean CNV 
profiles of tumor tissue samples were computed as the mean copy number signal of 
each gene across the tumor tissue samples. The copy number signal is calculated from 
log2(CN/2) ratios, which are available in TCGA level 4 data[21].  
B is used to estimate the extent to which one cell line contains mutations that 
are often mutated in the tumor samples of the same tissue origin but not in the other 
tumor samples.  It is defined as B =
n
Nt
, where N
t
 is the number of mutations that are 
often mutated in the tumors samples of the same tissue origin as the cell line but not in 
tumor samples of other tissue types; n is the number of tumor-specific mutations that is 
found in the cell line. To calculate this fraction, we first need to identify highly mutated 
genes in each tumor type. We retrieved the mutation profiles processed by MutSig2.0 
directly from TCGA[24], which contain indels, nonsense mutations, splice-site mutations 
and non-stop mutations. The mutation profile reports the number of tumor samples 
containing a mutation at a gene locus. The mutation frequency of a gene in one tumor 
type is calculated as f = n1/n2, where n1 is the number of tumor tissue samples with the 
mutated gene and n2 is the total number of tumor tissue samples. Then, we plotted the 
mutation frequency distribution for all genes (Supplementary Figure 1) and determined 
the cutoff of mutation frequency from the distribution plot to call frequently mutated 
genes (Supplementary table 1) in each tumor type. As for the mutation profile for tumor 
cell lines, CCLE measured the mutation status of 1667 genes across 905 cell lines with a 
coverage of 29 tumor types. Provided with the mutation profiles on both cell line and 
tumor tissue level, for each cell line, we counted i) the number of overlaps between 
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genes detected to be frequently mutated in the corresponding tumor tissue samples 
(N
t
) and genes included in the mutation detection array of the cell line, ii) the number of 
genes that are mutated both in the cell line and in the tumor tissue samples (n).
Moreover, for each cell line we counted i) the number of genes that are detected 
to be frequently mutated in the tumor samples with a different tissue origin of the cell line 
(M
t
), ii) the number of genes that are mutated both in the cell line and in the discordant 
tissue-origin tumor samples (m). Thus, the parameter C is calculated as C =
m
Mt
.
The fourth parameter, D, is defined to be 1 for hyper-mutated cell lines and 0 for 
non hyper-mutated ones. The mutation density of a cell line is determined as D = M
c
/B, 
where M
c
 is the mutation count and B is the number of bases covered in sequencing. 
CCLE provides coverage of the sequenced region, which is the number of reads per base. 
Thus, the number of bases covered in sequencing is calculated as the number of genome 
positions with at least one read. For each tumor type, we plotted the distribution of the 
mutation frequency of the cell lines (supplementary figure 2), from which we determined 
the cutoff of mutation frequency to call the hyper-mutated cell lines (supplementary 
table 1).
2.6 Database and interface design
The compiled SL interactions and all pre-calculated results are stored into an 
SQLite [25]database. The web interface of the database is implemented in Flask, a Python 
web framework. User queries are handled by Flask and the search results are generated 
by SQLAlchemy (http://www.sqlalchemy.org/) from the database. In the result pages, 
the dynamic and searchable tables were designed by using the DataTables plug-in of 
jQuery. HuSLDB is available at http://www.cmbi.ru.nl/psl/.
3. Results and Discussion
3.1 The structure and the statistics of HuSLDB
We compiled a list of 618513 unique synthetic lethal (SL) interactions, among 
which 15614 are experimentally identified in human cells and 602899 are computationally 
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predicted in the human genome[12, 14, 15]. Based on the detection methods, we 
defined four types of evidence for SL interactions: Cancer Genome Variation[15], 
Genome Evolution[12], DAISY[14], and Experiment. Cancer Genome Variation generates 
scores range from 0 to 1[15]. A higher score indicates that the prediction is more 
likely to be correct. In the paper[15], a cutoff on this score, 0.81, was applied to call 
SL pairs , which achieved a prediction precision of 67%. In HuSLDB, pairs with a score 
smaller than 0.81 were assigned with zero to indicate no strong evidence was found 
in Cancer Genome Variation. Genome Evolution predicts a gene pair A-B to have an SL 
interaction if the functions of A and B both depend on a common third gene C. For SL 
pairs predicted by this method, we listed the gene names of this common third gene C. 
DAISY predicts SL interactions based on the assumption that SL pairs are more likely to 
have an overexpressed gene when its partner is underexpressed than non SL pairs. It 
integrates predictive features extracted from genomic data of cancer samples. A binary 
value is assigned to the SD interactions predicted by DAISY, where 1 implies having an 
SL interaction and 0 implies having no SL interaction. SL pairs with direct experimental 
evidence (Experiment) are listed with their literature references, i.e., PubMed IDs. See 
the methods section for further details on the compilation of SL pairs.
The HuSLDB is designed to fulfill three main purposes, i) to provide a list SL 
interactions that involve query genes, ii) to predict potential anti-cancer drug targets on 
a personalized level on the basis of the mutation profile of a patient and iii) to predict 
potential anti-cancer drug targets that are specific to a tumor type, and propose the 
test and control tumor cells for the predicted targets based on CNV profiles from clinical 
tumors (Figure 1). 
For the first purpose, to retrieve the synthetic lethal interactions, users need 
to provide query genes, which can be either an Entrez gene ID or the gene symbol, in 
the query box. After users submit the query to the server, HuSLDB will return a table of 
synthetic lethal interactions involving at least one of the query genes. In addition to the 
gene ID and name, the retrieved table contains the evidence for the SL interactions and 
information indicating whether both genes of a SL interaction happen to be in the query 
gene list.
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A list of SL pairs A list of predicted
targets for a patient
A list of predicted
targets for a cancer type
Proposed cell lines for
further experiments 
validation of targets
- python ask
- jQuery
- Javascript
- html
- sqlite
Query
Genes
Database
Application
SL
Purpose 1
Purpose 2
Purpose 3
Data compilation
Experimentally 
identied SL pairs
Computationally 
identied SL pairs
CNV, RNA and mutation
 proles for 33 cancer types
CNV and mutation proles
for 1043 tumor cell lines
CCLETCGA
Figure1 The workflow of HuSLDB design. The database is composed of 3 different data sources, i.e., the 
compilation of both experimentally and computationally identified SL interactions, genomic profiles of 33 
different tumor types and the genomic features of more than 1000 tumor cell lines. HuSLDB is designed 
with three different purposes, which are colored in black, red and blue workflow lines. Provided with a list 
of query genes, HuSLDB can i) retrieve a list of SL interactions where at least one of the pairs is a query gene 
(the black lines); ii) retrieve a list of predicted personalized anti-cancer targets (the red lines); iii) retrieve a list 
of predicted targets for a specific cancer type and propose test and control cell line for further experimental 
validation (the blue lines). 
The second function of our database, which is more clinically relevant, is to 
predict the anti-cancer target on a personalized level. To do this, a list of genes where a 
loss of function mutation is detected in a patient is required. This needs to be provided in 
the query box. Next, the user needs to select the cancer type of the patient. Finally, the 
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user can decide to upload a list of genes for which a gene duplication or overexpression 
is identified.  These genes will be included as information to prioritize the predicted 
anti-cancer target for this patient. The underlying reason is that if two genes provide a 
function backup for each other, one gene may be overactive such that it compensates 
for the dysfunction of its partner as has e.g. been observed by an increase in the copy 
number of the compensating gene[14]. After submitting the query to the server, HuSLDB 
will return a table of SL interactions of which the query genes have a loss of function 
mutant in the patient and, as such, the SL interaction partners of these query genes 
are predicted to be drug targets. Moreover, the table shows information if the target 
genes are found to be frequently over-active, e.g. by an increase in copy number, in the 
cancer type of the patient, which can be used to further prioritize the predicted targets. 
A hyperlink to GeneCards[26] is created for each predicted target, from which users can 
easily check whether any drug compounds are available for the targets.
The third function that our database is specifically designed for is to identify 
tumor type specific drug targets. Recent studies have revealed the large amount of 
genetic heterogeneity across different tumor types[27-29], implying that killing cancer 
cells via an SL interaction may be effective in one tumor type but ineffective in others. 
This provokes the necessity to predict anti-cancer targets on a tumor-type specific level. 
To do that, for each tumor type, we integrated genome-wide copy number variants, 
mRNA expression variations and point mutations to the compiled SL interaction set and 
identified the potential targets. A gene is considered to be the potential target if its SL 
interaction partner is found to be mutated, deleted or under-expressed in the tumor 
tissue. Moreover, for each predicted target in a tumor type, we screened the CNV profile 
of ~1000 tumor cell lines and proposed the test and control cell lines for further validation 
of the targets in vitro. A test cell line is required to i) have the same tissue origin as 
the tumor type and ii) host a homozygous deletion of the SL interaction partner of the 
predicted target. Conversely, the SL interaction partner gene is required to be present 
in the genome of a control cell line. Current studies usually construct a control cell line 
from the test cell line by reintroducing the deleted SL interaction partner gene[30] or 
directly use the cell lines containing a normal copy of the SL interaction partner gene as 
control ones[31]. Here we propose control cell lines for each predicted target by selecting 
cell lines containing the SL interaction partner in their genome. In total, HuSLDB can 
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specifically predict targets for 33 tumor types and proposes test and control cell lines for 
the predicted targets in 28 out of 33 types. Due to the unavailability of experimental data, 
five tumor types are without cell line information in HuSLDB: adrenocortical carcinoma 
(ACC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), 
rectum adenocarcinoma (READ), testicular germ cell tumors (TGCT) and uveal melanoma 
(UVM). To predict tumor type-specific drug targets that have SL interactions with query 
genes that are absent in the tumor type, the first step is to submit a list of query genes 
or to submit all genes in the human genome as query. Next, the users can select the 
source of genomic variations, which will be used to filter out query genes that are not 
absent in the tumor type. After selecting the tumor type for which potential targets are 
to be predicted, the users can submit the query genes. HuSLDB will return two tables. 
One table lists all predicted targets in the specified tumor type. The other table contains 
the summary information of the proposed control and test cell lines for each predicted 
target. Additionally, this table also includes one column with information indicating the 
gene amplification or overexpression status of the predicted targets for further target 
prioritization. A hyperlink to drug compounds curated in the GeneCards database is 
created for each target. To better facilitate the experimental validation, the users can 
select one or multiple targets and submit the request to retrieve the information on 
which cell lines can be used as test cell lines and control cell lines. The test and control 
cell lines are inferred from CNV profiles of more than 1000 cancer cell lines[22]. Cell lines 
where the target is retained as normal copy or duplication but it SL interaction partner is 
homozygously deleted or under-expressed will be proposed to be test samples. Cell lines 
hosting a homozygous deletion of the target but not its SL interaction partner will be 
proposed to be control samples. Moreover, to quantify the extent to which a test cell line 
is representative for the mass of tumor tissues from patients, we calculated a score of the 
genetic similarity between a cell line and its corresponding tumor tissue samples. This 
score is determined by considering the similarity between the CNV and mutation profiles 
of a cell line and the corresponding tumor tissue (see methods for detail). As such, the 
predicted test cell lines with a high genetic similarity score can be proposed as the test 
cell line that is genetically representative for the tumor tissue samples for experimental 
validation.
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3.2 Applications and data usage
Search results 1: 54  targets that are predicted to have an SL 
interaction with VHL in lung cancer
                                               Search results 2: 
• proposed test and control cell lines for the 54 predicted targets
• 3 out 54 predicted targets are signicantly over-expressed or amplied
  in lung tumor tissue samples
Search results 3: prioritizing the proposed test cell lines that
 share high genetic similarity with the tumor tissue samples
Link to NCBI-Gene 
for query genes
Link to NCBI-Gene 
for target genes
Download search
results
Link to pubmed for
Experimental evidence
Proposed test cell lines where 
the query gene is homozygous deleted
Proposed control cell lines where 
the target gene is homozygous deleted
T: predicted targets is over-expressed 
or amplied in tumor tissue samples
Link to Genecards database to obtain 
drug inhibitor information of the target
click on the row of the interested target;
then click here to view the cell line info
Genetic similarity score, ranging from 0 to 1,
 between this cell line and the tumor samples 
of the same tissue origin
Information on whether this cell line can be
used as a test or control cell line. 0 represents 
it is neither a test or control cell line  
Start the analysis: searching SL partners 
for VHL in lung cancer
type query gene names VHL
choose the mutation proles
used to infer whether the query
 genes has loss of function mutations
choose the cancer type for which 
the user wants to search for drug 
candidates
Figure2 Screenshots of the application case 1. We applied HuSLDB to find anti-cancer targets with the Von 
Hippel-Lindau tumor suppressor gene, VHL, in lung cancer. Text in the orange boxes provides details on the 
inputs and outputs of the database. 
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By fixing VHL as query gene and using different genetic profiles in the filtration 
steps and varying the tumor type selection, we found that the targets in ccRCC are 
possible targets in 8 other tumor types, i.e., rectum adenocarcinoma (READ), kidney 
renal papillary cell carcinoma (KIRC), pheochromocytoma and paraganglioma (PCPG) 
and colorectal adenocarcinoma (COADREAD), cholangiocarcinoma (CHOL), lung 
adenocarcinoma (LUAD), skin cutaneous melanoma (SKCM) and testicular germ cell 
tumors (TGCT). In our database, 54 genes were annotated to have a SL interaction with 
VHL. Interestingly, CDK6, which is experimentally determined to have a SL interaction 
with VHL in ccRCC, is found to be an essential gene in lung cancer cells[32]12. In the LUAD 
lung tumor patient cohort, the VHL gene has been found to be homozygously deleted in 
110 out of 516 tumor samples, suggesting that CHK6 can also be an effective target for 
lung cancer.
To illustrate the functionality and usage of HuSLDB, we present two applications.
Case 1: Anti-cancer targets with the Von Hippel-Lindau tumor suppressor gene, VHL 
(Figure 2).
Given the genetic heterogeneity among different tumor types, the targets that 
are experimentally validated in one cancer type may not be effective in the cancer types 
where the SL interaction partner genes function normally. HuSLDB, which integrates 
genetic profiles of 33 tumor types, makes it feasible to quickly determine whether the 
targets can be potentially effective in other tumor types by screening the mutation status 
of the partner genes. Here, we illustrate an example that the targets validated in clear-
cell renal cell carcinoma (ccRCC) were found to be potentially inhibitive to the growth of 
lung tumor. VHL is a tumor suppressor gene and found to be frequently inactive in clear-
cell renal cell carcinoma (ccRCC). Several genes were experimentally detected to have SL 
interactions with VHL in ccRCC. These genes can potentially be translated to therapeutic 
targets in other tumor types where VHL is often mutated.
Taken together, HuSLDB can facilitate cancer researchers to find potential targets 
associated with their genes of interest in a tumor type by considering its mutation 
landscape.
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Case 2: Experimental design for testing potential anti-cancer drug targets
Another important application of HuSLDB is to propose clinically relevant 
test and control cell lines for further experimental validation of the predicted targets. 
One example that HuSLDB correctly identifies is the test cell line for validating the SL 
interaction between CDK12 and PARP1/2[33]. By using CDK12 as the query gene and 
selecting OV (ovarian serious cystadenocarcinoma) as the tumor, PARP1/2 is found to 
have a SL interaction with CDK12. The following research step would be to validate the SL 
interaction in vitro. Due to ovarian tumor heterogeneity, inhibiting PARP1/2 will only lead 
to lethality in ovarian tumor cells with a dysfunctional CDK12. There are two strategies to 
obtain such a test cell line:  i) creating the cell line by knocking out/down CDK12, and ii) 
selecting tumor cell lines that not only host a dysfunctional (absent) CDK12 but also share 
high genetic similarity with the clinical tumor tissue samples. The availability of genomics 
data of more than 1000 cancer cell lines makes the second strategy feasible, which can 
save both time and experiment cost required by the first strategy. Moreover, by taking 
the complete genetic background into consideration, the second strategy may propose 
test cell lines, which are genetically more representative of patient samples than the 
cell lines created by gene knocking out/down. Following this strategy, HuSLDB screened 
gene expression, CNV and mutation profiles of 51 ovarian tumor cell lines and proposed 
five test cell lines for experimental validation of PARP2 where CDK12 is dysfunctional: 
KURAMOCHI, OVKATE, JHOM2B, NIHOVCAR3 and CAOV3. Interestingly, CAOV3 is indeed 
one of the test cell lines used in the study to validate the SL interaction between CDK12 
and PARP2[33]. Moreover, HuSLDB can quantify the genetic similarity shared between 
each proposed test cell line and the available ovarian tumor tissue samples from TCGA. 
Here, all of the five cell lines have a high genetic similarity score when compared with 
the CNV and mutation profiles of the ovarian tumor tissue samples. This indicates that 
the cell lines are representative of clinical tumor tissues and the effectiveness verified in 
vitro can be extended to the in vivo level. Such type of usage can accelerate the design of 
validation experiments and is instructive for selecting clinically relevant candidate targets 
for further in vivo experiments.
4. Conclusions
SL interactions can be applied directly to identify anti-cancer targets. To increase 
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the application value of SL interactions in finding therapeutically effective targets, it is 
required to consider the widespread genetic heterogeneity in proposing cancer-type or 
patient specific anti-cancer targets. Here, HuSLDB was developed as a database to store 
and query the publicly available human SL interactions in a way that researchers are able 
to efficiently use SL interactions in the search for anti-cancer drug-targets via a user-
friendly interface. By integrating the genetic profiles from tumor patient samples, HuSLDB 
can be extensively used by cancer researchers to find potential targets in 33 different 
tumor types, or specifically in a patient. Moreover, to facilitate the design of subsequent 
in-vitro experimental validation of the targets, HuSLDB can propose suitable cell lines 
that share high genetic similarity with the tumor tissue from patients. Taken together, 
the construction of HuSLDB is expected to facilitate the identification of personalized 
anti-cancer drug targets.
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Supplementary table 1 Summary table for available data for each type of tumor. 
Tumor_Type
sample_
size
CNV RNA mutationInfo Cell_Line_CNV cutoff on hyper mutated 
cell lines (Mutation/MB)
ACC 90 T T T F F
BLCA 395 T T T urinary_tract 20
BRCA 977 T T T breast 15
CESC 194 T T T F F
CHOL 35 T T T biliary_tract 7.5
COAD 366 T T T large_intestine 50
COADREAD 488 T T T large_intestine 50
DLBC 0 T T F haematopoietic_and_lymphoid_tissue 25
ESCA 0 T T F oesophagus F
GBM 283 T T T central_nervous_system,autonomic_ganglia 9
GBMLGG 796 T T T central_nervous_system,autonomic_ganglia 9
HNSC 510 F T T F F
KIPAN 0 T T T kidney 10
KICH 66 F T T F F
KIRC 451 T T T kidney 10
KIRP 161 T T T kidney 10
LAML 197 T T T haematopoietic_and_lymphoid_tissue 25
LGG 513 T T T central_nervous_system, autonomic_ganglia 9
LIHC 197 T T T liver 10
LUAD 545 T T T lung 18
LUSC 178 T T T lung 18
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OV 466 T T T ovary 15
PAAD 146 T T T pancreas 14
PCPG 178 T T T central_nervous_system,autonomic_ganglia 9
PRAD 425 T T T prostate 30
READ 122 T T T F F
SARC 0 T T F bone,soft_tissue F
SKCM 290 T T T skin 20
STAD 289 T T T stomach 20
STES 289 T T T stomach,oesophagus 20
TGCT 149 T T T F F
THCA 401 T T T thyroid 12
UCEC 248 T T T endometrium 60
UCS 57 T T T endometrium,soft_tissue 60
UVM 80 T T T F F
The first column is the abbreviation for the types of tumors. The second column contains the number of tissue samples from tumor patients for each type. The third to the fifth column contain the 
information on whether CNV, RNA and mutation profiles are generated and available in TCGA. The sixth column lists the tissue origin of the ~1000 cell lines. The seventh column lists the cutoff on 
mutation density for calling hyper mutated tumor cell lines, which is determined from Supplementary figure 2.
Supplementary tables 2 and 3 are available from https://drive.google.com/drive/folders/0B3L0UQbkazbcY3ItQ19mbUZBOTQ
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Supplementary Figure 1 The mutation frequency of each gene in tumor tissue samples. The mutation fre-
quency of a gene was calculated as the number of tumor samples with the mutation out of the total number 
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of tumor samples. The top three ranked genes were determined as highly mutated genes for each tumor type.
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Supplementary Figure 2 Distribution of mutation density in each tumor cell line. The mutation density of a
tumor cell line was estimated by the number of mutations identify per MB in the sequenced genome. For each 
tumor type, the cutoff on mutation density for calling hyper-mutated cell lines was determined as the value of 
the peak outside the continuously distributed histogram or the tail of histogram plot.
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Abstract
A central challenge in evolutionary biology concerns the mechanisms by which 
complex metabolic innovations requiring multiple mutations arise. Here, we propose 
that metabolic innovations accessible through the addition of a single reaction serve 
as stepping stones towards the later establishment of complex metabolic features 
in another environment. We demonstrate the feasibility of this hypothesis through 
three complementary analyses. First, using genome-scale metabolic modelling we 
show that complex metabolic innovations in Escherichia coli can arise via changing 
nutrient conditions. Second, using phylogenetic approaches, we demonstrate that the 
acquisition patterns of complex metabolic pathways during the evolutionary history of 
bacterial genomes support the hypothesis. Third, we show how adaptation of laboratory 
populations of Escherichia coli to one carbon source facilitates the later adaptation to 
another carbon source. Our work demonstrates how complex innovations can evolve 
through series of adaptive steps without the need to invoke non-adaptive processes. 
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1. Introduction
Evolutionary novelties frequently depend on the fixation of multiple, highly 
specific mutations, where intermediate stages of evolution seemingly provide little or 
no benefit [1]. Such complex adaptations are widespread in molecular networks and 
include the origin of multimeric protein machineries, establishment of interactions 
between transcription factors and their binding sites, receptor-ligand interactions 
and multi-step metabolic pathways [2-4]. According to the notion that evolutionary 
adaptation proceeds by the sequential fixation of single beneficial mutations [5], 
complex adaptations are expected to occur only sporadically. One theory suggests that 
many evolutionary innovations, i.e. qualitatively new adaptive traits, have non-adaptive 
origins, where neutral mutations prepare the ground for later beneficial mutations that 
lead to innovations [6, 7]. Evidence for this process comes from laboratory evolution 
of RNA enzymes [8], but its role in the establishment of complex molecular pathways 
remains unclear. In the case of metabolic networks, the theory proposes that “many 
additions of individual reactions to a metabolic network will not change a metabolic 
phenotype until a second added reaction connects the first reaction to an already 
existing metabolic pathway” [7]. However, this non-adaptive process is expected to be 
extremely slow, and furthermore, there is no direct empirical support for this scenario 
in bacteria, which are especially prolific in producing metabolic innovations. Although 
free-living bacteria increase their genome size through horizontal gene transfer and 
gene duplication, their genomes remain compact, and nonfunctional sequences appear 
to be rare compared to most eukaryotes [9]. Genes under relaxed selection are rapidly 
inactivated and subsequently lost in free-living bacteria, not least because there is a 
pervasive mutational bias towards deletions of genomic segments [9]. Consequently, 
genes encoding functionally completely intact enzymes that provide no immediate fitness 
advantage are generally unlikely to be maintained for long periods. Even under a scenario 
where the neutral intermediate-step mutation is not required to reach high population 
frequencies (i.e. “stochastic tunneling” [10]), evolution is expected to be slower than 
traversing purely adaptive trajectories through natural selection. Thus, understanding 
the evolution of complex innovations remains a formidable challenge. 
Previous population genetic models[11] and computer simulations of genetic 
circuits and RNA molecules[12] offer a potential solution to the problem of complex 
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adaptations. These works indicate that complex or temporally fluctuating conditions can 
facilitate adaptation, partly by allowing populations to escape fitness plateaus and reach 
new adaptive peaks. Similarly, a study on digital organisms revealed that populations often 
evolve complex features by building on simpler functions that had evolved earlier[13]. 
However, the extent to which these abstract considerations apply to specific cellular 
subsystems remained unknown, partly due to the shortage of systems-level analysis that 
would combine computational modeling and evolutionary experiments.
In this work, we focus on bacterial metabolic networks to examine how novel 
nutrient utilization phenotypes can be acquired via the addition of new reactions to 
an organism’s enzyme repertoire. While not all complexity at the level of molecular 
systems are expected to provide a functional advantage[14, 15], metabolic pathways 
utilizing novel nutrients arguably qualify as adaptive traits. The problem of the evolution 
of novel metabolic pathways has two complementary aspects, relating to their origin 
and subsequent evolutionary establishment across multiple species. Previous works 
were large concerned by how novel biochemical reactions arise first during the course of 
evolution[16, 17]. In this paper, we ask how existing enzymatic reactions can assemble 
to form a novel metabolic pathway in an organism that already harbors a complex 
metabolic network. We extend and generalize an early suggestion that varying nutrient 
environments play a prominent role in the establishment of biosynthetic pathways[16]. 
Specifically, we employ detailed simulations on a pan-genome scale to 
demonstrate that complex metabolic innovations can evolve via the successive acquisition 
of single biochemical reactions that each confers a benefit to utilize specific nutrients. 
Thus, temporal changes in nutrient availability or complex environments (where multiple 
nutrients are available) can facilitate adaptive evolution of metabolic pathways through 
the step-by-step expansion of metabolic niches. Gene acquisition patterns across 
bacterial genomes and de novo laboratory evolution of nutrient utilizations in Escherichia 
coli (E. coli) provide clear support for the hypothesis. 
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2. Results
2.1 Most metabolic innovations demand only a few novel reactions 
In this work, we systematically studied the expansion of metabolic networks. We 
specifically asked whether metabolic innovations can evolve in a purely Darwinian manner 
through series of adaptive steps. Our starting point was the previously reconstructed 
metabolic network of Escherichia coli K-12, arguably the best studied and most 
reliable reconstruction of a genome-scale metabolic system, composed of 2077 unique 
reactions, including transport processes[18]. Previous studies showed that bacterial 
networks expand largely by acquiring genes involved in the transport and catalysis of 
external nutrients, driven by adaptations to changing environments[19]. Based on these 
observations, here we studied the potential selective advantages conferred by the 
addition of new metabolic reactions to the E. coli network. We compiled a dataset of 
2566 known enzymatic and 159 transport reactions across the three kingdoms of life 
(“universal reaction set”) absent from the E. coli model[20] (see Methods). We next 
defined a comprehensive sample of the external nutrient space, consisting of 1776 
environments comprised of nutrient sources that can potentially be imported into the 
network (Supplementary Data 1). We focused on minimal media that differ from each 
other in a single carbon, nitrogen, sulphur or phosphorus source, thereby maximizing the 
variability between conditions while remaining computationally feasible (Methods). We 
determined the phenotypic impact of adding one or more reactions from the universal 
reaction set to the E. coli network in each of these environments using flux balance analysis 
(FBA)[21]. FBA identifies a steady-state flux distribution that maximizes the production 
of biomass (a weighted combination of major biosynthetic components) from a given set 
of available nutrients. This framework successfully predicts the growth capacity of wild-
type E. coli across nutrient conditions[18], and it is biologically more realistic than graph-
theoretical approaches [22]. Prior to the addition of novel reactions, the reconstructed E. 
coli metabolic network was unable to grow (i.e., the rate of biomass production was zero) 
in 321 environments in which the network expanded by the complete universal reaction 
set was able to grow (Supplementary Data 1). Using a mixed integer linear programming 
(MILP) algorithm, we determined the minimal number of reactions from the universal 
reaction set that need to be added to the E. coli network to support growth in these 
CHAPTER 6
114
6
novel environments. Strikingly, growth in additional environments required the addition 
of only one to three enzymatic and transport reactions in 74% of the cases (239 out of 
321 environments, see Figure 1). In 21.5% of the novel environments, acquisition of only 
one reaction was sufficient for growth (69 out of 321 environments, see Supplementary 
Data 2). These results suggest that in the genotype space around the E. coli metabolic 
network, most metabolic innovations are only a few gene acquisition steps away. 
Figure 1. Metabolic innovations in the genotype space around the E. coli network. A) Only few reactions 
need to be added to the E. coli metabolic network to enable growth in metabolic environments where the 
wild-type cannot grow. The histogram shows the distribution of additional minimal reaction set sizes needed 
for biomass production in 321 novel nutrient environments. 
2.2 Complex innovations can arise via changing environments
One can envisage a simple adaptationist hypothesis by which complex metabolic 
innovations can arise. A metabolic phenotype accessible through the addition of a 
single reaction may serve as an exaptation[23] from which metabolic phenotypes that 
demand the acquisition of multiple reactions can be developed. A major corollary of 
this hypothesis is that evolutionary adaptation to temporally varying environmental 
conditions facilitates the expansion of metabolic networks (see also ref. [16]). In the 
parlance of fitness landscapes, varying environments result in dynamic landscapes with 
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moving peaks which can be more easily tracked by hill-climbing evolution (see Figure 
2A-B). 
To test the feasibility of the step-wise network expansion scenario, we focused 
on reaction pairs that are jointly required to provide a fitness benefit in at least one 
environment (for a list of the 538 such reaction pairs, see Supplementary Data 3). Next, 
we added each of the corresponding reactions individually into the network and asked 
whether their presence alone provides a selective advantage across the set of 321 
novel environments. Consistent with the hypothesis, we found that in 40% of the 538 
growth-promoting reaction pairs one of the reactions enables growth on its own in at 
least one environmental setting, which therefore can serve as stepping stones along 
adaptive trajectories. For example, while the ability to metabolize chorismate demands 
the simultaneous acquisition of two reactions, one of them also confers L-phenylalanine 
utilization when added individually to the network (Figure 2C). We note that many 
growth-promoting reaction pairs are phenotypically equivalent (i.e. confer growth in the 
same environment) and share the same stepping stone reaction (Supplementary Data 3). 
As a result, in total 8.5% of the 118 novel environments that require the simultaneous 
addition of two reactions becomes accessible through purely adaptive walks.
To more generally assess the potential for exaptation, we examined for each novel 
environment if its growth-promoting reactions are involved in adaptation to another 
(“intermediate”) environment. To this end, for each environment, we enumerated all 
possible minimal reaction sets that can support growth when added to the E. coli network 
from the universal reaction set. On average, 26% of the alternative minimal reaction sets 
required for growth in a given environment are also entirely present in at least one minimal 
growth-promoting reaction set of a second environment. This finding indicates that some 
of the growth-promoting reaction sets contribute to growth in multiple environments as 
parts of larger reaction sets. These figures are likely underestimates due to incomplete 
knowledge of available enzymatic reactions (including promiscuous side activities in 
the E. coli metabolic network[24]) and environmental conditions. We conclude that 
traversing complex evolutionary trajectories can be facilitated by exaptations when the 
environment varies.
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Figure 2. Evolution in varying environments is expected to facilitate the establishment of 
complex metabolic traits. A) The top panel shows a hypothetical fitness landscape over a two-
dimensional genotype space. The red genotype is well-adapted, i.e., it is located on the fitness 
peak of this starting fitness landscape. A change to the target environment shifts the fitness peak, 
so that the red genotype is no longer of high fitness (bottom panel). Adaptation to the shifted peak 
now cannot proceed purely through adaptive steps (i.e., hill-climbing); it requires the non-adaptive 
exploration of the neutral part of the landscape, illustrated by the yellow dotted line. B) depicts 
the same situation, but with an intermediate environment in which the fitness peak is only slightly 
shifted relative to the starting environment. The red genotype is located at the foot of the shifted 
fitness peak in this intermediate environment and can thus progress through purely adaptive 
steps, culminating in the yellow high-fitness genotype. When the environment now changes to 
the same target environment as in (A), the yellow genotype represents an exaptation, such that 
it can now progress towards the target fitness peak through purely adaptive steps. While (B) only 
shows one intermediate environment, the same reasoning applies to more complex scenarios 
including dynamic landscapes with moving peaks. C) Example from simulated metabolic network 
expansions. E. coli K-12 is unable to utilize chorismate and L-phenylalanine as sole carbon sources. 
Simulations show that while chorismate utilization demands the simultaneous addition of two 
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reactions to the network, one of these reactions (1st step; catalyzed by phenylalanine ammonia 
lyase) also confers L-phenylalanine utilization when added individually.
2.3 Metabolic gene acquisition patterns support the hypothesis 
The model predicts that acquisition of new metabolic genes during bacterial 
evolution should be contingent on the presence of other genes providing specific 
adaptations to intermediate environments. It has been established that a major source 
of metabolic network expansion is horizontal gene transfer in bacteria[19, 25]. Genes 
recently acquired by E. coli through horizontal gene transfer confer condition-specific 
advantages and contribute to growth only in specific environments[19]. To test whether 
acquisition of an enzyme pair that is potentially accessible via adaptive steps occurs via a 
defined order, we used genomic data from 943 bacteria to reconstruct gene gain events 
along the corresponding phylogeny using parsimony (Figure 3A, Methods). As expected 
under the hypothesis, enzymes that are predicted to confer fitness benefits on their own 
and can hence serve as stepping stones towards two-step adaptations in silico tend to be 
gained on an earlier branch of the phylogenetic tree than their partner enzyme (in 65% 
of cases, N=33, as opposed to 50% expected by chance, P=0.037, one-tailed one-sample 
Wilcoxon signed-rank test, see Methods). We note that this pattern holds for different 
parameter values of the gene gain reconstruction procedure (see Supplementary Table 
1).
In contrast to such cases, growth-promoting enzyme pairs not accessible gradually 
are the most likely candidates for co-gain via horizontal gene transfer. In agreement with 
this expectation, such enzyme pairs show a much higher co-gain fraction, i.e., number 
of co-gain relative to single gain events, compared to random gene pairs and growth-
promoting gene pairs predicted to be accessible gradually through adaptive evolution 
via environmental changes (P<0.001, randomization analysis and P=0.0038, one-sided 
Wilcoxon rank test, respectively, N=21, Figure 3B, see Methods). Also consistent with 
the hypothesis, growth-promoting enzyme pairs that are accessible gradually through 
adaptive evolution via environmental changes, have very low co-gain fractions that are 
indistinguishable from that of random gene pairs (P=0.64, randomization analysis, N=40, 
Figure 3B, see Methods). These conclusions are robust to changes in parameter values of 
the gene gain reconstruction procedure (see Supplementary Tables 2-3).
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Figure 3. Evolutionary history of gene gains supports the dynamic environment model. A) Schematic 
representation of the phylogenetic comparisons to study the interdependence between gene gain events. 
According to the dynamic environment model, if initial adaptation via a single gain of gene A serves as 
a stepping-stone for complex adaptation via a gain of gene B, then acquisition of B is expected to occur 
more frequently with gene A being present (contingent gain) compared to A being absent in the ancestral 
branch points of the bacterial tree (upper panel). Furthermore, enzyme pairs that confer a growth benefit 
only when present together are expected to be more frequently co-gained along branches of the bacterial 
tree in comparison to a gain of only one of the two (lower panel). Detailed description of the procedures is 
presented in Methods. B) Phylogenetic co-gain measure (see Methods) of jointly beneficial enzymes based 
on analysis of hundreds of bacterial genomes. Orthologs of enzyme pairs that are beneficial jointly but not 
accessible gradually (‘Beneficial without individual effect’, N=21) tend to be co-gained on the same branch 
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of the phylogenetic tree. This trend is statistically significant when compared both to randomized pairs and 
to enzymes that are growth-promoting as a pair but are accessible gradually through adaptive evolution 
via varying environments (‘Beneficial with combined and individual effect’, N=40), P<0.001 (randomization 
analysis) and P=0.0038 (one-sided Wilcoxon rank test), respectively. In addition, such ‘accessible’ pairs are 
not more likely to be co-gained than expected by chance (P=0.637).
2.4 Experimental evolution of a complex metabolic innovation 
New metabolic pathways can evolve not only through the acquisition of full-
blown enzymes from other organisms but also through the enhancement of weak side 
activities of existing enzymes [3, 24], possibly through regulatory mutations. Thus, a 
further prediction of the hypothesis is that evolutionary adaptation to a specific nutrient 
via accumulating mutations in endogenous genes can influence the accessibility of 
adaptive paths towards the utilization of other nutrients. An early work [26] suggests 
that acquiring the ability to grow on ethylene glycol (EG, Ethane-1,2-diol) and propylene 
glycol (PG, (S)-Propane-1,2-diol), two related carbon sources unavailable for utilization by 
wild-type E. coli K12, might depend on one another in a contingent manner. Specifically, 
according to the anecdotal report, E. coli mutants able to grow on ethylene glycol 
could be obtained from mutants that could grow on propylene glycol[26]. Using these 
phenotypes as a test bed we aimed at directly testing the step-wise metabolic niche 
expansion scenario by examining i) whether mutations that enable growth on propylene 
glycol per se increase adaptation rates to ethylene glycol and ii) whether the mutations 
conferring these two distinct growth phenotypes exhibit epistasis on ethylene glycol, as 
predicted by the hypothesis.
Table 1. Adaptation frequencies of different strains to propylene glycol (PG) and 
ethylene glycol (EG)
Strain Frequency of cells growing on 
propylene glycol (PG)
Frequency of cells growing on 
ethylene glycol (EG)
MG1655 up to 1.6 x 10-11 up to 1.6x10-11
MG1655 mutD5 1.5x10-9 up to 3.1x10-11
MG1655 mutD5 adapted to PG grows on PG 3.8x10-9
MG1655 + fucO overexpressed grows on PG 2.1x10-8
MG1655 is the reference wild-type strain, while MG1655 mutD5 refers to a strain with an approximately 1000-
fold increased mutation rate. Values are averages of 3 parallel replicates when PG+ or EG+ cells were observed 
and upper estimates[35] when no growing cells were obtained (see Supplementary Methods).
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First, we attempted to isolate mutants that can grow on ethylene glycol (EG+) or 
propylene glycol (PG+) from large populations of bacteria (Supplementary Methods). No 
EG+ or PG+ cells were isolated from ~1011 cells with wild-type mutation rate (Table 1), 
demonstrating that these substrates demand the acquisition of one or more very rare 
specific mutations. Next, we employed an E. coli strain with an approximately 1000-fold 
increased mutation rate[27]. In this case, PG+ cells occurred at a low, but detectable 
frequency of 1.5×10-9, but still no EG+ mutants were found (Table 1). As discussed, 
the evolution of EG utilization might be facilitated by prior adaptation to PG[26]. This 
was indeed so: EG-utilizing cells were detected in PG+ populations at a frequency of 
~3.8×10-9(Table 1), indicating an increase in adaptation rate of at least two orders of 
magnitude.
It has been reported that constitutive activation of fucO, a gene encoding 
an enzyme involved in fucose and rhamnose catabolism, is a prerequisite for growth 
in PG[28]. We therefore hypothesized that fucO upregulation acts as a stepping-
stone mutation towards EG utilization. To test this scenario, we overexpressed fucO 
from a strong constitute promoter in wild-type background[29]. As expected, fucO 
overexpression conferred the ability to utilize PG (Figure 4A). Remarkably, employing a 
fucO overexpressed PG+ strain yielded EG-utilizing cells at a frequency of ~2×10-8 (Table 
1). As this strain retained a wild-type mutation rate (Supplementary Figure 1), this finding 
shows that the ability to metabolize PG per se promotes adaptation to EG. Whole-genome 
sequencing of an EG-utilizing strain suggested that ~10-fold amplification of a genomic 
segment encoding aldA might underlie EG utilization (Supplementary Table 4). Indeed, 
simultaneous overexpression of both fucO and aldA in wild-type background conferred 
the ability to grow on EG (Figure 4B) with a growth kinetics akin to the strain adapted 
to EG (Supplementary Figure 2). Furthermore, as neither fucO nor aldA alone conferred 
growth on EG, this finding provides evidence that the two overexpression mutations act 
epistatically, as predicted by the step-wise metabolic niche expansion hypothesis. 
How do these two enzymes, FucO and AldA, contribute to EG utilization? 
FucO likely acts on ethylene glycol in addition to its native substrate to produce 
glycolaldehyde from EG[26]; AldA, an enzyme with broad substrate specificity, further 
converts glycolaldehyde to glycolate[30] (Figure 4C). Interestingly, in addition to their 
role in EG metabolism, both enzymes are involved in PG utilization as well, indicating 
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that regulatory rewiring of the same enzyme toolkit can produce multiple qualitatively 
different phenotypes.
Figure 4. Utilization of propylene glycol increases adaptation rates towards growth on ethylene glycol in 
the laboratory. A) Growth curve measurements demonstrating that overexpression of fucO (red) is sufficient 
for growth in propylene glycol. Wild-type MG1655 strain is depicted in grey. OD
600
 measurements of six 
independent replicates were taken every 60 minutes. B) Growth curve measurements demonstrating that 
joint overexpression of both fucO and aldA is required for growth on ethylene glycol (black). Neither fucO 
(red) nor aldA (blue) can achieve this when overexpressed individually. Wild-type MG1655 strain is depicted 
in grey. OD
600
 measurements of six independent replicates were taken every 240 minutes. One replicate 
population with joint overexpression of fucO and aldA failed to grow for unknown reason and is not shown. C) 
Schematic pathway diagram representing the role of FucO and AldA enzymes in the utilization of PG and EG. 
In the first step, FucO catalyzes the oxidation of PG and EG to glycolaldehyde and L-lactaldehyde, respectively. 
We note that the native activity of FucO operates in the reverse direction by reducing L-lactaldehyde to 
PG during the catabolism of L-fucose and L-rhamnose. In the next step, AldA oxidizes the products of FucO 
to hydroxycarboxylic acids which can be wired into central carbon metabolism following further enzymatic 
modifications. The affinity of AldA for L-lactaldehyde (PG utilization) is higher than for glycolaldehyde (EG 
utilization)[30], potentially explaining why growth on EG requires multiple copies of aldA.
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3. Discussion
Explaining the origin of evolutionary innovations that require the simultaneous 
acquisition of multiple mutations, none of which seemingly confer a benefit individually, 
remains a central challenge in evolutionary biology. Based on prior theoretical 
considerations[11, 12, 16], here we propose that metabolic innovations accessible through 
the addition of a single reaction serve as stepping stones towards the later establishment 
of complex metabolic features in another environment. We provided several lines of 
evidences in support of the hypothesis by focusing on the most well-studied molecular 
network, cellular metabolism, and by employing three complementary approaches. First, 
we simulated the adaptation of the E. coli metabolic network to novel environments. 
We revealed that new complex pathways can evolve via the successive acquisition of 
single biochemical reactions that allow the utilization of specific nutrients. Second, by 
reconstructing the evolutionary history of gene gains in bacteria, we demonstrated 
that complex metabolic pathways are indeed often established in a defined order as 
predicted. Finally, we conducted a laboratory evolution study of E. coli adaptation to two 
novel carbon sources; evolving the ability to utilize one nutrient remarkably facilitated 
later adaptation to the other. Thus, complex metabolic traits can emerge without the 
need to invoke neutral exploration of genotype space, a view that is in sharp contrast 
to non-adaptive scenarios of evolutionary innovation that rely on the accumulation of 
neutral intermediate mutations[6, 7, 31]. 
Taken together, our study demonstrates that complex metabolic innovations 
can evolve by adaptive means through the step-by-step expansion of nutrient utilization 
capacities. An important prediction is that metabolic innovations should be intertwined 
in nature: the ability to metabolize certain nutrients should act as a stepping stone 
towards the utilization of other nutrient sources[32]. A preliminary systems-level analysis 
based on nutrient utilization of 168 E. coli strains[33] suggests that it may indeed be so 
(Supplementary 
 3). Experimental case studies on the evolution of the catabolism of ß-galactoside 
sugars[34] and citrate utilization[35] are also consistent with the scenario, but it remains 
to be seen how general these findings are. Additionally, it is important to note that 
functionally linked enzymes frequently cluster in the bacterial genome or are encoded 
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in the same operon and tend to be acquired together during evolution[19]. Future 
systematic works should study the extent to which simultaneous uptake of multiple 
physiologically linked reactions by horizontal gene transfer speeds up the evolution of 
metabolic networks.
We speculate that the major barrier to the dynamic environment model of 
complex adaptation may be the absence of relevant series of environmental conditions. 
This restriction could be lifted when multiple novel substrates are simultaneously 
present in a single environment and evolution proceeds by successively acquiring the 
capacity to utilize them. We emphasize that other conceptually different mechanisms 
might also contribute to the adaptive expansion of metabolic networks. For example, 
stepping-stone reactions might evolve as repair processes in an adaptive response to 
metabolite damage[36], to degrade toxic environmental chemicals[3], or to produce 
novel secondary metabolites[37]. 
Our work has important ramifications for understanding genetic interaction 
networks and the development of industrially useful microbes. First, epistatic interactions 
between metabolic genes of the same pathway should often be environment-specific: 
our results suggest that in many cases, one of the genes should provide fitness benefits 
independently of the other in at least one environment. Large-scale mapping of genetic 
interactions across a broad range of environmental conditions would provide a direct 
way to test this prediction [38]. Second, we anticipate that evolutionary engineering of 
microbes to obtain desired phenotypes could be facilitated by temporally varying the 
traits under selection [39].
Finally, our study could have important implications beyond the evolution of 
metabolism. Earlier studies claimed that varying environments accelerate evolutionary 
adaptation in genetic circuits and RNA molecules [12]. In computer science, standard 
genetic algorithms have a tendency to quickly converge to a local solution, and hence 
frequently fail to identify more promising regions of the search space [40]. Application of 
dynamically changing “environments” offers a natural strategy to maintain the diversity 
required to explore the adaptive surface [41]. 
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4. Methods
4.1 Reconstruction of the universal reaction set 
To study the potential adaptive value of adding new reactions to the E. coli 
metabolic network, we compiled a dataset of metabolic reactions reported from species 
across the three kingdoms of life (“universal reaction set”) and absent from E. coli. First, 
we mapped the metabolites of the manually curated Escherichia coli genome-scale 
metabolic model [18] to the Model SEED database [20] (and http://blog.theseed.org/
model_seed/), a comprehensive resource for automatically generated genome-scale 
metabolic network reconstructions. Because Model SEED does not contain the most 
recent version (iJO1366 [42]) of the E. coli network reconstruction, we used an earlier 
version (iAF1260 [18]) that is widely utilized and has been extensively tested [43]. As a 
second step, we added all mass-balanced biochemical reactions from the Model SEED 
database to the E. coli model. From this draft network, we removed duplicate reactions. 
Next, we removed ‘perpetuum mobile’ cycles, i.e. flux distributions capable of producing 
energy without consuming any nutrients (see Supplementary Methods, Supplementary 
Table 5). Finally, we removed unconditionally blocked reactions (i.e. those unable to carry 
a flux under any condition). The resulting curated universal reaction network contains 
4949 metabolic reactions and 444 nutrient uptake reactions, of which 2566 and 159 are 
not present in the E. coli network, respectively. The universal network is available as a 
computational SBML model (Supplementary Data 4).
For more details on the reconstruction of the universal reaction set, see 
Supplementary Method.
4.2 Defining novel in silico nutrient environments
We first defined a comprehensive set of nutrient environments by starting 
from a glucose minimal medium for E. coli. For each environment, we replaced the 
carbon (C), nitrogen (N), phosphate (P), or sulfur (S) source by an alternative one. To 
obtain a list of environments that is both representative of novel nutrient compounds 
and computationally tractable, we focused on only those growth media that differed 
from glucose minimal medium by one compound instead of enumerating all possible 
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combinations of C, N, P and S-sources, as in previous works [24, 31]. Although this 
approach does not take into account more complex conditions, it allowed us to focus 
on single C, N, P and S-sources and to maximize the variability between conditions. See 
Supplementary Data 1 for the list of resulting 1776 conditions. 
Next, we determined the viability of both the E. coli network and the universal 
network across these conditions using flux balance analysis [21]. A network was deemed 
inviable in a given environment if its maximum biomass production was zero. Before 
adding novel reactions, the reconstructed E. coli metabolic network was unable to 
grow in 321 environments in which the network expanded by the universal reaction set 
allowed growth (Supplementary Data 1). We considered these 321 conditions as the set 
of available novel environments to which E. coli can possibly adapt by adding reactions 
from other species.
4.3 Finding growth-promoting reaction sets in new environments
To calculate the minimum number of active, non-coli reactions in a particular 
environment we applied a MILP-based algorithm on the universal metabolic model 
similar to the problem of finding the shortest elementary flux mode [44]. The basis of 
the MILP problem was the steady-state assumption:
Sv = 0
Where S is the stoichiometric matrix and v is the flux vector for all reactions. The 
reactions of the model were handled differently depending on whether they are part 
of the E. coli model or they can be added to the coli model during evolution. The flux 
constraints on the E. coli reactions were the same as in FBA:
li  vi  ui
Next, for each environment in which the universal network was viable but the 
wild-type E. coli network was not able to grow we set the nutrient uptake constraints to 
mimic the environment (li of the exchange reactions). The lower bound of the biomass 
production reaction was then constrained to 10-4 as the minimal growth requisite:
lbiomass = 1e
4
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The reversible non-coli reactions of the universal network were decomposed into 
two opposing irreversible reactions. This way the fluxes of the non-coli reactions can only 
take positive values. Let N’ be the number of non-coli reactions. We assigned a binary 
variable to each non-coli reaction, b
i
, which tells whether the non-coli reaction r’i (i = 
1,…,N’) is active (bi = 1) or not (bi = 0). The following equations ensure these rules:
v0i  "bi
u0i,maxbi v
0
i
Where v’i is the flux and u’i is the maximal possible flux of reaction r’i, while ε is 
the minimal flux value (in our calculations ε = 10-8). Also to avoid having two opposing 
reactions derived from the same reversible reaction being active simultaneously we 
introduced the following constraint:
bi + bj  1; (i, j) 2 {set of opposing reaction pairs}
Finally, the objective of the MILP problem was to minimize the active non-coli 
reactions:
minimize
X
bi; i 2 {1, ..., N 0}
The result of this minimization is the minimum number of non-coli reactions 
need to be added to the coli model to allow growth in a particular environment.
4.4 Enumerating all possible minimal reaction sets in silico 
The MILP optimization model described above not only provide the minimal 
number of reactions that support growth in new environments but also the list of the 
non-coli reactions involved in this solution: one of the minimal reaction sets. However, 
multiple equivalent minimal sets might exist for any given environment. To identify 
another minimal reaction set we extended the MILP problem with a new constraint 
which prevents the algorithm to find the same solution again:X
(Bibi) 
X
(Bi)− 1; i 2 {1, ..., N 0}
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Where Bi is the binary solution of the first minimal reaction set, and Bi equals to 
1 or 0 if reaction r’i was active or inactive in the first solution, respectively. This constraint 
is fulfilled only if the two solutions differ in at least one active reaction. We can harvest 
more minimal reaction sets in an iterative way where after each solution we add a new 
constraint and we run the algorithm again. Our algorithm stopped when the new solution 
had more active reactions than the size of the minimal reaction sets, that is, when we 
collected all minimal reaction sets. This algorithm is based on the method of finding the 
k-shortest elementary flux modes [44].
4.5 Defining growth-promoting reaction pairs using modelling
To systematically test the dynamic environment model, we investigated all 
possible two-step adaptation scenarios. First, we inactivated all non-coli reactions in 
the universal reaction network. Next, we activated two non-coli reactions at a time and 
applied FBA to calculate the fitness of the model in each environment where the native 
E. coli model cannot grow. By repeating this procedure we probed all possible reaction 
pairs in the universal reaction set and identified those that provide growth in at least one 
environmental condition (3,290,895 reaction pairs in total, 538 are beneficial in at least 
one condition). As a next step, we determined if the identified two-reaction adaptations 
can be accessed by the consecutive addition of single beneficial reactions to the network, 
i.e. whether at least one of the two reactions provide a fitness benefit on its own in any 
of the environments. For this purpose, we repeated the above procedure but instead 
of activating reaction pairs we activated single reactions and evaluated their fitness 
effect across environments using FBA. The list of 538 reaction pairs and corresponding 
environments can be found in Supplementary Data 3.
4.6 Software and computation used in metabolic network analyses
All simulations were implemented in GNU R [45] using the sybil package for 
constraint based modelling [46]. As optimizer for linear programming and mixed integer 
linear programming we used ILOG CPLEX 12.5. The linear programming was done on a 
64-bit Ubuntu Linux system with an Intel Core-i7 quadcore processor. MILP problems 
were solved on a Red Hat Enterprise Linux Server release 6.2 with 96 Intel Xeon CPUs.
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4.7 Phylogenetic analysis of gene gain events
To investigate contingent gain and co-gain in the evolutionary history of genes, 
we first generated the phylogenetic presence and absence profile across present-day 
species for each reaction by mapping the profiles from gene to reaction level. Presence 
and absence profiles of orthologous genes across 943 bacterial species were obtained 
from eggnog v3.0[47]. Reactions catalysed by enzyme complexes consisting of multiple 
gene products (‘AND’ relationships) are considered to be present in a species only when 
all genes of the complex are present in the genome. Reactions catalysed by isoenzymes 
(‘OR’ relationships) are considered to be present when at least one isoenzyme is encoded 
in the genome. 
Next, we inferred the most parsimonious ancestral presence/absence states of 
each reaction by using a phylogenetic tree of the 943 eubacteria, retrieved from STRING 
v9.05 (http://string905.embl.de/newstring_download/species.tree.v9.05.txt) [48]. 
Reaction presence and absence states across branch points along the phylogenetic tree, 
i.e., the ancestral states, are calculated by using the tree and the present-day presence/
absence state of the reaction. The ancestral state is inferred by minimizing the number 
of gene gain and loss events across the tree that matches the present-day state. Such 
a maximum parsimony strategy is commonly used as it allows for the analysis of genes 
genome-widely in a computationally efficient manner, and has shown to be successful 
in explaining patterns in genome content and evolution[19, 49, 50]. Calculations were 
carried out using PAUP[51] with a gain/loss penalty ratio of 2/1[52]  and a delayed 
transition assumption (‘DELTRAN’) [49]. We note that our results are robust against 
variations in PAUP parameter values (See Supplementary Tables 1-3).
4.8 Contingent gain analysis
For each stepping-stone reaction pair A-B, A is defined as the reaction that is 
beneficial in a given nutrient environment without B, while a gain of B is only beneficial 
in another environment when A is already present. For each A-B pair we calculated the 
phylogenetic contingent gain fraction (f), defined as f = p1/(p1+p2), where p1 is calculated 
by dividing the number of evolutionary events where B is gained in the descendent (d) 
when A is already present in the ancestor (a) (a10_d11) by the total number of all possible 
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gain and loss scenarios taking place in the descendant when A is present but B is absent in 
the ancestor (a10_dXX, where X = 0 or 1), and p2 is calculated by dividing the number of 
evolutionary events where B is gained in the descendant when A is absent in the ancestor 
(a00_d01) by the total number of all possible gain and loss scenarios taking place in the 
descendant when both A and B are absent in the ancestor (a00_dXX, where X = 0 or 1). 
The observed distribution of fractions was then compared to the null-hypothesis that a 
gain of B is independent of the presence of A, i.e., f=0.5, using a one-tailed one-sample 
Wilcoxon signed-rank test.
4.9 Co-gain analysis
For the phylogenetic co-gain analysis we calculated for reaction pairs the co-gain 
fraction, defined as f = n1/(n1+n2), where n1 is the number of evolutionary events where 
both reactions were absent in the ancestor (a) and both were gained in the descendent 
(d) (a00_d11), and n2 is the number of evolutionary events where both reactions were 
absent in the ancestor and only one was gained in the descendent (a00_d10 or a00_d01). 
We compared the fractions (f) from reaction pairs that are predicted to be beneficial 
for growth only when they are simultaneously gained, referred to as ‘Beneficial without 
individual effect’, with the fractions from reaction pairs that are beneficial for growth in a 
specific environment when co-gained, but at least one of the reactions is also beneficial 
on its own in a different environment (‘Beneficial with combined & individual effect’) 
(see Figure 3B in main text). A one-sided Wilcoxon rank test was used. Additionally, we 
compared the fractions from ‘Beneficial without individual effect’ reaction pairs with 
the expected co-gain fraction by chance (‘Randomization (without individual effect)’). 
To do that, we broke the pairing between reactions and shuffled the reactions into new 
pairs, thereby generating a new list of gene pairs. This was repeated 1000 times. Then we 
determined for each of the 1000 reaction pair list if the mean co-gain fraction is higher 
than that of the ‘Beneficial without individual effect’ and summed these (n1). P-value 
was calculated as P = (n1+1)/1001. The randomization analysis was also carried out for 
reaction pairs that are beneficial for growth in a specific environment when co-gained, 
but at least one of the reactions is also beneficial on its own in a different environment 
(‘Beneficial with combined & individual effect’ vs ‘Randomization (combined & individual 
effect)’).
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4.10 Strains, plasmids, primers for laboratory adaptation
E. coli K-12 MG1655 was considered as the wild-type strain in our experiments. 
MG1655 mutD5 was constructed using a suicide plasmid-based genome engineering 
method incorporating a C -> T mutation at position 236110 on the genome (within the 
dnaQ gene) resulting in a T15I mutation of the encoded enzyme described previously 
[27]. Standard steps and plasmids (pST76-A, pSTKST) of this methodology have been 
described [53]. Briefly, an approximately 800-bp long targeting DNA fragment carrying 
the desired point mutation in the middle was synthesized by PCR, then cloned into a 
thermosensitive suicide plasmid (pST76-A). This plasmid construct was then transformed 
into the cell, where it was able to integrate into the chromosome by way of a single 
crossover between the mutant allele and the corresponding chromosomal region. The 
desired cointegrates were selected by the antibiotic resistance carried on the plasmid 
at a non-permissive temperature for plasmid replication (42°C). Next, the pSTKST helper 
plasmid was transformed, then induced within the cells, resulting in the expression of the 
I-SceI meganuclease enzyme, which cleaves the chromosome at the 18-bp recognition 
site present on the integrated plasmid. The resulting chromosomal gap is repaired by way 
of RecA-mediated intramolecular recombination between the homologous segments in 
the vicinity of the broken ends. The recombinational repair results in either a reversion 
to the wild-type chromosome, or in a markerless allele replacement, which can be 
distinguished by sequencing the given chromosomal region. See Supplementary Table 6 
for the primers used for the mutation construction.
For the overexpression of FucO, the pCA24N plasmid containing the fucO 
gene was selected from the ASKA library [29] and isolated from the host strain, then 
electroporated into the MG1655 strain. Overexpression of the gene was achieved by the 
addition of 50 μM IPTG. 
For the simultaneous overexpression of fucO and aldA, the chloramphenicol 
resistance cassette (CmR) of the pCA24N-aldA plasmid from the ASKA library was exchanged 
to the kanamycin resistance marker (KmR), resulting in pCA24N-aldA-Km. The pCA24N-
aldA plasmid was first linearized by inverse PCR amplification using the pCA24N_frame_1 
and pCA24N_frame_2 primer pair flanking the CmR cassette. The PCR product was treated 
with DpnI for 60 minutes at 37°C and purified using the DNA Clean & Concentrator-5 Kit 
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(Zymo Research #D4004). The KmR marker was PCR amplified from a pSTKST template 
using the ASKA-Gibson_Kan_Fw and ASKA-Gibson_Kan_Rev primers. The PCR fragment 
was then isolated from 1 % agarose gel using the GeneJET Gel Extraction Kit (Thermo 
Scientific #K0691).  The resulting DNA fragments were assembled using Gibson assembly 
cloning (Gibson Assembly Master Mix, New England Biolabs #E2611), according to the 
manufacturer’s protocol, then electroporated into electrocompetent E. coli DH10B cells. 
Correct assemblies were verified by colony PCR using the ASKA-S2 and aldA-1 primer 
pair. Sequences of primers used in this construction are listed in Supplementary Table 7.
4.11 Media used in laboratory adaptation
Minimal salts (MS) medium was used as described previously [34], supplemented 
either with 0.4 % glycerol, 30 mM (S)-Propane-1,2-diol (propylene glycol, PG), or 30 mM 
Ethane-1,2-diol (ethylene glycol, EG). Antibiotics were employed in the following working 
concentrations: 50 μg/ml ampicillin (Ap), 25 μg/ml chloramphenicol (Cm), and 25 μg/ml 
kanamycin (Km).  
4.12  Adaptation of strains for growth on PG and EG
3 replicates of each individual strain were started from single colonies grown 
on MS + 0.4 % glycerol agar plates (with Cm added where the fucO overexpression 
plasmid was present) at 30°C. An MG1655 strain carrying the pCA24N-fucO plasmid was 
previously found to grow at 30°C in 2 ml MS media supplemented with 30 mM PG (with 
25 μg/ml Cm and 50 μM IPTG added). This culture was subsequently plated onto MS 
+ 0.4 % glycerol (+ Cm) agar plates, from which the PG+ colonies, starters for selection 
for EG-utilization, were isolated. We opted for glycerol as a base carbon source to avoid 
catabolite repression (i.e. the inhibition of utilization of various other carbon sources) 
as in [28]. Starter cultures were then grown in 2 ml MS + 0.4 % glycerol (+Cm where 
needed), from which 250 μl was then transferred to 25 ml fresh liquid MS media + 0.4 
% glycerol (and Cm where needed). Cultures were grown to stationary phase at 30°C, 
after which total cell count was determined by plating of appropriate dilutions onto MS 
+ 0.4 % glycerol agar plates. The remainder of the cultures were then harvested and 
resuspended in 400 μl MS media without carbon source and finally plated in two halves 
onto MS agar plates supplemented with either 30 mM PG or 30 mM EG (with Cm and 50 
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μM IPTG added where the fucO overexpression plasmid was present). Plates were then 
incubated at 30°C for 40 days after which adapted colonies were counted and isolated. 
The plates were placed in plastic bags for the duration of the incubation to prevent 
significant drying of the agar media. Rates of adaptive mutations were calculated based 
on 3 replicate experiments as follows. When adapted colonies were observed, we simply 
calculated the average ratio of the number of adapted colonies per total cell number. 
In cases where no growing colonies were obtained, we calculated an upper limit to the 
adaptive mutation rate following the approach presented in ref. [35]. Specifically, we 
made use of the fact that the Poisson distribution has a 5% probability of yielding zero 
events when the expected number of events is three. Thus, assuming no more than 3 
adaptive mutations among all the cells tested in the three replicate experiments gives an 
upper bound on the adaptive mutation rate per cell per generation.
4.13 Growth curve measurements
Individual colonies of strains MG1655, MG1655 + pCA24N-fucO, MG1655 + 
pCA24N-aldA-Km, and MG1655 + pCA24N-fucO + pCA24N-aldA-Km were grown and 
isolated from MS + 0.4 % glycerol plates carrying the desired antibiotic for the given 
plasmids. Starter cultures from single colonies were grown in 5 ml liquid MS media 
supplemented with 0.4 % glycerol, as well as 50 μM IPTG and 25 μg/ml Cm and/or 25 
μg/ml Km in the case of plasmid-harboring strains. Cultures were grown until saturation 
after which 10 ml MS media supplemented with 30 mM of either PG or EG as well as 50 
μM IPTG and 25 μg/ml Cm and/or 25 μg/ml Km where needed, were inoculated with 
the overnight cultures at a 100x dilution. 100 μl of these samples were then placed in 6 
separate wells on a 96-well tissue culture plate (Jet Biofil), and placed in a PowerWave 
XS2  (BioTek) microplate spectrophotometer and grown at 30°C. The edges of the plate 
were sealed with Breathe-Easy gas permeable sealing membrane (Diversified Biotech) to 
prevent evaporation. 
4.14 Mutation rate measurements
We estimated mutation frequencies of BW25113 (wild-type) and BW25113 
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overexpressing the FucO protein from the pCA24N_fucO plasmid. Briefly, cells resistant 
to rifampicin (carrying mutations in rpoB [54]University of Wisconsin, Madison 53706.
Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to 
rifampicin resistancewere selected and counted. After overnight growth at 37°C, ten 
tubes of 1 ml LB (+ 25 mg/ml chloramphenicol in the case of pCA24N_fucO carrying 
samples) were inoculated with approximately 104 cells each. FucO overexpression was 
induced by adding 50 mM IPTG after 2 hours of growth, and cultures were grown to 
early stationary phase, all at 37°C. Appropriate dilutions were spread onto non-selective 
LB agar plates and LB agar plates containing rifampicin (100 mg/ml). The samples were 
incubated at 37°C and colony counts were performed after 24 or 48 hours, respectively. 
Mutation rates were calculated with the Ma-Sandri-Sarkar maximum-likelihood method 
[55] using the FALCOR web tool [56].
4.15 Ion Torrent library construction for whole-genome sequencing
Fragment libraries were constructed from purified genomic DNA using NEBNext 
Fast DNA Fragmentation & Library Prep Set for Ion Torrent (New England Biolabs) 
according to manufacturer’s instructions. Briefly, genomic DNA was enzymatically 
digested and the fragments were end-repaired. Ion Xpress Barcode Adaptors (Life 
Technologies) were than ligated and the template fragments size-selected using AmPure 
beads (Agencourt). Adaptor ligated fragments were then PCR amplified, cleaned-up using 
AmPure beads, quality checked on D1000 ScreenTape and Reagents using TapeStation 
instrument (Agilent) and finally quantitated using Ion Library TaqMan Quantitation Kit 
(Life Technologies). The library templates were prepared for sequencing using the Life 
Technologies Ion OneTouch protocols and reagents.  Briefly, library fragments were clonally 
amplified onto Ion Sphere Particles (ISPs) through emulsion PCR and then enriched for 
template-positive ISPs.  More specifically, PGM emulsion PCR reactions utilized the Ion 
OneTouch 200 Template Kit (Life Technologies), and as specified in the accompanying 
protocol, emulsions and amplification were generated using the Ion OneTouch System 
(Life Technologies). Enrichment was completed by selectively binding the ISPs containing 
amplified library fragments to streptavidin coated magnetic beads, removing empty 
ISPs through washing steps, and denaturing the library strands to allow for collection of 
the template-positive ISPs.  For all reactions, these steps were accomplished using the 
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Life Technologies ES module of the Ion OneTouch System. Template-positive ISPs were 
deposited onto the Ion 318 chips (Life Technologies); finally, sequencing was performed 
with the Ion PGM Sequencing Kit (Life Technologies).
4.16 Ion PGM sequencing data processing and mutation calling
The PGM sequencing data was processed using Ion Torrent Suite v4.2.1 in 
order to perform signal processing and base calling. Read mapper module of Torrent 
Suite (tmap) was used to align raw reads to the E. coli K12 MG1655 genome sequence 
(U00096.3). Torrent Variant caller (tvc) module of Torrent Suite was subsequently applied 
to detect single nucleotide mutations as well as small in/del variants. Variant caller was 
programmed to run in high stringency mode requesting at least 12x read coverage and 
at least 66% mutation frequency. Only those variants were taken into account that were 
supported by sequencing on both strands. BAM alignment files were imported in CLC 
Genomics Workbench v7.5.1 (CLCBio) and variant regions were manually inspected in all 
strains. Large genomic rearrangements (deletions or amplifications with lengths above 
10 kb) were manually identified using CLC Genomics Workbench Tool. 
Sequencing data of the ancestral and evolved strains are deposited in the NCBI 
SRA database (accession numbers SRX1167076 and SRX1167031).
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Three different computational methods for genetic interaction prediction 
are presented in this thesis (Chapters 2, 3 and 4). Additionally, with an aim to achieve 
personalized cancer treatment, a web application for prioritizing targets on tumor type 
and patient specific level was developed and described in Chapter 5. In this chapter, I 
discuss the challenges and future perspectives in the research field of genetic interactions. 
Combining metabolic modeling and machine learning to predict and understand the 
phenotypic contribution of genetic interactions
One of the main messages of this thesis is that both metabolic modeling and 
machine learning that can integrate various genomic features, such as evolutionary 
profiles, gene expression and copy number profiles, are powerful techniques for genetic 
interaction identification (Chapters 3 and 4). These two methods can also be used in 
combination, which is described in Chapter 2. First, so-called directionally coupled enzyme 
pairs were predicted by Flux Coupling Analysis[1] of metabolic networks. Directional 
coupling means that two enzymes A and B in alternative compensatory pathways depend 
for their function on another enzyme C, but that enzyme does not depend on either 
of the two compensatory enzymes. As such, the relationship between A-C and B-C is 
defined as directional functional coupling. Consequently, enzymes A-B have a synthetic 
lethal genetic interaction. The directionally coupled enzyme pairs were used as training 
set for a machine learning classifier to predict functional directional coupling in protein 
complexes, which lays the basis for genetic interaction identification that goes beyond 
metabolism. The combination of the two techniques can also be implemented to predict 
phenotypes other than genetic interactions. In a recent study[2], the inhibitory effect of a 
drug on certain enzymes is simulated in the human genome-scale metabolic network and 
the lower and upper flux bounds of all the reactions are used as features for a classifier 
to predict whether a drug has any physiological side effect. The weights assigned to 
the reaction bounds generated by the machine learning procedure are informative to 
determine which reactions are detrimental with respect to the drug side effect[2], i.e., a 
positive weight indicates the flux change of the reaction may lead to a drug side effect.
To better understand the contribution of genetic interactions (GIs) to tumor 
relevant phenotypes, such as tumor size or survival rate of tumor patients, it is possible 
to propose an analysis that combines machine learning and the method described in 
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Chapter 4, i.e., predicting synthetic dosage lethal (SDL) interactions via genome-scale 
metabolic network simulation. In such analysis, we first need to infer the presence and 
absence of any predicted SDL pair from RNAseq data or gene copy number profiles. By 
imposing the presence of the SDL pairs on the genome-scale metabolic network, we can 
obtain the lower and upper flux bounds of all the reactions. The flux bound information 
can further be used as a predictive feature of a classifier for the clinical phenotypes such 
as tumor size or patient survival. This will be in addition to the presented quantitative 
feature of SDL strength as described in Chapter 4. After the classifier training procedure, 
we can obtain a weight vector, which is analogous to parameter coefficients of a simple 
regression model and can illustrate the relationship between these predictive features 
and their effect on the outcome. The predictive features that are less relevant to the 
response variable, i.e. the tumor size and survival time, will be suppressed in the 
classifier by having smaller weights. Based on the weights, we can investigate i) which 
SDL pairs determine a reduction of tumor size or provide longer survival and ii) whether 
non-SDL interactions have any effect on these clinical phenotypes and what their effect 
is; a hindering or stimulating effect. 
Genetic interactions and complex adaptations
The evolutionary patterns that were used to construct two GI prediction tools 
described in Chapters 2 and 3 indicated that the genes of a genetic interaction pair do 
not evolve independently and genetic interactions therefore affect genomic evolution. 
A long-standing question in evolution is whether genetic interactions affect adaptive 
evolution and shape the evolutionary trajectories. Understanding the mechanism of 
adaptive evolution is pivotal to find solution for medical problems, such as antibiotic 
resistance and drug resistance in cancer treatment. A study[3], which experimentally 
demonstrated that the evolutionary rescue of deleterious mutations depend on the 
genomic background, implied that genetic interactions may play a role in limiting the 
paths that adaptive evolution can take. 
A cell can evolve and restore the fitness upon a deleterious mutation via two 
mechanisms; i) replacing the mutated protein with a similarly functioning protein by large 
scale duplication of segmental or whole chromosomes[4], or ii) acquiring another loss of 
function mutation that dilutes the fitness defect caused by the deleterious mutation. 
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Genetic redundancy provided by duplicated genes in ancestor lineages does not have 
major impact on adaptive evolution since duplicated gene products only share partial 
functional overlap after undergoing function diversification in evolution[5, 6]. However, 
the observation that the adaptive mutants are more likely to have co-membership 
in protein complexes, show co-expression or share GI profiles[4] indicates that a 
replacement of function for deleterious mutations via dosage compensation may only 
take place in protein pairs with high degree of functional overlap. The second mechanism 
was supported by a recent experimental study in yeast[7]. Laan et al studied the adaptive 
evolution of a Bem1-deleted yeast lineage. Bem1, which is a scaffold protein, recruits 
Cdc42 and forms a complex together with Cdc24 that regulates polarized growth in yeast. 
In the evolved Bem1-deleted lineage novel point mutations were detected in Bem2 and 
Bem3. These mutations disrupt their function as Cdc42 in-activators and consequently 
compensate for the reduction of Cdc42 activity in the Bem1-deleted lineage. Thus, the 
function of Bem1 and Bem2/3 on Cdc42 regulation is opposite, i.e. Bem1 has a positive 
effect to recruit Cdc42 and Bem2/3 have a negative effect. As such, the functional 
relationship between Bem1 and Bem2/3 may be synthetic dosage lethality (SDL). SDL 
could thus be one of the explanations for the second mechanism of adaption evolution. 
The extent to which SDL defines adaptive trajectories in a general sense requires, 
however, the design of future experiments that combine large-scale dosage lethality 
screens and adaptive evolution.
The adaptive evolution experiments also revealed that the adapted lineages do not 
restore the genetic expression pattern of the wild type[4]. A relevant question for a future 
study would be how much variation exists between the genetic interaction landscape of 
cells before, during and after adaptation to WT fitness values. The quantification of such 
difference may i) show which genetic interactions facilitate adaptation and ii) which ones 
are scaffold genetic interactions that remain unchanged in adaptive evolution. To answer 
this question, we first need to overcome the challenges in identifying context-specific 
genetic interactions, which will be discussed in next section.
Challenges and future perspectives on identifying genetic interactions
A remarkable development has been achieved in GI screens in recent years[8-12]; 
however, there still remain several challenges. First, the majority of studies based on 
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current GI experimental identification techniques are carried out to find GIs only in 
one optimal growth condition or one genetic background. The single condition style 
of genetic interaction screens is useful in understanding gene function and the genetic 
architecture within cells. Nonetheless, proper design of comparative analysis of GI 
networks in different environments or genetic backgrounds can substantially broaden 
and sharpen the applicability of GIs in understanding a certain biological process. Cells 
are not operating in a static status, instead they need to constantly sense and adapt 
to the genetic and growth environmental perturbations[13]. Currently, several studies 
modified the available techniques and measured GIs between genes in stress response 
pathways under various stress conditions, and obtained genetic interaction networks 
in S.cerevisiae that differed between them[14, 15]. Within these different genetic 
interaction networks, the condition-specific contribution of signaling pathways as well as 
the crosstalk between these pathways was detected. 
However, the number of such comparative GI network studies is still limited due 
to two reasons; i) The work and finances required to modify and optimize the available 
experimental techniques that are mostly developed under specific growth conditions, ii) 
the in-depth knowledge required about the biological process of interest to reduce the 
number of pairs to be measured.
To better facilitate the comparative analysis of GI networks, future work 
should also focus on developing computational tools to identify context-specific GIs. 
One strategy would be to modify the method described in Chapter 3 into a context-
specific model that can predict cancer-type specific synthetic lethal interactions by using 
predictive genomic features and empirical SLs from a specific cancer type. Another 
possible strategy is to use condition-specific protein interaction networks as input 
for the methods described in 2 and 5. A new method, NetDecoder[16], was recently 
developed to reconstruct context-specific protein interaction networks by comparing 
the ‘information flow’ change, i.e., the binary on-off or active-inactive state switch of 
biomolecules between two phenotypes. The phenotypes can either be a disease state 
or the activity of certain proteins. Based on the simple logic that transcription regulators 
(TRs) affect gene expression and differentially expressed genes (DGEs) have an impact on 
phenotypes, the ‘information flow’ is tracked in a reverse style. This means that in the 
phenotype specific protein interaction network, the DEGs are used as source nodes, TRs 
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are used as target nodes and edges between these nodes are weighted by co-expression 
coefficient across samples in the same context. The paths connecting source proteins 
and target proteins via intermediary proteins are distinguished based on a minimum-cost 
flow optimization principal where the cost is defined to be the logarithm-transformed co-
expression coefficient of gene pairs. These paths are then predicted to be context-specific 
sub-networks. This method can be modified to find protein interaction networks in other 
context such as sub-networks involved in disease pathogenesis by using disease DGEs 
as sources and disease genes as targets. These context-specific protein networks can be 
used for conditional specific GI network identification using the methods presented in 
Chapters 2 and 5. 
Another challenge in GI identification is the identification of higher-order genetic 
interactions, i.e., GI involving more than two genes. Due to technical limitations, only few 
studies exist on higher-order genetic interactions[17, 18]. Consequently, the shortage 
of available experimental data hinders the development of computational methods 
to predict higher-order GIs, which depend on experimental data to extract prediction 
features and to benchmark the model performance. 
Even though these obstacles exist, the new state-of-the-art genome editing 
techniques bear potential to tackle these challenges and generate required training 
datasets for developing more advanced computational methods, which in return can 
prioritize potential GI pairs and reduce the experimental cost. One exciting breakthrough 
is the genome editing technique that is based on the CRISPR-Cas9 system[19, 20]. 
Compared to the most widely used gene inactivation technique, i.e., RNAi, it has two main 
advantages, i) the mutations created via DNA editing are more persistent and precise and 
ii) the CRISPR system can be repurposed to create gene activation screens[21]. The latter 
one is particularly interesting since it would allow for the detection of dosage lethality 
on a large-scale. Another breakthrough is CombiGEM[22], a high-order barcode system 
that can simultaneously tag more than two genetic mutations on the genome scale. 
Promisingly, it has been demonstrated that this technique can be combined with CRISPR-
Cas9, which paves the way for detecting higher-order GIs[23]. 
Taken together, the various computational approaches that have been developed 
and presented in this thesis lay the basis for GI prediction in the future. Importantly, 
145
7
Summarizing discussion
the approaches already provide the life science research community a rich resource of 
thousands of novel synthetic (dosage) lethal gene interactions, which can be used to i) 
advance our understanding of cellular physiology and adaptation, ii) identify novel anti-
cancer and anti-microbial drug targets, and iii) understand phenotypic variation among 
individuals in health and disease.
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Vanuit de klassieke moleculaire biologie bestuderen biologen individuele genen 
of gen producten één voor één of een klein aantal tegelijk. Deze reductionistische aanpak, 
waarin het complexe biologische system opgebroken wordt in kleinere componenten, 
heeft geleid tot de ontdekking van veel biologische principes. Echter, het bestuderen van 
individuele componenten is niet voldoende om een begrip te krijgen van het hele system, 
omdat de eigenschappen van het system voortkomen uit de extreme complexiteit van de 
interacties tussen de componenten en de invloed van de omgeving. 
Tegenwoordig is het onderzoek naar biologische processen dan ook meer gericht 
op complexe netwerken, zoals metabolisme en signaal netwerken, waarin de biologische 
moleculen de nodes zijn en de connecties tussen de nodes de functionele relaties. De 
functionele relatie heeft een brede definitie, bijvoorbeeld de fysieke interactie tussen 
eiwitten of de co-expressie van genen die coderen voor eiwitten. Genetische interactie 
(GI) is een type functionele relatie tussen twee genen, waarbij het  fenotypische effect van 
een genetische mutant afhankelijk is van één of meerdere mutanten in het genoom. Een 
alomvattend GI netwerk kan helpen om i) te onthullen hoe eiwitcomplexen samenwerken 
om verschillende biologische processen uit te voeren, ii) een beter inzicht te krijgen in 
de genotype - fenotype relatie, en iii) het ontdekken van nieuwe anti-tumor of anti-
microbiële drug targets. Verschillende experimentele platforms zijn recent ontworpen 
om GIs te meten op grote schaal. Echter, de hoge experimentele kosten, als gevolg van 
een explosie van het aantal paarsgewijze gen combinaties, belemmert de ontwikkeling 
van GI netwerken via empirische metingen op genoom-schaal.
Met als doel om genoom-schaal GI netwerken te creëren voor verschillende 
organismen heb ik twee computationele methoden ontwikkeld op basis van de integratie 
van genoom evolutie informatie. Waarom heb ik genoom evolutie informatie gebruikt? 
Genoom sequenties kunnen gezien worden als een product van evolutie en de kenmerken 
van genoom evolutie, zoals conservering van gen volgorde of het samen aan of afwezig 
zijn van genen (‘co-occurrence’), zijn informatief om functionele relaties tussen genen 
te bepalen. De methoden zoals beschreven in hoofdstuk 2 en 3 zijn ontwikkeld om 
zogenaamde negatieve GIs te voorspellen. Twee genen hebben een negatieve GI als 
een mutatie in beide genen leidt tot een ernstiger fenotype dan het product van de 
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fenotypische effecten van een mutatie van beide genen individueel. De meest extreme 
vorm van een negatieve GI, genaamd synthetisch letaliteit (SL), is met name van waarde 
voor het bepalen van anti-kanker drug targets. In het geval van SL is een mutatie in twee 
genen dus dodelijk, maar een enkele mutatie niet. Het onderliggende concept voor anti-
kanker drug targets is dat het onderdrukken van de activiteit van één gen, waarvan de 
SL partner in alleen tumorcellen gemuteerd is, zal resulteren in het selectief uitschakelen 
van tumorcellen en niet de normale cellen. 
Naast het voorspellen van negatieve GIs heb ik ook bijgedragen aan de 
ontwikkeling van een netwerk modelerings methode om een ander type GI, namelijk 
synthetisch dosering letaliteit (SDL), te voorspellen in metabolisme. SDL tussen twee 
genen bestaat wanneer een overexpressie van het ene gen en een onderexpressie van 
het andere gen lethaal is voor de cel. Het identificeren van SDL partners van oncogenen 
levert ook een basis voor een therapeutische strategie voor kanker patiënten.  
Tussen verschillende patiënten, tumor types, en zelfs tussen cellen van hetzelfde 
tumor weefsel bestaat genetische heterogeniteit. Voor een effectieve tumor behandeling 
is het dus van belang om genetische heterogeniteit te bepalen en therapeutische 
strategieën te ontwikkelen op individueel patiënt niveau. Om anti-kanker drug targets 
te identificeren op individueel patiënt niveau heb ik een database ontwikkeld genaamd 
Human Synthetic Lethality Database (HuSLDB). Deze database bevat humane SL gen 
paren. Daarnaast bepaalt HuSLDB patiënt en tumor specifieke drug targets door mutatie 
profielen van patiënten, zoals DNAseq and RNAseq, te integreren. Om portentiele drug 
targets te testen in-vitro levert HuSLDB ook het experimentele ontwerp door aan te 
geven welke test en controle cellijnen geschikt zijn. 
Ik heb verschillende computationele methoden voor de voorspelling van GIs 
ontwikkeld en beschreven in deze thesis. Deze methoden maken het mogelijk om GI 
netwerken te construeren en geven de mogelijkheid om inzicht te krijgen in verschillende 
biologische processen, zoals het ontrafelen van de relatie tussen genotype en fenotypen 
en het onderzoeken van de onderliggende moleculaire processen van complexe ziekten. 
Een belangrijke bijdrage is dat de voorspelde GIs op genoom-schaal en HuSLDB een rijke 
bron zijn voor het identificeren van anti-kanker drug targets op individueel patiënt niveau.
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In classical molecular biology studies, biologists usually study the function of 
individual genes and gene products one or few at a time. This reductionist approach, 
which dissects the complex biological system into smaller components composing one or 
a few biological molecules, and determines the function of these isolated components, 
has been shown to succeed in discovering a substantial number of biological principles. 
However, understanding these isolated molecules is not sufficient to understand the 
whole system because of the extreme complexity resulting from the inter-component 
interactions and the influence from the environment. 
Current biological studies have diverted to consider biological processes 
as complex networks, such as metabolic networks or signaling networks, where 
biological molecules are nodes and functional relationships are edges. The functional 
relationship has a broad definition, like the physical interaction between proteins or the 
co-expression between their genes. Among them, genetic interaction (GI) is a type of 
functional relationship between two genes where the phenotypic effect of a genetic 
mutant depends on another or more other mutants in the genome. A comprehensive 
GI network can help to i) reveal how protein complexes cooperate to mediate different 
biological processes, ii) better understand the genotype-phenotype relationship, and iii) 
discover novel anti-tumor or anti-microbial drug targets. Several experimental platforms 
were designed to measure GI on a large scale. However, the high experimental costs due 
to the high number of pairwise gene combinations hampers the successful generation of 
GI maps via empirical measurements on a genome wide scale.
With an aim to achieve genome-scale genetic landscapes in various species, I 
developed two computational tools to predict genetic interactions via exploiting and 
integrating genome evolution information. Why did I use genome evolution information? 
Genome sequences can be considered as a record of evolution and the extracted genome 
evolution features, such as conserved gene order, co-occurrence and gene fusion, are 
deemed to be informative to infer the functional relationships between genes and gene 
products. The methods presented in Chapter 2 and Chapter 3, are designed to predict 
negative GI. Two genes are defined to have negative GI if a mutation in both genes 
leads to a more severe phenotype than can be expected based on the phenotype of 
Summary
150
the two single mutations. The extreme case of negative GI, namely synthetic lethality 
(SL), is particularly valuable in prioritizing anti-cancer drug targets. The underlying 
mechanism is that inhibiting the gene whose synthetic lethal interacting partner is only 
mutated in tumor cells but not in normal cells can result in selective depletion of tumor 
cells. Moreover, I contributed to the development of a metabolic-network modeling 
based method to predict another type of GI, synthetic dosage lethality (SDL) where 
an overexpression of one gene and an under-expression of another gene are lethal to 
cell growth. Identifying SDL partners of oncogenes provides an alternative therapeutic 
strategy for cancer patients with oncogenic mutants. 
Genetic heterogeneity is found among different tumor types, different patients 
or even different cells within the same tumor tissue. Thus, an effective tumor treatment 
requires taking the genetic heterogeneity into consideration and designing a personalized 
therapeutic strategy. In order to facilitate finding personalized anti-cancer drug targets, I 
designed a database, Human Synthetic Lethality Database (HuSLDB), in which I compiled 
a list of SL pairs identified in human and inferred patient and tumor type specific 
targets by integrating mutation profiles of tumor patients, such as DNAseq and RNAseq. 
Furthermore, as an effort to expedite the setup of the in-vitro validation of the drug 
target, our database proposes suitable test and control cell lines.
Taken together, I developed and described several computational methods for 
GI predictions in the thesis, which paved the way to construct a systematic GI map and 
provide insight into various biological research aspects, ranging from unraveling the 
relationship between genotypes and phenotypes to better understanding molecular 
mechanisms underlying complex diseases. More importantly, combined with the 
database, HuSLDB, the genome-scales GIs predicted in human by these methods are a 
rich resource for prioritizing personalized anti-cancer drug targets.
Acknowledgements
151
Acknowledgements
First of all, I would like to express my sincere thanks to my supervisor Prof. Dr. 
Martijn Huynen for providing me with such a great opportunity to carry out my 
PhD study at Radboud University Nijmegen. I can still remember vividly that you 
always helped me improve the spoken English, which is painful but turns out to be 
really useful. Also, I appreciated the freedom you gave me to think and determine 
my own research interest and directions, which is essential to develop myself 
into an independent researcher. 
My earnest gratitude goes to Dr. Richard Notebaart, who is my co-supervisor. The 
whole procedure of my PhD study is a mixture of failure and success, frustration 
and happiness. When the bad moments happened, luckily, I always had you next 
to me in the office to help solving my puzzling, provide insightful suggestion and 
cheer me up. Your patience, openness and kindness lay the basis of this thesis. I 
could not have imagined having a better co-supervisor for my PhD study.
Many thanks to everyone at the CMBI, both current and former group members. 
With you, I had a very good time at work: Gert, Philip, John, Bas, Radek, Rob, 
Robin, Selma, Daniel, Dei, Lisette, Caroline, Jon, Sergio and Wouter. Thank you 
for not only all the scientific input, but also the joyful activities after working 
hours. Especially, Robin, Rob, Jon, Gert and Wouter, thank you for visiting and 
bringing liveliness to my ‘remotely-located and silent’ office. My special thanks 
to Barbara for all the administrative help she provided before, during and after 
my life at CMBI.
I also want to express my warmest thanks to all my collaborators during my 
study. They are Wout Megchelenbrink, Rotem Katzir, Prof. Dr. Eytan Ruppin and 
Prof. Dr. Balazs Papp. Without them, this thesis would not have been possible. I 
am also very grateful for the help from Jon Black and Wouter Touw. Thank you 
for all your generous help in setting up the web application described in Chapter 
5.
Living and studying abroad alone for the first time was definitely a challenge for 
me at the beginning. However, I was so lucky to have so many cherished friends 
in the Netherlands. Dongling（贾冬琳), the first friend I made here turned out to 
be my best friend of lifelong. I will always remember all the wonderful moments 
we had together, e.g., nice trips, fun chat and of course the delicious Chinese 
dishes you made. Qianqian（酒倩倩） and Runhua（周润华）, I will never forget 
our great time together during the study in Groningen. Yiwei (陈奕炜), it was such 
a nice experience to meet you in Nijmegen and I wish you all the best with your 
PhD study. Yang (李扬), Jingyuan (傅静远), Xiangyu（饶翔宇) and my two sweet 
Acknowledgements
152
housemates, Marloes and Karin, thank you for the help in my life. All my dear 
friends, thank you for all the help and company, which smoothed my homesickness 
and made my life in the Netherlands so homey.
At the end, and most importantly, my deepest thanks go to my lovely family 
members. Thank you, Dad and Mom, for your non-ending love and caring. You are 
always so supportive of all the decisions I have made. Without you, I would have 
never made this far. My elder brother and sister-in-law, thank you for taking 
care our parents so well when I am abroad. Xinyue, my most lovely niece, thank 
you for your sweet company during my every vacation in China.（亲爱的爸爸
妈妈，感谢你们一直以来对我的爱和支持，对我的任性无条件的包容。我爱你
们！老哥和姐姐，感谢你们对爸爸妈妈的照顾。最后还有我亲爱的王囡囡，每
次假期看到你都会让我很愉快。我爱你们，我的家人们。）
Xiaowen Lu
Nijmegen
Sep. 19, 2016
Curriculum Vitae
153
Curriculum Vitae
Xiaowen Lu was born on 5 February 1987 in Shanghai of China. After she finished her 
education at High School Affiliated to Shanghai Jiao Tong University in 2004, she started 
to study plant biotechnology at Shanghai Jiao Tong University and obtained a Bachelor 
in Science degree. In 2008, awarded with Huygens Scholarship from Netherlands 
Universities Foundation for International Cooperation, she came to the Netherlands and 
followed the master program in molecular biology and biotechnology at Rijksuniversiteit 
Groningen. During her master study, she focused on bioinformatics study. In 2010, she 
started a PhD project under the supervision of Prof. Dr. Martijn A. Huynen at the Centre 
of Molecular and Biomolecular Informatics of Radboud University. The project was part 
of the BioRange project BR4.4 of the Netherlands Bioinformatics Center, supported by 
a BSIK grant through the Netherlands Genomics Initiative. Under the supervision of 
Prof. Dr. Martijn A. Huynen and co-supervision of Dr. Richard A. Notebaart, she worked 
on developing computational models to predict genetic interactions in microbial 
and mammalian cells. Since October 2015, she is a post-doctoral researcher at the 
bioinformatics group at Wageningen University.
Curriculum Vitae
154
Publications
155
Publications
Szappanos B, Fritzemeier  J, Csörgö B, Lázár V, Lu X, Fekete G, Bálint B, Herczeg R, Nagy I, Richard A. 
Notebaart, Lercher MJ, Pál C, Papp B. Adaptive evolution of complex innovation through stepwise 
metabolic niche expansion. Nature Commutations, 2016. 7
Megchelenbrink W, Katzir R, Lu X, Ruppin E, Notebaart RA. Synthetic dosage lethality in the human 
metabolic network is highly predictive of tumor growth and cancer patient survival. Proceedings 
of the National Academy of Sciences of the United States of America, 2015. 112(39)
Lu X, Megchelenbrink W, Notebaart RA, Huynen MA. Predicting human genetic interactions from 
cancer genome evolution. Plos One, 2015, 10(5)
Lu X, Kensche PR, Huynen MA, Notebaart RA. Genome evolution predicts genetic interactions in 
protein complexes and reveals cancer drug targets. Nature Communications, 2013. 4.
Wain, L.V., et al., Genome-wide association study identifies six new loci influencing pulse pressure 
and mean arterial pressure. Nature Genetics, 2011. 43(10): p. 1005-1011.
Sotoodehnia, N., et al., Common variants in 22 loci are associated with QRS duration and cardiac 
ventricular conduction. Nature Genetics, 2010. 42(12): p. 1068-1076.
Zhao L, Lu L, Zhang L, Wang A, Wang N, Liang Z, Lu X, Tang K. Molecular evolution of the E8 
promoter in tomato and some of its relative wild species. Journal Bioscience, 2009. 1(34): p. 71-
83.
Nguyen DD, Melnik AV, Koyama N, Lu X, Schorn M, Fang J, Aguinaldo K, Lincecum Jr.TL, Ghequire 
MGK, Carrion VJ, Cheng TL, Duggan BM, Malone JG, Mauchline TH, Laura M, Sanchez LM, 
Kilpatrick AM, Raaijmakers JM, De Mot R, Moore BS, Medema MH, Dorrestein PC. Indexing 
the Pseudomonas specialized metabolome enabled the discovery of poaeamide B and the 
bananamides. Nature Microbiology, 2016. accepted
Lu X, Notebaart RA, Huynen MA. Experimental Design of Personalized Anti-Cancer Targets. 
manuscript to be submitted
